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Abstract 
The use of a solid dispersion (SD), a mixture of an active pharmaceutical ingredient and a 
polymer excipient, may significantly enhance the aqueous solubility and oral 
bioavailability of a hydrophobic drug, but the role of the polymer is poorly understood. For 
example, hydroxypropyl methylcellulose acetate succinate (HPMCAS) is considered to be 
one of the best performing excipients, but its effectiveness is not universal to all drugs. 
Elucidation of the critical properties of HPMCAS is inhibited due to the poor spatial 
resolution and sensitivity of the techniques traditional used to characterize SDs. To address 
this shortcoming, the studies in this dissertation focus on the development of novel 
analytical methods for characterizing SDs in both the solid-state and during dissolution. 
First, transmission electron microscopy (TEM) and electron diffraction evaluates drug 
crystallinity in SDs with a spatial resolution and sensitivity superior to the traditional 
methods. Second, energy-dispersive X-ray spectroscopy probes the spatial distribution of 
drug and polymer in a SD particle. Third, electron energy-loss spectroscopy quantitatively 
measures the concentration of drug and polymer in a SD with both high concentration and 
spatial resolution. Fourth, cryogenic TEM and small-angle X-ray scattering reveal a direct 
correlation between SD dissolution and nanostructure evolution in solution. Finally, the 
utility of these novel tools and possible future research directions are discussed. 
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Chapter 1: Introduction 
 
 
1.1 Motivation 
During the early 1990s, simultaneous advances in genomics, combinatorial chemistry, 
and ultra-high-throughput automated assay technology initiated a new approach for rapidly 
discovering novel orally administered drug molecules. This paradigm shift caused the 
pharmaceutical industry to make brash predictions for the success rate of bringing new 
clinical candidates to market.1 Although these techniques did lead to the discovery of drugs 
that had high binding affinity and selectivity for various enzyme targets, they were biased 
towards identifying molecules that had poor aqueous solubility (< 100 µg/mL)2 and, 
consequently, low oral bioavailability. The poor solubility arose from a combination of 
crystallinity and the molecules containing hydrophobic moieties that facilitate drug 
potency. Due to this bias, 40% of currently marketed drugs and 90% of drugs in the 
discovery pipeline are insoluble in water.3 The shortcoming of this drug discovery 
paradigm—possibly the most challenging and critical issue facing the pharmaceutical 
industry today—motivates the development of several drug formulation strategies to 
overcome poor aqueous solubility and enhance bioavailability. 4 
Many of these strategies for surmounting solubility limitations rely on the use of 
polymers, molecular chains comprised of repeating subunits (i.e., monomers) connected 
by covalent bonds. The chain-like nature of polymer molecules imparts fascinating 
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properties that may be precisely tuned by altering the chain length (molecular weight), 
repeat unit (chemical composition), and architecture.5 By striking a particular balance 
among these three parameters, polymers may exhibit properties (e.g., amphiphilicity and 
pH-responsiveness) that are useful for increasing controlled delivery efficacy. Formulation 
strategies exploit these properties by using polymers to stabilize drug nanocrystals6,7,8 or 
incorporate drug into amphiphilic nanoparticles.9,10 Perhaps the most straightforward of 
these strategies is the use of a solid dispersion (SD), a mixture of an active pharmaceutical 
ingredient (API) and a polymer excipient. The two components are blended in such a way 
that the API transforms from a thermodynamically stable crystal to a metastable glass. 
Because the glass exists in a higher free energy state relative to the crystal, the API achieves 
a significantly higher aqueous solubility (often by orders of magnitude)11,12,13,14 and greatly 
improved efficacy. Furthermore, solid dispersions may be prepared at a large-scale by 
high-throughput processes like spray drying and hot melt extrusion.15 Due to the versatility 
and scalability of solid dispersions, this formulation strategy has attracted much attention 
from both academic and industrial communities.4,15,16 Nevertheless, a fundamental 
understanding of solid dispersion materials is needed to enable rational SD design. 
In particular, the role of the polymer excipient needs to be clarified. Ideally, the 
polymer prevents the drug from crystallizing—both in the solid-state and in solution—and 
facilitates the dissolution of the drug in aqueous solvent. Thus, the choice of polymer 
significantly influences the physical stability and bioavailability of the API.15,17 
Identification of an appropriate excipient for a particular drug, however, typically requires 
inefficient and expensive trial-and-error experiments.18,19 Expedition of this process is 
hindered by poor understanding of polymer-drug interactions and the metastable state of 
SDs. Moreover, formulation composition, processing conditions, and storage environment 
also affect the effectiveness of the polymer as an excipient. 
In spite of these intricacies, several classes of polymers have been identified as 
effective excipients for a wide variety of drugs. Acrylic and methacrylic polymer excipients 
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may be judiciously designed to incorporate functional groups that interact with the drug. 
Eudragit®, a family of copolymers derived from esters of acrylic and methacrylic acids, 
significantly improved the release of APIs like itraconazole and curcumin.20,21 Because 
Eudragit® copolymers are pH-responsive, they may be used to prevent solid dispersions 
from dissolving in the acidic environment of the stomach.22 Acrylic statistical copolymers 
featuring two, four, or five unique monomers also enhanced the supersaturation of various 
drugs.23,24,25 Unfortunately, acrylates and methacrylates offer poor protection from drug 
crystallization in the solid-state due to the flexibility of the polymers.26  Conversely, 
poly(vinyl pyrrolidone) (PVP), a water-soluble polymer, is commonly used as an excipient 
because its relatively high rigidity (the glass transition temperature is 177 °C) impedes the 
mobility of amorphous drug, thereby inhibiting crystallization.27 The polymer may also 
stabilize amorphous drug through hydrogen bonding between the drug and the carbonyl 
group of PVP.28 Though PVP is highly hygroscopic (absorption of substantial amounts of 
water by the excipient will induce crystallization of drug),29,30 the hygroscopicity of the 
excipient may be reduced by copolymerizing vinyl pyrrolidone with vinyl acetate.31  
While the aforementioned polymers are suitable excipients, cellulosic derivatives—the 
most prominent class of excipients—are especially effective at inhibiting crystallization 
and maintaining supersaturated drug concentrations in solution. These polymers exhibit 
little or no human toxicity because they are not absorbed by the GI tract and undergo 
minimal degradation during digestion. The rigid anhydroglucose backbone of cellulosics 
imparts the polymers with a high glass transition temperature (typically above 100 °C) and 
hinders drug crystallization. While cellulose itself is insoluble in water due to its strong 
tendency to crystallize, the three hydroxyls on each anhydroglucose unit may be partially 
or fully reacted with various molecules to make the derivative soluble in solvent (either 
aqueous, organic, or both) and give specific functionality.32 Hydroxypropyl 
methylcellulose (HPMC), a water-soluble cellulose ether, provides exceptional 
crystallization inhibition and supersaturation enhancement for such drugs as nifedipine, 
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felodipine, and etravirine.33,34,35 Novel cellulose w-carboxyesters (such as cellulose 
adipate, suberate, and sebacate derivatives) can prevent the nucleation and growth of drug 
crystals in solution.36,37,38,39,40 
The most remarkable cellulosic derivative—and perhaps polymer excipient, in 
general—is hydroxypropyl methylcellulose acetate succinate (HPMCAS). As seen in 
Figure 1.1A, the anhydroglucose backbone of the polymer is randomly substituted by five 
different substituents: hydroxyl, methoxyl, hydroxypropyl, acetate, and succinate. These 
moieties make HPMCAS both pH-responsive, due to the ionizable succinate, and 
amphiphilic, due to substituents that are either hydrophobic (methoxyl and acetate) or 
hydrophilic (hydroxyl, hydroxypropyl, and deprotonated succinate). Because HPMCAS is 
amphiphilic, it may be dissolved in the same organic solvent as the drug, unlike HPMC, 
allowing for simpler and more economical processing of spray dried SDs. HPMCAS-based 
SDs typically have longer shelf-life stability than HPMC and PVP-based SDs because the 
HPMCAS is less hygroscopic than the other two polymers. Moreover, HPMCAS regularly 
outperforms other polymers at maintaining supersaturated drug and impeding 
crystallization in solution. For these reasons, HPMCAS is considered to be the premier 
polymer excipient on the market today. 41,42 
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Figure 1.1. (A) Chemical structures of hydroxypropyl methylcellulose acetate succinate 
(HPMCAS), phenytoin, and probucol. The pictured structure of HPMCAS is merely 
illustrative and not representative of the actual substitution pattern. (B) Dissolution 
profiles of SDs featuring HPMCAS as the excipient and either probucol or phenytoin as 
the drug. The targeted drug concentration for both SDs is 1000 µg/mL. Each data point 
and error bar represent the average and standard deviation, respectively, of three 
measurements. HPMCAS maintains the concentration of probucol over 6 hours, but 
cannot stabilize the concentration of phenytoin. 
 
Yet, HPMCAS is not a panacea. The polymer’s effectiveness as an excipient is 
contingent on the identity of drug in the SD. As seen in Figure 1B, HPMCAS can maintain 
a high concentration of the drug probucol for over six hours, but cannot stabilize the drug 
phenytoin for more than 20 minutes. These opposing trends illustrate the need for a better 
understanding of the interactions between polymer and drug to allow for rational SD 
design.  
To that end, the work described in this thesis expands the understanding of polymer-
drug interactions by focusing on nanoscale (<100 nm) characterization of HPMCAS-based 
SDs for numerous poorly-soluble drugs. Though many hypotheses regarding polymer-drug 
interactions invoke nanoscale phenomena, the techniques traditionally used to characterize 
SDs either lack the resolution or sensitivity for probing these length scales and, 
consequently, only allow for incomplete understanding of SD structure-property 
  
6 
relationships. I addressed this shortcoming by developing novel nanoscale techniques for 
characterizing SDs in both the solid-state and during dissolution. These techniques not only 
achieved superior resolution and sensitivity compared to the traditional techniques, but also 
revealed critical information regarding the dissolution enhancement mechanism for SDs. 
The remainder of this chapter first details pertinent background on these three topics: (i) 
synthesis and characterization of HPMCAS, (ii) solid-state characterization of SDs, and 
(iii) solution characterization of SDs. Then, unresolved questions regarding solid 
dispersions and an outline of the dissertation are discussed. 
 
1.2 Background 
1.2.1 Hydroxypropyl methylcellulose acetate succinate (HPMCAS) 
 HPMCAS, first patented by the company Shin-Etsu in 1987,43 is a derivative of 
cellulose, a ubiquitous polysaccharide that is a major component of wood, cotton, and 
plants, and is produced by sea organisms and microorganisms. Cellulose consists of linear 
chains of anhydroglucose units (AGU) connected by b-D-(1®4) linkages. Each AGU has 
three hydroxyls that may undergo both intra- and interchain hydrogen bonding; as a result, 
cellulose is highly crystalline and insoluble in water. To solubilize and functionalize 
cellulose, the hydroxyls may be substituted with moieties (e.g., ethers and esters) that 
disrupt the hydrogen bonding. The bulk and solution properties of these cellulose 
derivatives depend not only the identity of the substituents, but also on the degree of 
substitution (DS), which is the average hydroxyl substitution per AGU of the cellulose 
backbone; it ranges from 0 to 3.32 
HPMCAS features four unique substituents: methoxyl, hydroxypropyl, acetate, and 
succinate. As described in Scheme 1.1, the derivatization of the cellulose backbone is a 
two-step process. First, cellulose pulp is treated with chloromethane, propylene oxide, and 
sodium hydroxide to create HPMC. Second, the intermediate is reacted with acetic 
anhydride and succinic anhydride to form HPMCAS. The two anhydrides may be 
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introduced to the reaction vessel simultaneously or separately. The molar amount of each 
anhydride loaded into the reaction vessel is 1 to 10 times the desired degree of esterification 
of the AGUs.45 The typical DS values for the methoxyl, hydroxypropyl, acetate, and 
succinate substituents range from 1.84–1.92, 0.23–0.26, 0.44–0.70, 0.13–0.43, 
respectively.43 HPMCAS is further subdivided into different grades based on the molar 
ratio of acetate to succinate substituents on the polymer; L grade has a ratio less than 1, M 
grade has a ratio that is approximately 1, and H grade has a ratio that is greater than 1. This 
ratio affects not only the hydrophilicity, but also the pH-responsiveness of the polymer. To 
dissolve the polymer in aqueous buffer, the pH of the solvent must be above 5.5, 6, and 6.8 
for HPMCAS-L, HPMCAS-M, and HPMCAS-H, respectively.44  
 
Scheme 1.1. Synthesis of (A) hydroxypropyl methylcellulose and (B) hydroxypropyl 
methylcellulose acetate succinate. 
 
 
Although the synthesis of HPMCAS is relatively simple, the microstructure of the 
polymer is complex. Like most polysaccharides, HPMCAS has large molecular weight 
dispersity (Đ) due to the natural dispersity of cellulose.32 The four moieties not only add to 
the hydroxyls on the AGU backbone in a random fashion, but may also react with the 
hydroxyl group on the hydroxypropyl substituent to form oligomeric side chains. 
Furthermore, the average molecular weight of commercially produced HPMCAS is much 
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higher than expected, based on the molecular weight of the precursor HPMC measured by 
size-exclusion chromatography. This discrepancy is posited to be caused by aggregation of 
HPMCAS in solution or crosslinking reactions between HPMCAS chains.45 Because these 
heterogeneities make the structure of HPMCAS challenging to characterize, the structure 
of the polymer is still ambiguous.  
The ill-defined complexities of the HPMCAS molecule potentially enable its unique 
solution behavior. By performing molecular dynamic simulations, Xiang et al. predicted 
that water molecules form clusters around the oxygen atoms of HPMCAS.46 Fukasawa et 
al. observed that molecular weight measurements of HPMCAS in aqueous solvent agree 
with the expected values based on the molecular weight of the precursor HPMC, but 
measurements of HPMCAS in organic solvent produced much higher molecular weight 
values. To rationalize this behavior, they posited HPMCAS formed aggregates in organic 
solvent.47 Chen reported unusually high molecular weights of HPMCAS in a mixed solvent 
of aqueous buffer and acetonitrile. Based on this observation, Chen hypothesized that 
HPMCAS formed aggregates in solution due to a heterogeneous distribution of the acetate 
and succinate moieties across the HPMCAS backbone. He also posited that HPMCAS 
underwent a conformation change in solution as the molecular weight increased.48 In 2011, 
Chen et al. identified mixed solvents that minimized the molecular weight and, in theory, 
the tendency to aggregate for HPMCAS in solution.49 Consistent with the SEC studies, 
many researchers presume HPMCAS forms colloids in solution by attributing 
amphiphilicity arguments.41,42,50  
Yet, to the best of my knowledge, no direct evidence of these colloids has been reported 
in the literature. Moreover, none of these studies considered the presence of cross-linked 
HPMCAS. To more accurately elucidate the dissolution enhancement mechanism of 
HPMCAS SDs, a rigorous characterization of HPMCAS in solution is needed. 
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1.2.2 Solid-state characterization of solid dispersions 
The spatial distribution of drug throughout the polymer matrix of an SD 
significantly influences the properties of the material. An SD may potentially exhibit any 
of these three morphologies: (i) a single domain of drug molecularly dissolved in the 
polymer matrix; (ii) phase-separated domains enriched in amorphous drug or polymer; (iii) 
crystalline domains of drug in the polymer matrix. The contemporary SD design approach 
desires intimate mixing between the drug and polymer and considers phase separation and 
crystallization as signs of poor API stability and efficacy.20  
To identify appropriate excipients for various APIs, thermodynamic models have 
been used to predict the miscibility between drugs and polymers. One frequently used 
model is Flory-Huggins theory, which was independently developed by Paul Flory and 
Maurice Huggins in the early 1940s.51,52 It describes the free energy of mixing between a 
polymer and a small molecule, Δ𝐺*, by: 
 Δ𝐺*𝑘𝑇 = 𝜙/𝑁/ ln𝜙/ + 𝜙4 ln𝜙4 + 𝜙/𝜙4𝜒 (1.1) 
 
where 𝑘 is Boltzmann’s constant, 𝑇 is temperature, 𝜙/ is the volume fraction of polymer 
in the blend, 𝑁/ is the degree of polymerization of the polymer, 𝜙4is the volume fraction 
of the small molecule, and 𝜒 is the Flory-Huggins interaction parameter, which quantifies 
the interaction between the two species. Because 𝜒 only considers short-ranged dispersion 
interactions between the two species, it may be expressed as:  
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𝜒 = 𝑉4𝑅𝑇 𝛿4 − 𝛿/ : (1.2) 
 
where 𝑉4 is the molar volume of the small molecule, 𝑅 is the universal gas constant, 𝛿4 is 
the solubility parameter of the small molecule, and 𝛿/ is the solubility parameter of the 
polymer. Based on this equation, 𝜒 ³ 0. Equation 1.2, however, is rarely quantitatively 
reliable for predicting experimental data of SDs because it fails to consider non-dispersion 
forces (e.g., hydrogen bonding and p-p stacking) and non-ideal entropy of mixing. Instead, 
experimentalists typically fit data to an effective interaction parameter, 𝜒;<<, that follows 
the form: 
 𝜒;<< = 𝛼𝑇 + 𝛽 (1.3) 
 
The constants 𝛼 and 𝛽 describe the non-ideal enthalpy of mixing and non-ideal entropy of 
mixing, respectively. For species that are miscible or have favorable non-dispersion 
interactions,  𝜒;<< is 0.45 or lower. Using Flory-Huggins theory, Pajula et al. predicted the 
miscibility or immiscibility between blends of two different drug molecules. For 23 out of 
26 of the blends, the Flory-Huggins model correctly predicted mixing or demixing between 
the two components.53 Tian et al. used Flory-Huggins theory to develop phase diagrams 
for blends of the drug felodipine with either the HPMCAS or Soluplus® as the polymer 
excipient. Based on the phase diagram, they concluded that felodipine was more miscible 
with Soluplus®.54 Tian et al. also used Flory-Huggins to predict the miscibility of 
felodipine-PVP dispersions produced by spray drying and melt extrusion.55  
Despite the literature precedent, the use of Flory-Huggins theory or any 
thermodynamic model to predict the physical stability of SDs is insufficient. Flory-
Huggins theory was derived for systems at equilibrium, not a metastable system like a SD, 
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where the drug is thermodynamically driven to crystallize. Therefore, rigorous solid-state 
characterization needs to be performed to confirm the morphology of a particular SD. 
Identification of SD morphology, however, is non-trivial. If phase separation or 
crystallization occurs, the domains may be smaller than 100 nm because the crystal nucleus 
of a typical API is potentially on the order of 10 nm.5 Yet, sub-100 nm detection is 
challenging for most traditional SD characterization techniques. Furthermore, 
distinguishing between drug and polymer is difficult because both species are composed 
of similar constitutive atoms (i.e., carbon, nitrogen, oxygen). Nevertheless, many 
techniques are used to probe the morphology of solid dispersions, such as wide-angle X-
ray scattering, optical microscopy, calorimetry, dielectric relaxation spectroscopy, solid-
state nuclear magnetic resonance, and atomic force microscopy. The following sections 
detail a broad overview of the application and weaknesses of these techniques for 
characterizing SDs. 
	
1.2.2.1 Wide-angle X-ray Scattering 
Lab-scale wide-angle X-ray scattering (WAXS, also known as X-ray diffraction) is 
the most common tool for detecting crystallinity in SDs. In WAXS, a collimated X-ray 
beam of a specific wavelength irradiates a sample while a detector is rotated around the 
sample stage to collect X-rays that are scattered from the material. This scattering produces 
an X-ray diffraction pattern (Figure 1.2). If the sample is glassy, the pattern will have a 
diffuse shape. This “amorphous halo” is due to the lack of order in the glassy structure; the 
X-rays are scattered over a wide range.  If the sample is crystalline, the pattern will have 
relatively sharp peaks. These Bragg peaks are caused by the long-range order of crystalline 
structures; the X-rays mostly scatter at angles that are related to the arrangement of the 
atoms in the crystal. The intensity of the Bragg peaks relative to the whole diffraction 
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pattern is proportional to the crystalline fraction of the material, while the peak width is 
indicative of the minimum crystal grain size.56 
 
 
Figure 1.2. Wide-angle X-ray scattering patterns of pure phenytoin and SDs with 10 
wt% phenytoin and various HPMC esters of substituted succinates. The scattering 
pattern of phenytoin, which is crystalline, exhibits sharp Bragg peaks, while the 
scattering patterns of the SDs, which contain amorphous phenytoin, each display a broad 
amorphous halo. Adapted with permission from Yin, L.; Hillmyer, M. A. Mol. Pharm. 
2014, 11, 175–185. Copyright 2014 American Chemical Society.57 
 
For SDs, WAXS is typically used to quickly screen API-polymer pairings and 
probe the mechanism of drug crystallization in the polymer matrix. Rumondor studied the 
influence of humidity on the crystallization of the drug felodipine in PVP or HPMCAS 
SDs. Based on changes in the Bragg peak intensity, the authors determined felodipine 
crystallization rates were sensitive to humidity for PVP SDs, but not HPMCAS SDs. They 
hypothesized that felodipine and PVP underwent moisture-induced phase separation, while 
HPMCAS stabilized amorphous felodipine, even at high levels of humidity.58  Chiou 
confirmed the presence of griseofulvin crystals in pulverized dispersions of 
griseofulvin:polyethylene glycol using WAXS. A larger loading of griseofulvin in the 
dispersion led to the formation of larger crystals and, as a result, poorer dissolution 
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enhancement.59 Yamamura et al. characterized the crystallization mechanism for 
griseofulvin. By comparing experimental and simulated diffraction patterns, they 
determined crystallization of the drug occurred over two distinct stages.60 
Although the use of laboratory-scale WAXS is routine, its sensitivity is limited. 
The practical lower limit of detection for WAXS is approximately 5 vol%, so the technique 
cannot distinguish between an SD that contains completely amorphous and one that has 
trace levels of crystallinity (≲ 5 vol%).60 Thus, WAXS may potentially misdiagnose the 
miscibility between drug and polymer. Sensitive techniques are also required for 
elucidating the dissolution enhancement mechanism because trace levels of crystallinity 
can facilitate crystallization in solution.61,62 
 
1.2.2.2 Polarized optical microscopy 
Polarized optical microscopy (POM) may be used to directly image anisotropic 
drug crystals within the polymer matrix of an SD. When light enters an isotropic material, 
which has a uniform index of refraction, it propagates at a velocity that is invariant to the 
material orientation. When light enters an anisotropic material, which has orientation-
dependent indices of refraction, it is refracted into two orthogonal rays that travel at 
different velocities. This phenomenon is known as birefringence. When a birefringent 
crystal (e.g., those with monoclinic, orthorhombic, or tetragonal lattices) is analyzed under 
cross-polarized white light illumination, as is the case with POM, interference between the 
components of the refracted rays that pass through the analyzer produces color contrast 
between the crystal and background.63 
 Because drug molecules typically form anisotropic crystals, POM may be used to 
study a wide variety of APIs. Ghebremeskel et al. characterized the influence of surfactants 
on the physical stability of various SD systems. By using POM and WAXS, they 
determined that the surfactants inhibited crystallization and improved the API stability 
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within the SDs.64 Kestur and Taylor investigated the relationship between drug-polymer 
hydrogen bonding and API crystallization inhibition for felodipine with various polymers. 
By measuring the size of drug crystals within the polymer matrices over a period of two 
days, they correlated the inhibition of crystallization with the presence of hydrogen 
bonding between the species (Figure 1.3).65 
 
 
Figure 1.3. Polarized optical micrographs from undercooled melts of (a) pure felodipine 
and mixtures of 97 wt% felodipine and 3 wt% of (b) PVP, (c) HPMCAS, (d) poly(vinyl 
pyrrolidone-co-vinyl acetate), and (e) poly(vinyl acetate). The scale bar in each image 
represents 100 µm. Adapted with permission from Kestur, U. S.; Taylor, L. S. 
CrystEngComm 2010, 12, 2390. Copyright Royal Society of Chemistry 2010.65 
 
While POM is a versatile technique for characterizing SDs, it cannot be used to 
detect nanosize crystals because the diffraction-barrier limits its spatial resolution to 250 
nm. Therefore, POM provides limited information regarding nucleation or early stages of 
crystal growth.66 
 
 
 
  
15 
1.2.2.3 Thermal analysis 
SDs have complex thermal properties because both drug and polymer excipient 
exist, ideally, as glasses. Unlike a crystalline solid, the structure of a glass (also known as 
an amorphous solid) resembles a liquid; the packing of the molecules lacks long-range 
order. The molecules are also essentially frozen, so that the material does not flow over 
relevant timescales. As a glass is heated over a particular temperature range, the heat 
capacity of the material increases, the density decreases, the molecular relaxations speed 
up, and the material becomes a liquid and flows. This progression is the glass transition, 
while the temperature range at which it occurs is the glass transition temperature (𝑇@). 
During this transition, thermodynamic variables (such as entropy, enthalpy, and volume) 
exhibit a change in slope with increasing temperature. Although this behavior may be 
suggestive of a second-order phase transition, a thermodynamic description of the glass 
transition is not completely appropriate because a glass is a non-equilibrium state; the 
measured value of 𝑇@ is affected by processing, aging, and characterization technique. As 
a result, the glass transition is typically classified as a pseudo second-order transition.5 
For SDs, measurement of Tg gauges the physical stability of a particular 
formulation. Well below Tg, the drug cannot crystallize because both drug and polymer 
molecules do not have sufficient thermal energy to move. Near Tg, the drug may potentially 
phase separate or crystallize because drug and polymer molecular mobilities increase. 
These relaxations, however, are still relatively slow relative to the time scale of 
experimental observation, so the kinetics of phase separation and crystallization are slow. 
Above Tg, the drug has a strong tendency to phase separate or crystallize because the 
molecules may easily move. To minimize the risk of drug crystallization, formulations are 
designed so that the Tg of the drug:excipient blend is 50 °C above the storage temperature. 
The 𝑇@  of a binary blend, 𝑇@,*BC, may be estimated by the expression: 
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ln 𝑇@,*BC = 𝑤E∆𝐶/,E ln 𝑇@,E + 𝑤:∆𝐶/,: ln 𝑇@,:𝑤E∆𝐶/,E + 𝑤:∆𝐶/,:  (1.4) 
𝑤B is the weight fraction, ∆𝐶/,B is the change in heat capacity, and 𝑇@,B is the 𝑇@ of the ith 
component. Assuming ln 1 + 𝑥 ≈ 𝑥, Equation 1.4 may be simplified to form the 
Couchman-Karasz equation: 
 
𝑇@,*BC = 𝑤E𝑇@,E + 𝑤: ∆𝐶/,:∆𝐶/,E 𝑇@,:𝑤E + 𝑤: ∆𝐶/,:∆𝐶/,E  (1.5) 
This equation assumes that the two components only exhibit dispersive interactions and 
that their ideal volumes are additive.17 Other variations of the Couchman-Karasz equation 
have been developed to account specific interactions.67,68 Though these models are not 
quantitatively robust, they do predict that 𝑇@,*BC will be sufficiently larger than the storage 
temperature if the polymer excipient (which has a higher 𝑇@ than the drug) comprises a 
significant weight fraction of the SD, has an exceptionally high 𝑇@, or both. Generally, 
polymers that have stiff backbones (like cellulose derivatives), large rigid side groups, high 
molecular weight, or high polarity have sufficiently high 𝑇@s, though these correlations are 
not completely universal.5 The measurement of 𝑇@  of an SD is also performed to evaluate 
miscibility between drug and polymer. For this “miscibility evaluation”, if an SD exhibits 
only a single 𝑇@, drug and polymer are judged to be miscible. Conversely, if an SD exhibits 
multiple 𝑇@’s, drug and polymer are judged to be immiscible.17  
 The most common method for measuring 𝑇@ of an SD is differential scanning 
calorimetry (DSC). In this technique, a material is placed in an aluminum DSC pan and the 
pan is put on a heating stage alongside an empty reference pan that sits on a separate heating 
stage. The two pans simultaneously undergo a controlled temperature variation. The 
amount and direction of heat flow into the sample pan is adjusted to keep the its temperature 
the same as the reference pan. The measurement of the heat flow reveals the thermal 
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transitions of the material.5 Figure 1.4 shows a DSC trace of HPMCAS. The temperature 
variation of the experiment proceeded in three stages. First, the polymer was heated to an 
elevated temperature that is high enough to erase thermal history. Second, it was rapidly 
cooled to the beginning temperature. Third, the sample was heated again. During this 
second heating cycle, the heat flow exhibited a gradual increase because the heat capacity 
of the material increases. The midpoint of the increase is taken to be the 𝑇@ of HPMCAS. 
While this protocol is commonly used for the 𝑇@ measurement of the pure polymer and, if 
experimentally accessible, pure drug, the 𝑇@ measurement of the SD should be performed 
on the first heating cycle because the influence of thermal history is critical to 
understanding the material properties. DSC may also be used to evaluate drug crystallinity 
and crystallization in SDs. The heat released during crystallization or heat consumed during 
melting appear as exothermic or endothermic peaks, respectively, in the DSC trace. The 
magnitudes of these peaks are related to the fraction of crystalline drug in the sample.5,17 
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Figure 1.4. Differential scanning calorimetry trace of HPMCAS H-grade for a heating 
ramp of 10 °C/min. Only second heating ramp data is shown. The 𝑇@ of this polymer is 
defined as the midpoint of the transition region. This criterion is reliable only if enthalpic 
overshoot is not too large. 
 
 For many SD systems, the 𝑇@ and drug crystallization temperature (𝑇K) overlap. To 
separate these thermal events, modulated differential scanning calorimetry (MDSC) may 
be used. For MDSC, the sample and reference pan undergo a sinusoidal temperature ramp. 
For the material to achieve the required temperature profile, the heat flow for the sample is 
also sinusoidal. The measured heat flow may be deconvoluted into three signals (Figure 
1.5). First, the Fourier transform of the heat flow signal generates a total heat curve, which 
is a facsimile of a conventional DSC trace. Second, the amplitude of the heat flow signal 
may be converted to a reversing heat curve, which accounts for heat capacity changes in 
the material (indicative of a glass transition event). Third, the difference between the total 
and reversing heat curves produces the non-reversing heat curve, which accounts for all 
other thermal events.  
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Figure 1.5. Modulated differential scanning calorimetry traces of a 10 wt% griseofulvin 
and 90 wt% HPMCAS H-grade SD. Data, shifted for clarity, were recorded upon first 
heating using an average temperature heating rate of 1 °C/min, a temperature modulation 
amplitude of 1 °C, and a temperature modulation period of 40 s. The reversing heat curve 
reveals 𝑇@, while the non-reversing curve shows the crystallization temperature and 
enthalpy (𝑇K and ∆𝐻K, respectively) of griseofulvin. 
 
 The use of conventional DSC and MDSC has revealed critical physical properties 
of SDs. Gupta et al. studied the thermal transitions of ternary systems of the drug celecoxib, 
PVP, and the amino sugar meglumine. The 𝑇@ of these ternary blends deviated from 
theoretical predictions, which suggested the drug had favorable interactions with one of the 
other components.69 Janssens et al. studied the influence of the preparation method on the 
ultimate thermal properties of various SD formulations. They observed that film cast SDs 
exhibited phase separation and crystallization at lower temperatures than spray dried SDs.20 
Marsac et al. probed the miscibility of crystalline drugs in various excipients by measuring 
the melting point depression of the drug. Systems that had been previously reported as 
miscible exhibited a significant melting point depression, whereas systems that had been 
reported as immiscible did not. By relating the melting point depression to Flory-Huggins 
theory, the authors also estimated 𝜒 for various drug:polymer pairings.70 
 Although DSC is routinely used to evaluate SDs, its utility is limited because 𝑇@ is 
not a reliable gauge of miscibility and physical stability. Miscible blends may exhibit 
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multiple 𝑇@s, whereas immiscible blends may exhibit a single 𝑇@.71,72,73,74,75 Drugs that have 
identical 𝑇@s can exhibit vastly different tendencies to crystallize from the amorphous state. 𝑇@ is also a poor indicator of the nucleation rate of drug in various polymers.76,77 
Furthermore, similar to WAXS, trace levels of crystallinity are challenging to detect by 
DSC.17  
 
1.2.2.4 Dielectric relaxation spectroscopy 
Although 𝑇@ itself is a poor indicator of crystallization inhibition, the molecular 
motions of the drug and polymer below 𝑇@ may significantly influence the physical stability 
of the glassy drug in the SD. As the temperature of a liquid is cooled towards 𝑇@, the 
viscosity and structural relaxation time (the time that it takes for a molecule to diffuse an 
interparticle distance) increase by orders of magnitude. The temperature dependence of the 
structural relaxation time, 𝜏O, may be described by the Vogel-Fulcher-Tammann model: 
 𝜏O = 𝜏P exp 𝐷𝑇P𝑇 − 𝑇P  (1.6) 𝜏P is the relaxation time constant for the unrestricted material (~ 10–14 s), 𝐷 is the strength 
parameter, 𝑇 is temperature, and 𝑇P is the zero-mobility or Kauzmann temperature. The 
molecular motions that affect 𝜏O  (i.e., molecule translation and rotation) are known as a-
relaxations. These “global” a-relaxations (0.1–100 s) are affected by the diffusion and 
position of neighboring molecules. Glassy materials also exhibit b-relaxations, which are 
much faster than a-relaxations (< 0.1 s) and obey Arrhenius kinetics. These relaxations are 
presumably “local”, but the identity of the processes is not always well understood.5,20,78 
 Both a- and b-relaxations may be probed by dielectric relaxation spectroscopy 
(DRS), where the dielectric properties of a material are measured under the influence of a 
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variable frequency electric field. The material’s response to the electric field is a complex 
dielectric function, 𝜀∗ 𝜔 , that may be expressed as: 
 𝜀∗ 𝜔 = 𝜀′ 𝜔 + 𝜀″ 𝜔  (1.7) 
𝜀′ describes the energy stored by the material and 𝜀" is the energy dissipated by the material. 
These functions may be fit to mathematical models to extract relaxation times.78 Kothari et 
al. used DRS to study the influence of drug loading on the physical stability of 
nifedipine:PVP SDs. They observed that lower drug loadings correlated with longer 𝜏O  
(i.e., a decrease in molecular mobility) and slower nifedipine crystallization rates.79 Mehta 
et al. measured 𝜏O, using DRS, and crystallization time, using synchrotron-sourced WAXS, 
as a function of water absorbed by the SD. For both dry and wet SDs, they determined that 
the crystallization had a power-law relationship with 𝜏O.80,81 
 Though DRS provides deep insight into the physics of glass materials, the 
understanding of the relationship between molecular mobility and SD physical stability is 
primitive. The identity and role of b-relaxations is ambiguous, while interpretation of DRS 
data is also non-trivial. Low frequency data may be obscured by interference from 
conductivity and relaxation events in multi-component blends may overlap.17,78 
 
1.2.2.5 Solid-state nuclear magnetic resonance spectroscopy 
Solid-state nuclear magnetic resonance spectroscopy (SS-NMR) may overcome the 
sensitivity and resolution limitations of WAXS and DSC to provide quantitative structural 
and composition information for SDs. This technique, in which a solid sample is exposed 
to magnetic fields, elucidates intermolecular interactions (such as hydrogen bonding) 
between any two molecular species. Tobyn et al. characterized SDs featuring a novel API 
and PVP by both MDSC and SS-NMR. While MDSC confirmed the two components were 
miscible, SS-NMR revealed that the API engaged in hydrogen bonding with PVP.82 SS-
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NMR may also identify nanostructures within SDs through relaxometry experiments, 
where the relaxation of particular NMR signals are correlated with the domain size of 
heterogeneities in the formulation.83 Aso et al. performed 19F-NMR relaxometry to track 
the crystallization of flufenamic acid in SDs containing PVP or HPMC as the excipient. 
By measuring the spin-lattice relaxation times of the fluorine atoms in the API, they 
determined that PVP was better than HPMC at inhibiting drug crystallization.84 Yuan et al. 
used 1H-NMR relaxometry to evaluate the miscibility of nifedipine:PVP SDs at various 
nifedipine loadings. For nifedipine loadings above 75 wt%, they observed that the drug 
formed amorphous domains 5–20 nm in size.85 
Although SS-NMR probes SDs at the molecular level, adoption of the technique as 
a routine characterization tool is hampered by many challenges. To obtain a sufficient 
signal-to-noise ratio, the acquisition times for the technique are long; single measurements 
may require a run time of 1 week.86 Therefore, SS-NMR is inappropriate for systems that 
undergo structural evolution at timescales shorter than the acquisition time. Furthermore, 
the interpretation of the relaxometry experiments is challenging because the data may be 
obscured by heteronuclear coupling effects.83 
	
1.2.2.6 Atomic force microscopy 
In recent years, many researchers used atomic force microscopy (AFM) techniques 
to qualitatively characterize SD morphology. For AFM, a sharp tip that is connected to a 
cantilever is rastered across a sample surface. Interatomic van der Waals interactions 
between the AFM tip and sample cause the cantilever to bend. The displacement of the 
cantilever correlates with sample height and material properties (e.g., adhesion, modulus, 
and viscoelasticity). Because the AFM tip radius is ~ 10 nm, AFM may resolve structures 
that are tens of nanometers in size.87  
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The high spatial resolution of AFM makes the technique appropriate for studying 
the onset of phase separation or crystallization in SDs. Marsac et al. used AFM to image 
moisture-induced phase separation in felodipine:PVP SDs. When a 50 wt% felodipine SD 
was exposed to a relative humidity of 94% for 1 hr, amorphous drug-rich domains 
approximately 100 nm in size were observed. After 4 hr of exposure, drug crystals 500 nm 
in size were detected.88  
Because imaging alone cannot distinguish between drug and polymer, some 
researchers have used photothermal-induced resonance (PTIR), a related technique that 
couples AFM and infrared spectroscopy, to evaluate local chemical composition. In PTIR, 
a laser irradiates an AFM sample to cause it to mechanically oscillate. By measuring the 
oscillations with the AFM cantilever, local composition and topology may be elucidated.89 
Using PTIR, Qi et al. unambiguously identified drug crystals in felodipine:Eudragit SDs 
that were processed by melt extrusion. In related work, Li et al. detected phase separated 
regions of amorphous telaprevir, ranging from 50 to 100s of nanometers in size, within 
matrices of various polymers (Figure 1.6). The spatial resolution of PTIR, however, is only 
~ 100 nm, making this technique inappropriate for resolving the onset of phase separation 
or crystallization.90,91 
 
 
Figure 1.6. (A) AFM topological map of a telaprevir:HPMC 6:4 w/w SD. (B) Local 
infrared spectra from continuous or discrete domains in the film. Based on the 
differences in the spectra, the authors deduced that the dispersed phases were telaprevir 
rich, while the continuous phases were telaprevir poor. Adapted with permission from 
Li, N.; Taylor, L. S. Mol. Pharm. 2016, 13, 1123–1136. Copyright American Chemical 
Society 2016.91 
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1.2.3 Solution characterization of solid dispersions 
SDs are designed so that upon dissolution the drug becomes supersaturated in the 
gastrointestinal fluid, thereby driving rapid absorption of drug into the blood stream. 
Supersaturation, 𝑆, is defined as: 
 𝑆 = 𝐶𝐶K\]^ (1.8) 
𝐶 is the concentration of drug is the supersaturated solution and 𝐶K\]^ is the solubility of 
the thermodynamically stable crystal. SDs achieve supersaturation because the drug in the 
formulation exists as a glass, which has a higher apparent solubility relative to the crystal. 
Although true equilibrium between glassy drug and drug dissolved in solution cannot exist 
because the glass is not the lowest free-energy state, a metastable partitioning of drug 
between the two phases is still obtained. The apparent solubility of the glassy drug, 𝐶@_`^^ , 
may be estimated by: 
 𝐶@_`^^ = 𝐶K\]^𝛾 expΔ𝐺@→K𝑅𝑇  (1.9) 
Δ𝐺@→K = −∆𝐻<𝑅 𝑇* − 𝑇𝑇*𝑇  (1.10) 
𝛾 is the activity coefficient of glassy drug saturated with water (ranges from 0.5-1 for 
various drugs),12 Δ𝐺@→K is the free energy different between glassy and crystalline drug, ∆𝐻< is the enthalpy of fusion of crystalline drug, 𝑇* is the melting temperature of 
crystalline drug, 𝑇 is temperature, and 𝑅 is the universal gas constant. Because 𝐶@_`^^  is 
significantly larger than 𝐶K\]^, SDs can achieve large values of 𝑆.12,13,14 Supersaturation, 
however, also induces crystallization of drug, so an optimal excipient for an API needs to 
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simultaneously stabilize glassy drug and inhibit crystallization. This stability of these 
phases affects not only the behavior of drug and polymer in aqueous solution, but also the 
release of both species from SD particles. The following sections discuss the physics and 
characterization of these stages of SD dissolution. 
 
1.2.3.1 Dissolution of drug and polymer from SD particles 
 The release of drug from an SD particle is a fairly complex process. When an SD 
particle is submerged in aqueous solvent, it imbibes water molecules. Unlike the 
dissolution kinetics of particles of pure drug, which is limited by the diffusion and 
convection of the drug in water, the dissolution kinetics of SDs is controlled by both drug 
mass transfer and dissolution of the polymer matrix. Polymer dissolution, illustrated in 
Figure 1.7 for a slab of hydrophilic glassy polymer, occurs in three stages. (i) Water 
penetration causes the polymer to simultaneously swell and devitrify. The gel-water 
interface (front S) moves outward, while the gel-glassy polymer interface (front R) moves 
inward. (ii) Polymer chains begin to disentangle at the gel-water interface and dissolve into 
solution when the water concentration in the swollen polymer exceeds a critical 
concentration. The rate of disentanglement is affected by both molecular weight and the 
reptation time of the polymer chains. Both fronts S and R retreat towards the center of the 
film. (iii) Polymer chains at the gel-water interface continue to disentangle and dissolve 
after the glassy core disappears. Front S continues to move inward until all the polymer is 
dissolved.92 
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Figure 1.7. Schematic of the dissolution of a slab of hydrophilic glassy polymer. (A) 
Slab before immersion in solvent. L is the initial thickness. (B) Initial swelling of 
polymer. Solvent swelling causes the gel-solvent interface to move outwards (front S), 
while devitrification leads to the gel-glassy polymer interface to move inwards (front R). 
(C) Disentanglement of polymer from gel-solvent interface. Both fronts S and R move 
inwards. (D) Depletion of glassy polymer. Front S moves inward until all polymer 
dissolves. Adapted with permission from Narasimhan, B.; Peppas, N. A. J. Pharm. Sci. 
1997, 86, 297–304. Copyright Wiley Periodicals and the American Pharmacists 
Association.92 
 
 The coupled rates of dissolution for drug and polymer influence the ultimate 
dissolution profile of the drug. Faster dissolution of polymer relative to drug may also cause 
enrichment of drug at the dissolution interface and, consequently, crystallization.93 
Furthermore, high drug loadings decrease the dissolution rate of SDs.94,95,96 Although 
several mathematical models have been developed for predicting the dissolution rate of 
drug from polymer matrices,92,97,98,99 the influence of drug:polymer interactions on the 
dissolution rate is not fully understood. 
 
1.2.3.2 Phase behavior of SDs during dissolution 
For SD formulations that target a concentration of drug above the crystalline 
solubility, release of drug from SD particles during dissolution will cause the solution to 
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be supersaturated. However, studies of the phase behavior of drug and polymer in 
supersaturated solutions were rare until the late 2000’s. In 2008 and 2009, Curatolo et al. 
published two studies focused on HPMCAS SDs. To rationalize the performance of 
HPMCAS as an excipient, the authors claimed the polymer formed nanosized aggregates 
with drug. They hypothesized that these aggregates replenished the concentration of fully 
dissolved drug in solution. In spite of the claims by the authors, these two publications did 
not include any characterization of the structures in the dissolution media.41,42  
In 2012, Taylor et al. developed a new assay for characterizing SD dissolution 
media using UV extinction. By irradiating the sample with UV light at a non-absorbing 
wavelength and measuring light transmission, they discovered the formation of structures 
in the dissolution media for a variety of SD systems.100,101,102,103,104 UV extinction, 
however, could not distinguish between amorphous structures and crystalline structures. 
To complement these studies, Taylor et al. developed a fluorescence spectroscopy assay 
for characterizing SD dissolution. This technique involves the addition of a fluorophore 
that interacts with amorphous drug (but not crystalline drug) in the dissolution media. By 
simultaneously monitoring both light transmission through the solution and the emission 
spectra of the sample, they determined that many SD systems formed amorphous drug-rich 
nanodroplets. They observed that these nanodroplets only formed when the concentration 
of drug in solution surpassed the glassy drug solubility (Figure 1.8).101,105,106   In agreement 
with the claims by Curatolo et al., Taylor proposed that these nanodroplets serve as 
reservoirs that maintain the concentration of fully dissolved drug. The stability of the 
nanodroplets was contingent on the drug:polymer pairing and the structures typically 
coarsened over time. Furthermore, drug was removed from solution by crystallization, 
which led to accelerated depletion of the nanodroplets.16 Although polymers are recognized 
as necessary for inhibiting nanodroplet coalescence and drug crystallization, their 
interaction with drug during dissolution is still not well understood. Additional studies are 
needed to resolve this mechanism.  
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Figure 1.8. UV extinction and fluorescence data for glassy phenylbutazone in 
phosphate-buffered saline. When the concentration of the drug exceeded ~ 50 µg/mL, 
UV extinction detected the formation of structure, while fluorescence confirmed the 
structure was amorphous. Based on the data, the authors concluded the drug formed 
amorphous nanodroplets in solution. Adapted with permission Almeida e Sousa, L.; 
Reutzel-Edens, S. M.; Stephenson, G. A.; Taylor, L. S. Mol. Pharm. 2015, 12, 484–495. 
Copyright American Chemical Society.105  
 
1.3 Unresolved questions and dissertation outline 
 Although physical stability and dissolution performance are contingent on 
nanoscale phenomena, the tools routinely used to characterize SDs lack the spatial 
resolution and sensitivity for evaluating these properties. Correspondingly, reports of SD 
characterization often provide unclear and conflicting interpretations of structure-property 
relationships. For example, the relationship between SD morphology and dissolution is 
ambiguous. Do trace levels of crystallinity or phase separation significantly diminish 
solubility enhancement? How can trace levels of crystallinity or phase separation be 
detected? Furthermore, the behavior of drug and polymer during SD dissolution is not well 
understood. Some reports claim drug forms amorphous aggregates in solution, but what is 
their structure? Do all drugs form aggregates, or only some? What is the role of the polymer 
in forming and sustaining these aggregates? 
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To address the unresolved questions, the goal of the work in this thesis is to elucidate 
structure-property relationships of SDs by directly evaluating their nanoscale properties. I 
developed several SD characterization tools that achieved spatial resolutions and 
sensitivities superior to those of the traditional techniques. Using these novel tools, we 
discovered that the stability and performance of HPMCAS SDs are directly controlled by 
their nanoscale structures. This insight reveals crucial steps of the dissolution enhancement 
mechanism and will ultimately guide the efforts of the pharmaceutical community in 
establishing design principles for SDs. The following chapters discuss these findings in 
detail: 
 
• Chapter 2 describes the materials and methods for all subsequent chapters. 
 
• Chapter 3 focuses on the development of transmission electron microscopy and 
electron diffraction as tools for detecting trace amounts of crystalline drug within 
the polymer matrix of SDs. 
 
• Chapter 4 explores the use of energy-dispersive X-ray spectroscopy as a potential, 
but ultimately limited, technique for mapping the spatial distribution of drug 
throughout SDs. 
 
• Chapter 5 chronicles the development of electron energy-loss spectroscopy as a tool 
for quantifying, with high sensitivity and < 100 nm spatial resolution, concentration 
of drug and polymer in spin-coated SDs. 
 
• Chapter 6 reports the use of cryogenic transmission electron microscopy and small-
angle X-ray scattering for characterizing the dissolution media of HPMCAS SDs. 
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I discovered that the dissolution profiles of these SDs directly correlates with the 
presence of nanoscale structures in solution. 
 
• Chapter 7 discusses the implications of the studies in the dissertation and proposes 
possible future directions. 
 
• The appendices include experimental data not featured in the main chapters. 
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Chapter 2: Materials and methods 
 
 
2.1 Introduction 
This chapter details the hydroxypropyl methylcellulose acetate succinate 
(HPMCAS) samples, solid dispersion (SD) preparation methods, and characterization 
techniques used for the dissertation studies. The characterization techniques described in 
this chapter include wide-angle X-ray scattering (WAXS), modulated differential scanning 
calorimetry (MDSC), transmission electron microscopy (TEM), electron diffraction, 
energy-dispersive X-ray spectroscopy (EDS), electron energy-loss spectroscopy (EELS), 
cryogenic transmission electron microscopy (cryo-TEM), dynamic light scattering (DLS), 
static light scattering (SLS), and small-angle X-ray scattering. 
 
2.2 Hydroxypropyl methylcellulose acetate succinate samples 
 All HPMCAS samples were provided by The Dow Chemical Company under the 
trade name AFFINISOL™. Similar to HPMCAS produced by Shin-Etsu, AFFINISOL™ 
is sub-divided into different grades based on the molar ratio of acetate to succinate 
moieties. 716 grade has a ratio that is less than 1, 912 grade has a ratio that is approximately 
1, and 126 grade has a ratio that is greater than 1. Table 2.1 specifies the grade, molar mass, 
and weight percent of acetate and succinate moieties, as measured by Dow, for the three 
different HPMCAS batches used for the studies described in this dissertation. 
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Table 2.1 Grade, molar mass, and acetate and succinate composition of AFFINISOL™ 
HPMCAS batches used for dissertation studies. Molar mass was measured by size-
exclusion chromatography with a multi-angle light scattering detector. Weight percents of 
methoxyl and hydroxypropyl moieties for all batches were 24 and 8 %, respectively. 
    Weight percent [%] 
Chapter Grade Mn 
[kg/mol] 
Đ Methoxyl Hydroxy-
propyl 
Acetate Succinate 
3 & 4 126 32 3.4 24 8 14 6 
5 126 80 2.1 24 8 12 7 
6 912 60 24 24 8 10 11 
 
2.3 Preparation of solid dispersions 
 To prepare SDs, targeted amounts of drug and HPMCAS were first dissolved in 
tetrahydrofuran to form a solution with a total solids loading of 2 wt%. The precursor 
solution was then processed by either spray drying (Chapters 3, 4, and 6) or spin coating 
(Chapter 5). For spray drying, the solution was spray dried by a mini spray dryer (Bend 
Research) using a nitrogen flow rate of 12.8 L/min, an inlet temperature of 68 °C, and a 
solution flow rate of 0.65 mL/min. The outlet temperature fluctuated between 24 and 27 
°C. SD powder was recovered from filter paper placed in the outlet of the spray dryer. For 
spin coating, an approximately 10 µL drop of the precursor solution was filtered through a 
0.2 µm PTFE syringe filter and placed onto a 200-mesh copper TEM grid that was 
supported by a 1 cm × 1 cm silica wafer. The TEM grids had an ultrathin (nominally 5 nm) 
amorphous carbon film to support the SD. The samples were spun at 2500–3000 for 1 min. 
For both types of processing, the freshly-prepared SD was dried under reduced pressure at 
ambient temperature for at least 12 h and stored in a desiccator under reduced pressure at 
ambient temperature until use. 
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2.4 Wide-angle X-ray scattering 
 WAXS was used to evaluate crystallinity of drug in SDs (Chapter 3 and Appendix 
D.2). For ambient temperature measurements, approximately 50 mg of sample was loaded 
into a 0.5 mm-deep zero-background sample holder and analyzed using a Bruker-AXS 
D5005 diffractometer with a Cu Kα source (λ = 1.54 Å). For in situ WAXS measurements 
(Chapter 3), approximately 50 mg of sample was loaded into a 0.8 mm-deep, zero-
background, temperature-controlled sample holder and characterized by a Bruker D8 
Discover diffractometer with a Cu Kα source filtered with a nickel foil (λ = 1.54 Å). The 
holder was placed in a sample chamber and immersed under nitrogen gas at a flow rate of 
15 mL/min. For both types of measurement, diffraction patterns were collected from a 
scattering vector (q) range of 4–28 nm–1 with a scan rate of 0.01 nm–1s–1. The overall 
crystallinity (vol%) was calculated by dividing the area of the Bragg peaks after 
background subtraction by the total area of the diffraction pattern. The crystal grain size 
was calculated using the Scherrer equation, a routine procedure.107 
 
2.5 Modulated differential scanning calorimetry 
 Thermal properties of various drugs, HPMCAS, and SDs were evaluated by MDSC 
using a Discovery DSC (TA Instruments). 5–8 mg samples were put inside TzeroTM 
aluminum pans with standard lids. While immersed under nitrogen gas at a flow rate of 50 
mL/min, each sample was heated from 0 to 160 °C using an average temperature heating 
rate of 1°C/min, a temperature modulation amplitude of 1 °C, and a temperature 
modulation period of 40 s. During the heat cycle, total, reversing, and non-reversing heat 
flow curves were measured. The glass transition temperature (Tg) was determined from the 
reversing heat flow curve, and the crystallization temperature and enthalpy (Tc and DHc) 
were estimated from the non-reversing heat flow curve. All samples were analyzed by 
MDSC in triplicate. 
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2.6 Transmission electron microscopy (TEM) 
 A major aspect of this dissertation is the use of transmission electron microscopy 
(TEM) techniques to evaluate structure-property relationships of SDs at the nanoscale. To 
provide context for the dissertation studies, theory and application of TEM is detailed in 
the following sections. 
 
2.6.1 Basic TEM theory 
 TEM is a workhorse characterization tool for nanoscale materials (defined as 
materials that have at least one dimension roughly 1 to 100 nm in size). The usefulness of 
the technique stems from the wave-like characteristics of the electron. The spatial 
resolution—i.e., the minimum distance in which two separate objects may be 
distinguished—of both optical and transmission electron microscopy is proportional to the 
wavelength of the incident radiation. Because wavelengths of visible light are hundreds of 
nanometers, the best spatial resolution physically achievable by optical microscopy is ~ 
250 nm, insufficient for resolving nanoscale objects. TEM, however, may theoretically 
resolve atomic detail because the electrons used in the technique, whose kinetic energies 
are ³ 100 kV, have picometer wavelengths. Although lens aberrations may inhibit full 
atomic resolution, TEM easily resolves nanoscale structures.108 
 Figure 2.1 displays a simplified ray diagram of a transmission electron microscope. 
The incident electron beam is produced by an electron source and passes through electron 
lenses and a condenser aperture for collimation (not shown). When the beam impinges the 
sample, some incident electrons scatter from the electron cloud and nucleus of the 
constituent atoms. Scattering may be elastic (electrons do not lose kinetic energy) or 
inelastic (electrons transmit energy to the sample). The scattering angle of the electrons is 
related to the microstructure of the material; scattering from an amorphous material will 
occur over a broad range of angles, whereas scattering from a crystal will peak at discrete 
angles contingent on the arrangement of atoms in the sample. Inelastic scattering may also 
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cause the sample to emit other forms of radiation (e.g., X-rays, secondary electrons, Auger 
electrons). These signals are passed through a series of optics to form an image, scattering 
pattern, or spectrum. This array of information projected from a TEM sample enables 
rigorous characterization of nanostructured materials.108 
 
 
Figure 2.1. Simplified ray diagram of the electron beam in a transmission electron 
microscope.  
 
2.6.2 TEM imaging and electron diffraction 
 TEM image interpretation relies on evaluating contrast, the difference in intensity 
between two adjacent distinct regions. For amorphous organic samples, contrast typically 
results from variations in the mass and thickness of the sample; thicker or denser regions 
of the sample cause the incident electrons to scatter more because the electrons encounter 
more atoms. Thus, the resulting scattering pattern is comprised of two types of beams: (i) 
the direct beam and (ii) scattered beam. An objective aperture is placed in the beam path 
so that only the direct beam passes to the detector. In the resulting “bright-field” image, 
the darker areas represent thicker or denser regions (Figure 2.2). 
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Figure 2.2. Bright-field TEM image of 10 wt% griseofulvin and 90 wt% HPMCAS 126 
SD particles. 
  
Unlike amorphous samples, the electron scattering pattern of a crystalline sample 
contains sharp spots produced by Bragg diffraction (see Figure 2.3B). Not only do sharp 
diffraction spots confirm a sample is at least partially crystalline, but also the reflections 
may be indexed to verify or elucidate the crystal structure and orientation. Analysis of 
electron diffraction patterns is analogous to the analysis of X-ray diffraction patterns. By 
placing the objective aperture over a reflection so that only specific diffraction electrons 
pass to the detector, crystalline regions of the sample may be imaged. In the “dark-field” 
TEM image in Figure 2.3C, the intensely white domains represent crystals that have an 
orientation that satisfies Bragg’s law with the electron beam. The grey and dark regions 
may be amorphous or they contain crystals that have an orientation that does not satisfy 
Bragg’s law with the beam.108 
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Figure 2.3. (A) Bright-field TEM image, (B) electron diffraction pattern, and (C) dark-
field TEM image of a spin coated griseofulvin film. Red circle in (B) represents 
approximate position of objective aperture during the collection of (C). 
  
 Although the main utility of TEM is collection of a diffraction pattern and image 
from the same region of interest, the influence of beam damage must be considered. Unlike 
hard materials, which are fairly resistant to beam damage, soft matter (such as the organic 
molecules and polymers studied in this dissertation) are very sensitive to electron dosage. 
Electron irradiation may cause incipient radical formation, leading to irreversible chemical 
changes and destruction of crystallinity in the material. Figure 2.4 illustrates this effect of 
beam damage on a spin coated film of phenytoin. After a cumulative beam dosage of 1000 
e-/nm2, the electron diffraction pattern exhibited intense diffraction spots. After a dosage 
of 26000 e-/nm2, however, the diffraction spots disappeared and only diffuse scattering was 
observed. Because soft matter is sensitive to beam damage, electron dosage must be 
carefully minimized to preserve the microstructure of the pristine sample. 
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Figure 2.4. Electron diffraction pattern of a spin coated phenytoin thin film after a 
cumulative electron dose of (A) 1000 and (B) 26000 e-/nm2. 
 
2.6.5 Scanning TEM (STEM) and high-angle annular dark-field (HAADF) imaging 
 The preceding sections detailed imaging and electron diffraction for conventional 
TEM, in which a parallel and wide beam (relative to the size of the region of interest) 
irradiates the sample. Alternately, bright- and dark-field images may be collected using 
scanning transmission electron microscopy (STEM), in which a narrow collimated electron 
probe (~1 nm in diameter) rasters across a region of interest. Instead of placing an objective 
aperture in the beam path, the bright- and dark-field signals are collected by separate 
detectors (see Figure 2.5). STEM also offers a third mode of image collection: high-angle 
annular dark-field (HAADF) imaging. For HAADF imaging, contrast arises from mass-
thickness and atomic number variations. Another advantage of STEM is that the narrow 
electron beam diameter allows sampling of structural features smaller than 10 nm in size, 
which is necessary to achieve nanoscale spatial resolution for EDS and EELS. Many 
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modern-day transmission electron microscopes are capable of performing both 
conventional TEM and STEM.108 
 
 
Figure 2.5. Comparison of electron beam optics for conventional TEM and STEM. For 
conventional TEM, the objective aperture may be shifted to collect either a (A) bright-
field (BF) TEM image or (B) a dark-field (DF) TEM images. For STEM, separate 
detectors record either (C) bright-field STEM images or (D) annular dark-field (ADF) 
STEM images. Adapted from Williams, D.; Carter, C. Transmission Electron 
Microscopy, 2nd ed; Springer: Boston, 2009. Copyright Spinger Science.108 
 
2.6.6 Energy dispersive X-ray spectroscopy 
 Although they are routine characterization techniques, TEM imaging and electron 
diffraction are limited. Imaging forms 2D projections of 3D samples, which may cause 
ambiguous or incorrect evaluation of nanostructure. Electron diffraction patterns may 
contain artifacts caused by crystal defects that obscure interpretation of the crystallographic 
properties of a material. To overcome these shortcomings, analytical electron microscopy 
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techniques, which characterize secondary signals emitted by the TEM sample, may be used 
to reveal the chemical composition of a material with high spatial resolution. 
 The most important secondary signal emitted by a TEM sample is X-ray emission. 
As an incident electron passes through a material, it penetrates the electron cloud of various 
atoms. If the incident electron interacts with a core electron and transfers a critical amount 
of energy, the core electron becomes excited and is ejected into an unfilled energy level, 
leaving behind an electron hole in the inner shell. To return the atom to its ground state, an 
outer-shell electron may relax into the hole in the inner-shell. This relaxation results in the 
emission of various photons, such as an X-ray, with an energy that is “characteristic” of the 
ionized atom. The emitted X-rays may be collected by an energy dispersive X-ray 
spectroscopy (EDS) detector that sits above the TEM sample. 
 Figure 2.6 features an EDS X-ray spectrum of griseofulvin. The spectrum contains 
four peaks produced by constituent atoms of the molecule: carbon, oxygen, and chlorine. 
The chlorine peaks (Ka and Kb refer to different types of transitions) serve as characteristic 
tags that allow for the molecule to be spatially mapped within a SD particle (see Chapter 
5). EDS spectra may also be quantitatively analyzed to calculate the local composition of 
a material. The weight concentration ratio of arbitrary elements A and B, 𝐶c and 𝐶d, are 
related to the peak intensities by the Cliff-Lorimer equations: 
 𝐶c𝐶d = 1𝑘cd 𝐼c𝐼d (2.1) 
𝑘cd = 𝜎𝜔𝑎 c 𝑀c𝜎𝜔𝑎 d 𝑀d (2.2) 
 𝐼B is the characteristic peak intensity for the ith element, 𝑘cd is the Cliff-Lorimer factor, 𝜎 
is the ionization cross-section, 𝜔 is the fluorescence yield, 𝑎 is the relative transition 
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probability, and 𝑀B is the molecular weight. 𝜎 and 𝜔 may be approximated by the 
equations: 
 
𝜎 = 𝜋𝑒k𝑏^𝑛^𝐸P𝐸K ln 𝑐^𝐸P𝐸K  (2.3) 𝜔 = 𝑍k𝜁 + 𝑍k (2.4) 
 𝑒 is electron charge, 𝐸P is electron beam energy,  𝐸K is ionization energy, 𝑛^ is number of 
electrons in the ionization subshell, 𝑏^ and 𝑐^ are ionization constants, 𝑍 is atomic number, 
and 𝜁 is a fluorescence constant.108  
 
 
Figure 2.6. Experimental EDS spectrum and chemical structure of griseofulvin. 
Characteristic peaks are observed for carbon, oxygen, and chlorine. Ka and Kb refer to 
different types of electron transitions. 
 
2.6.7 Electron energy-loss spectroscopy 
 Inelastic scattering may also be studied by directly evaluating the transmitted 
electron beam using electron energy-loss spectroscopy (EELS). In this technique, the 
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transmitted beam first passes through a magnetic prism that deflects the electrons. Because 
the deflection angle of the electron is inversely proportional to its kinetic energy, viz. speed, 
the magnetic prism separates the electron beam similar to how a glass prism disperses white 
light into a rainbow. The dispersed beam then enters an EELS spectrometer. While EDS 
only evaluates composition, EELS may elucidate composition, chemical bonding, and 
electronic properties. EELS also achieves better signal-to-noise than EDS because the 
transmitted electron beam has excellent counting statistics, whereas the rarity of X-ray 
emission from a TEM sample causes EDS counting statistics to be poor.108,109 
 Figure 2.7 is an EELS spectrum from a thin film of griseofulvin. The spectrum 
contains several pieces of unique information. The peak at 0 eV is the zero-loss peak, which 
is created by electrons that undergo only elastic scattering or no scattering at all. The area 
between 5 and 50 eV, known as the low-loss regime, assesses electrons that interacted with 
outer-shell electrons in the material. The intensities in zero-loss peak and low-loss regime 
are related to sample thickness by: 
 𝑡 = 𝜆/ ln 1 + 𝐼tt𝐼utv  (2.5) 𝜆/ = 2𝑎P𝑚P𝑣:𝐸v ln 1 + 𝛽: 𝜃:  (2.6) 
 𝜆/ is the mean free path length of inelastic scattering, 𝐼tt is the integrated intensity of the 
deconvoluted low-loss EELS spectrum, and 𝐼utv is the integrated intensity of the zero-loss 
peak spectrum, 𝑎P is the Bohr radius, 𝑚P is the rest mass of an electron, 𝑣 is the velocity 
of the incident electron (modified to account for relativistic effects), 𝐸v is the plasmon 
energy, 𝛽 is the collection semi-angle, and 𝜃 is the plasmon scattering angle. For a 
composite material (such as a polymer blend or a SD), a multiple least-square (MLS) 
analysis may be used to estimate composition from the low-loss regime. This analysis, 
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which assumes the low-loss spectrum of the composite is a linear combination of the pure 
species, may be described by: 
 𝑆K{*/ = 𝑎B𝑆BB  (2.7) 
𝑎B = 𝑤B𝜉B 𝑀B𝑤B𝜉B 𝑀BB  (2.8) 
 𝑖 is the index of each component, 𝑎B is a fitting coefficient, and 𝑆B is the reference spectra 
of the pure drug, 𝑤B is the weight fraction, 𝜉B is the inelastic scattering cross section, and 𝑀B is the molecular mass of the pure species.110,111,112 The area past 50 eV, known as the 
high-loss regime, features ionization “edges” created by beam interactions with the core 
electrons. Similar to peaks in an EDS spectrum, ionization edges may be analyzed to 
evaluate elemental composition.108,109 
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Figure 2.7. Experimental EELS spectrum and chemical structure of griseofulvin. 
Appearance of p-p* transition is consistent with aromatic structure of the molecule. 
 
2.6.8 Cryogenic transmission electron microscopy (cryo-TEM) 
 The high-vacuum environment of a TEM forbids the loading of most liquid samples 
into the microscope. While there have been recent advances in imaging liquids in situ using 
flow-cell holders,113 the most practiced strategy for imaging complex fluid nanostructure 
is thermal fixation. In this method, a small volume of liquid (< 10 µL) is placed on a TEM 
grid. The grid is blotted by filter paper to remove excess liquid and subsequently plunged 
into a cryogen (e.g., liquid ethane, nitrogen, or helium). Because plunging cools the grid at 
a rate of ~100,000 K/s, the liquid does not crystallize, which would destroy the fluid 
structure, but instead vitrifies so that the sample retains its original structure. The sample 
is then placed into a cryo-transfer holder maintained at cryogenic temperatures and directly 
imaged. While cryo-TEM is a powerful technique, the sample preparation process and 
microscope itself may introduce several artifacts that complicate image interpretation. Ice 
or solvent crystals may form due to incomplete vitrification or poor temperature control. 
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The cryogenic temperature of the holder may also induce deposition of water vapor or 
hydrocarbon contaminants onto the sample surface.114 
 
2.6.9 TEM sample preparation and instrumentation 
 TEM imaging, electron diffraction, and EELS measurements were performed using 
a FEI Tecnai G2 F30 cryogenic transmission electron microscope at an accelerating voltage 
of 300 kV. Crystal detection samples were prepared by spreading a small amount of SD 
from a spatula onto a 300-mesh copper TEM grid that had either a lacey carbon or a thin 
(15–25 nm) amorphous sheet substrate. EELS samples were prepared using the spin 
coating method described in Section 2.3. 
 For the crystal detection measurement (Chapter 3), the sample was cooled to –180 
°C using a cryogenic sample holder filled with liquid nitrogen to reduce the rate of beam 
damage. Electron diffraction patterns, dark-field TEM images, and bright-field TEM 
images were collected under low-dose conditions to preserve the sample crystallinity. 
Specifically, particles in a region of interest (ROI) were inspected in bright-field TEM at 
low magnification (4700×) using an electron dose rate of ≲ 10 e–/nm2s. Alignments at a 
higher magnification (39,000×) were executed on sacrificial areas far removed from the 
desired ROI. A selected-area aperture was introduced into the electron beam path to reduce 
the sampled ROI to an area of ~ 1 µm2. Selected-area electron diffraction patterns of the 
ROI were recorded under an electron dose rate of ~ 50 e–/nm2s. Dark-field TEM images 
were collected after centering the objective aperture over selected Bragg peaks in the 
electron diffraction pattern. Bright-field TEM images were captured after centering the 
objective aperture over the direct electron beam. Electron diffraction patterns were indexed 
using the DiffTools plug-in for Gatan DigitalMicrograph.115 Single crystal diffraction 
patterns of various drugs were simulated using Web Electron Microscopy Applications 
Software.116 
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 For drug and HPMCAS concentration measurements (Chapter 5), EELS spectra 
were collected in STEM mode using a post-column Gatan Image Filter. Radiation damage 
was minimized using the same low-dose condition strategy as the crystal detection 
measurements. The electron beam energy distribution, defined as the zero-loss peak full-
width at half maximum, was 0.9 eV. EELS spectra were collected from ROIs by rastering 
the electron beam over an area of a chosen size for a collection time of 10 s. For collection 
area sizes of 200 nm × 200 nm, 100 nm × 100 nm, and 50 nm × 50 nm, the electron dosage 
was 2800, 11000, and 46000 e–/nm2, respectively. HAADF STEM images were recorded 
after EELS spectra acquisition. Collection of conventional TEM EELS spectra is described 
in Appendix C.2. EELS spectra were analyzed using custom-made Matlab scripts. 
 EDS measurements (Chapter 4) were implemented using a FEI Tecnai G2 F30 
transmission electron microscope at an accelerating voltage of 300 kV in STEM mode. 
Samples were made by sprinkling SD powder onto a 300-mesh copper TEM grid with a 
lacey carbon substrate. EDS spectra were collected at acquisition times of 10 s. Spectrum 
map data were recorded by collecting EDS spectra from a ROI in a grid pattern where each 
lattice point was separated by 10 nm. Spectrum maps were analyzed using ImageJ. 
 Cryo-TEM samples of dissolution media were made using a FEI Vitrobot Mark III 
automated vitrification device. Glow discharge was applied to a 200-mesh copper TEM 
grid with a lacey carbon support film to increase the surface energy of the grid. The grid 
was then placed into the sample chamber of the vitrification device, which had a relative 
humidity and temperature of 100% and 26 °C, respectively. SD dissolution was initiated 
using the method described in Section 2.7. After centrifugation of dissolution media at 
various time points, a 2 µL aliquot of the supernatant was collected and deposited onto the 
aforementioned TEM grid. The grid was then immediately plunged into a pool of liquid 
ethane to vitrify the dissolution media. Vitrified samples were stored at cryogenic 
temperature until imaging. Cryo-TEM imaging and electron diffraction were accomplished 
using a FEI Tecnai Spirit BioTWIN transmission electron microscope with an accelerating 
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voltage of 120 kV. The temperature of the sample during imaging was maintained between 
–179 to –175 °C.   
 
2.7 Microcentrifuge dissolution and solubility assays 
 For dissolution measurements, a SD was loaded into a 1.5 mL microcentrifuge tube. 
Phosphate-buffered saline (PBS, 82 mM sodium chloride, 20 mM sodium phosphate 
dibasic, 47 mM potassium phosphate monobasic, pH 6.5) at 37 °C was added to the 
microcentrifuge tube to achieve the desired targeted drug concentration (e.g., to achieve a 
concentration of 1000 µg/mL, 12 mL of PBS was added to 12 mg of 10 wt% phenytoin 
SD). The sample was then mixed in a vortex mixer for 1 min and placed in an isothermal 
aluminum sample holder at 37 °C. At various time points (4, 10, 20, 40, 90, 180, and 360 
min), the sample was centrifuged at 13000 g for 1 min. 50 µL of the supernatant was 
collected and subsequently diluted with 350 µL of methanol. The remaining solution was 
re-vortexed for 30 s and placed back in the aluminum sample holder until the next time 
point. 
 For solubility measurements, 4 mg of crystalline drug (phenytoin or probucol) was 
loaded into a 1.5 mL microcentrifuge tube with a small stir bar and deluged with 1.2 mL 
of solution of HPMCAS dissolved in PBS (concentrations of 1, 3, and 9 mg/mL were used). 
Samples were sealed with ParafilmTM, vortexed for 1 min, placed in a sand bath heated to 
37 °C, and stirred for 72 hrs. The samples were then centrifuged at 13000 g for 1 min. 
Aliquots of the supernatant were collected, passed through a 0.25 µm GHP filter, and 
diluted by 350 µL of methanol. 
 The diluted aliquots for both dissolution and solubility assays were analyzed by 
high-performance liquid chromatography using an Agilent 1260 liquid chromatograph 
system with multi-wavelength UV-vis detection and a reversed-phase EC-C18 column 
(Poroshell 120, 4.6 × 50 mm, particle size 2.7 µm, Agilent). The mobile phase was 45:55 
and 96:4 (v/v) MeCN/H2O for SDs containing phenytoin and probucol, respectively. For 
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both drugs, calibration curves ranging from 10–1000 µg/mL were developed. All 
dissolution and solubility measurements were repeated in triplicate. 
 
2.8 Light and X-ray scattering of polymer solutions and dissolution media 
 As shown in Chapter 6, scattering techniques are powerful tools for characterizing 
not only polymer solutions, but also dissolution media of SDs. By fitting scattering data to 
appropriate models, nanostructure, polymer-solvent interactions, and polymer-drug 
interactions can be revealed. The following sections detail scattering techniques that use 
either light or X-rays as the radiation source. 
 
2.8.1 Basic scattering theory 
 For all types of radiation, elastic scattering of a plane wave traveling through a 
molecular mixture is produced by two separate processes. First, concentration fluctuations 
caused by thermal motion of the particulates in the mixture give rise to incoherent 
scattering (angle-independent). The amplitude of scattering created by these composition 
fluctuations (i.e., the scattering power) is proportional to specific material properties. 
Second, intra- or interparticulate spatial correlations produce scattered waves that have a 
phase relationship characteristic of the pair correlation function of the scatterers in the 
material. This coherent scattering (angle-dependent) may be expressed in terms of the 
scattering vector, 𝑞: 
 
𝑞 = 𝑞 = 4𝜋𝜆 sin 𝜃2  (2.9) 
 𝜆 is the wavelength of radiation and 𝜃 is the angle between incident and scattered waves. 𝑞, which has dimensions of inverse length, describes the length scale probed by scattered 
radiation. For 𝑞E ≪ 𝐿, where 𝐿 is a relevant length scale of the material, constituents 
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behave as point scatterers, so no structural information may be obtained. As 𝑞E increases, 
the influence of structure on the scattering pattern becomes more apparent. This concept 
may be mathematically expressed as a form factor, 𝑃 𝑞 . 
 While the basic physics of scattering is universal to all radiation sources, light and 
X-ray scattering are distinguished by the relevant material property that defines scattering 
power and the accessible 𝑞 range. Scattering power contrast is proportional to the 
incremental refractive index increment K :for light and electron density for X-ray. The 𝜆 and 𝑞 range for both light and X-ray scattering are listed in Table 2.2. 
 
Table 2.2. Comparison of 𝝀 and 𝒒 for light and X-ray scattering. 
Radiation source 𝝀 [nm] 𝒒 [nm-1] 
Light 350 to 700 0.007 to 0.05 
X-rays 0.1 to 1 0.01 to 1 
 
2.8.2 Static light scattering (SLS) 
For solutions containing polymers with modest molecular weight (103 ≲ 𝑀  ≲ 105 
g/mol), the 𝑞 range probed by light scattering reveals information regarding the size of 
polymer structures in solution, but not the shape. Intensity of light scattered from a dilute 
polymer solution may be expressed by Equation 2.10, which is a convolution of three 
factors: the mean amplitude of the concentration fluctuations, the phase relationship 
between the scattered waves, and a contrast factor. 
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𝑅 = 𝐾𝑐𝑀𝑃 𝑞 1 − 2𝐴:𝑐𝑀𝑃 𝑞  (2.10) 
𝑅 = 𝐼;C𝑟:𝐼P  (2.11) 
𝐾 = 4𝜋 𝜕𝑛 𝜕𝑐 :𝑛:𝜆k𝑁c  (2.12) 
𝑃 𝑞 = 1 − 𝑞:𝑅@:3 +⋯ (2.13) 
 𝑅 is the Rayleigh ratio (essentially a normalized intensity), 𝐾 is the optical constant, 𝑐 is 
concentration (g/mL), 𝑃 𝑞  is the form factor, 𝐴: is the second virial coefficient, 𝑀 is 
weight-average molecular weight of the polymer, 	𝐼;C is the excess scattering intensity, 𝑟 
is the sample-to-detector distance, 𝐼P is the incident light intensity, 𝑛 is the solution index 
of refraction, 𝜆 is the wavelength of the incident light, 𝑁c is Avogadro’s number, 𝑞 is the 
scattering vector, and 𝑅@ is the radius of gyration of the polymer in solution. By recasting 
Equation 2.10 in a linear form, the fundamental Zimm equation may be obtained:  
 𝐾𝑐𝑅 = 1𝑀 1 + 𝑞:𝑅𝑔:3 +⋯ + 2𝐴:𝑐 + ⋯ (2.14) 
 
Light scattering data may be analyzed using Equation 2.14 to form a Zimm plot (see Figure 
2.8).117 By extrapolating the data to both zero-angle and zero-concentration, 
thermodynamic (𝑀 and 𝐴:) and structural (𝑅@) parameters may be simultaneously 
obtained.5,118 To correct for the effect of the third virial coefficient, 𝐴, Berry proposed a 
modified Zimm equation that cast 𝐴 in terms of 𝐴::119 
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𝐾𝑐𝑅 = 1𝑀E : 1 + 𝑞:𝑅𝑔:6 +⋯ + 2𝐴:𝑐 + ⋯ (2.15) 
 
 
Figure 2.8. Zimm plot of methylcellulose in water at 20 °C. Image adapted from 
Kobayashi, K.; Huang, C. I.; Lodge, T. P. Macromolecules 1999, 32, 7070–7077. 
Copyright the American Chemical Society.117 
 
2.8.3 Dynamic light scattering (DLS) 
 The concentration fluctuations that give rise to scattering have a characteristic 
relaxation time, 𝜏, related to the structure of the particle or particles in solution. 𝜏 may be 
extracted by calculating the second-order time autocorrelation function of the scattering 
intensity, 𝑔(:), and fitting the function to the Siegert relation: 
 
𝑔(:) 𝑞, 𝑡 = 1𝐼 𝜏 : lim→ 1𝑇 𝐼 𝜏 𝐼∗ 𝑡 + 𝜏 𝑑𝜏P = 1 + 𝛽 𝑔(E) 𝑞, 𝑡 : (2.16) 
 𝑔(E) is the first-order time autocorrelation functions, 𝐼  is the scattered intensity, 𝑡 is time, 
and  𝑇 is the total time interval.118 Figure 2.9 displays the autocorrelation functions for 
multicompartment micelle systems.120 To directly calculate 𝜏 from Equation 2.15, 𝑔(E) 
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must be defined a priori. Common 𝑔(E) models are a single exponential decay for systems 
that are monodisperse and double exponential decay to for systems that have two well-
separated relaxation modes. The distribution may also be estimated by taking an inverse 
Laplace transform of either  𝑔(E) or 𝑔(:) (see Figure 2.9B), but this method is prone to 
producing artifacts. For dilute particle solutions (𝑐 → 0), 𝜏 may be related to the particle 
hydrodynamic radius, 𝑅, by the equations: 
 
𝑅 = 𝑘𝑇6𝜋𝜂^𝐷 (2.17) 
𝐷 = 1𝑞:𝜏 (2.18) 
 𝑘 is Boltzmann’s constant, 𝑇 is temperature, 𝜂^ is solvent viscosity, and 𝐷 is the tracer 
diffusion coefficient.5,118 
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Figure 2.9. (A) Second-order time autocorrelation functions and (B) inverse Laplace 
transform results for dynamic light scattering measurements of multicompartment 
micelles at various time points. Adapted from Li, Z.; Hillmyer, M. A.; Lodge, T. P. 
Macromolecules 2006, 39, 765–771. Copyright the American Chemical Society.120 
 
2.8.4 Light scattering sample preparation and instrumentation 
 To prepare samples for static light scattering measurements (Chapter 6), HPMCAS 
912 was first dissolved in tetrahydrofuran to form a 2 wt% solids solution. The solution 
was successively passed through 0.45 and 0.25 µm PTFE filters. The filtered solution was 
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then spray dried using the process described in section 2.3. The resulting dried polymer 
was dissolved in PBS to form a stock solution with a concentration of 0.25 mg/mL 
HPMCAS. Aliquots of the stock solution were subsequently diluted to form 11 additional 
static light scattering samples that had concentrations ranging from 0.01–0.235 mg/mL 
HPMCAS. To prepare samples for dynamic light scattering measurements (Chapter 6), 
HPMCAS 912 was dissolved directly in PBS or tetrahydrofuran to form solutions with a 
concentration of 9 mg/mL HPMCAS. The solution was then passed through a 0.25 µm 
filter (GHP or PTFE for PBS and tetrahydrofuran, respectively) into a dynamic light 
scattering sample tube. 
 Both experiments were performed using a Brookhaven BI-200SM light scattering 
instrument with a wavelength of 637 nm, laser power of 30 mW, and an avalanche 
photodiode detector with a pinhole size set to 1 mm and 200 µm for static light scattering 
and dynamic light scattering, respectively. Data analysis was performed using custom-
made Matlab scripts. 
 
2.8.5 Small-angle X-ray scattering sample preparation and instrumentation 
 Dissolution media of various SDs were characterized using synchrotron-sourced 
SAXS (Chapter 6) performed at DND-CAT (beamline 5-ID-D) at the Advanced Photon 
Source in Argonne National Laboratory (Argonne, IL). The sample-to-detector distance 
and X-ray wavelength were 8500 nm and 0.729 Å, respectively. Samples were prepared by 
loading a SD into a 20 mL scintillation vial. PBS at 37 °C was added to the scintillation 
vial to achieve the desired targeted drug concentration. The vial was vortexed for 1 min 
and placed in an aluminum vial holder heated to 37 °C. At specific time points (4, 10, 20, 
40, 90, 180, and 360 min), the vial was vortexed to remix the dissolution media. 
Approximately 0.1 mL of the solution was collected and injected into a 1.5 mm quartz 
capillary. The solution was re-inserted into the vial holder and held at 37 °C. The aliquot 
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capillary was immediately placed in a multi-capillary heating stage set to 37 °C. 2D SAXS 
scattering patterns were then recorded and subsequently integrated to form 1D intensity 
(arbitrary units) vs. 𝑞. SAXS data analysis was performed using custom-made Matlab 
scripts.
 †
Reproduced and modified with permission from Ricarte, R.G.; Lodge, T.P.; Hillmyer, M.A. Molecular 
Pharmaceutics 2015, 12, 983–990. 
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Chapter 3: Detection of pharmaceutical drug crystallites in solid 
dispersions by transmission electron microscopy† 
 
3.1 Introduction 
 Trace levels of drug crystallinity (≲ 5 vol%) within a SD are hypothesized to have 
a damaging influence on solubility enhancement. However, the traditional methods for 
characterizing crystallinity in solid dispersions (i.e., wide-angle X-ray scattering and 
differential scanning calorimetry) lack the sensitivity for detecting small amounts of 
crystals. To overcome this limitation, I demonstrate the use of TEM for evaluating the 
crystallinity of solid dispersions. The model API is griseofulvin (GF), a well-studied drug 
that has a strong tendency to crystallize.121,122 The model excipient is hydroxypropyl 
methylcellulose acetate succinate (HPMCAS), one of the most promising excipients.41,42 
The molecular structures of GF and HPMCAS are shown in Scheme 3.1. The crystallinity 
of GF/HPMCAS solid dispersions are assessed using WAXS, differential scanning 
calorimetry, and TEM. We compare the crystal detection sensitivity of each of the 
techniques, and use TEM to directly observe small amounts of nanoscale crystals in solid 
dispersions of GF and HPMCAS. 
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Scheme 3.1. Molecular structures of griseofulvin (GF) and hydroxypropyl 
methylcellulose acetate succinate (HPMCAS). 
 
 
 
3.2 Experimental details 
3.2.1 Materials  
Griseofulvin (GF) (Sigma-Aldrich, 97+%) and tetrahydrofuran (Acros Organics, 
99.9%, stabilized with BHT) were used as received. Hydroxypropyl methylcellulose 
acetate succinate (HPMCAS) (AFFINISOL™ 126 G, 14 wt% acetate, 6 wt% succinate, The 
Dow Chemical Company) was dried under vacuum at 70 °C for at least 12 h prior to use. 
 
3.2.2 Preparation of solid dispersions by spray drying  
Solid dispersions of varying GF loading were prepared by spray drying. Solid 
dispersions with GF loadings of 5, 10, and 50 wt%, spray dried GF (pure drug), and spray 
dried HPMCAS (pure polymer) were used for this study. For each sample, the required 
amounts of GF and HPMCAS were first dissolved in tetrahydrofuran to form a precursor 
solution that had a total solids loading of 2 wt%. The precursor solution was then sprayed 
by a mini spray dryer (Bend Research) using the following operating conditions: nitrogen 
flow rate = 12.8 L/min, inlet temperature = 68 °C, solution flow rate = 0.65 mL/min. The 
outlet temperature ranged between 24–27 °C. The solid dispersion was collected from filter 
paper in the spray dryer and subsequently dried under reduced pressure at ambient 
temperature for at least 12 h. Solid dispersions were stored in a desiccator under reduced 
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pressure at ambient temperature until use. The resultant particle morphologies were 
investigated using scanning electron microscopy (see Appendix A.1). A physical mixture 
containing 3 vol% spray dried GF (pure drug) and 97 vol% spray dried HPMCAS (pure 
polymer) was prepared by mixing the two solid components with a mortar and pestle. 
 
3.2.3 Wide-angle X-ray scattering (WAXS)  
Approximately 50 mg of solid dispersion were loaded into a 0.5 mm-deep zero-
background sample holder and analyzed at ambient temperature by a Bruker-AXS D5005 
diffractometer with a Cu Kα source (λ = 1.54 Å). The operating voltage and current were 
45 kV and 40 mA, respectively. Diffraction patterns were collected from a scattering vector 
(q) range of 4–28 nm–1 with a scan rate of 0.01 nm–1s–1. Overall crystallinity was estimated 
by dividing the area of the Bragg peaks after background subtraction by the total area of 
the diffraction pattern (this ratio corresponds to vol%), while the crystal grain size was 
calculated using the Scherrer equation, a routine procedure.107 
 
3.2.4 Modulated differential scanning calorimetry (MDSC)  
MDSC was run using a Discovery DSC (TA Instruments). 5–8 mg of solid 
dispersion were placed inside TzeroTM aluminum pans with standard lids. While under 
nitrogen gas with a flow rate of 50 mL/min, each sample was heated from 0–160 °C using 
the following parameters: average temperature heating rate = 1 °C/min, temperature 
modulation amplitude = 1 °C, temperature modulation period = 40 s. During this heating 
cycle, total, reversing, and non-reversing heat flow curves were recorded. The solid 
dispersion glass transition temperature (Tg) was determined from the reversing heat flow 
curve, while the crystallization temperature and enthalpy (Tc and ΔHc, respectively) were 
estimated from the non-reversing heat flow curve. All solid dispersions were examined by 
MDSC in triplicate. 
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3.2.5 Transmission electron microscopy (TEM)  
TEM analysis of solid dispersions was performed using a FEI Tecnai G2 F30 
cryogenic transmission electron microscope at an accelerating voltage of 300 kV. Samples 
were prepared by spreading a small amount of solid dispersion from a spatula onto a 300-
mesh copper TEM grid with either a lacey carbon or a thin (15 to 25 nm) amorphous carbon 
substrate film. To reduce the rate of electron beam damage, the sample was cooled to –180 
°C by using a cryogenic sample holder filled with liquid nitrogen. To preserve the 
crystallinity of the particles in each TEM sample, low-dose conditions were used to obtain 
electron diffraction patterns, dark-field TEM images, and bright-field TEM images. 
Briefly, particles in a region-of-interest (ROI) were first surveyed in bright-field TEM at 
low magnification (4700×) using an electron dose rate of ≲ 10 e–/nm2s. Focusing and beam 
alignment at a higher magnification (39,000×) were performed on a sacrificial area far 
removed from the desired ROI. A selected-area aperture was inserted into the electron 
beam path to restrict the field of view to an area of ~ 1 µm2. Selected-area electron 
diffraction patterns of the ROI were then collected using an electron dose rate of ~ 50 e–
/nm2s. Dark-field TEM images were recorded after centering the objective aperture on 
various diffraction spots in the electron diffraction pattern. Bright-field TEM images were 
finally obtained after centering the objective aperture on the direct electron beam. Electron 
diffraction patterns were evaluated with the DiffTools plug-in for Gatan 
DigitalMicrograph.115 Kinematical simulations of GF single crystal diffraction patterns 
were performed using Web Electron Microscopy Applications Software.116  
 
3.2.6 In situ WAXS  
In situ WAXS diffraction patterns of 10 and 50 wt% GF solid dispersions were 
recorded by a Bruker D8 Discover diffractometer with a Cu Kα source filtered with a nickel 
foil (λ = 1.54 Å). Approximately 50 mg of solid dispersion were loaded into a 0.8 mm-
deep, zero-background, temperature-controlled sample holder. The sample holder was 
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inserted into the sample chamber and immersed under nitrogen gas with a flow rate of 15 
mL/min. First, a diffraction pattern was recorded with the sample stage at 25 °C. Second, 
the sample stage was heated at a rate of 1 °C/min to an elevated temperature above the Tc 
of the solid dispersion (130 °C for 50 wt% GF solid dispersion and 140 °C for 5 and 10 
wt% GF solid dispersions). Third, diffraction patterns were recorded continuously over a 
period of at least 2 h. After in situ WAXS, the sample was removed from the sample holder, 
ground into a powder using a spatula, and analyzed by TEM.  
 
3.2.7 Growth of GF crystals from a 50 wt% GF solid dispersion on a TEM grid  
Glow discharge was performed on a TEM grid with a thin amorphous carbon 
substrate film to increase the surface energy of the film.123,124 The TEM grid was exposed 
to plasma for 1 min at a pressure of 500 millitorr and 50 DC amperes. A 50 wt% GF solid 
dispersion was then deposited on the modified TEM grid. Using a temperature-controlled 
oven, the sample was heated from 0 to 130 °C at a ramp rate of 1 °C/min and held at 130 
°C for 12 h. The sample was then removed from the oven and analyzed by TEM. 
 
3.3 Results 
3.3.1 Wide-angle X-ray scattering of solid dispersions 
 Representative WAXS patterns of GF/HPMCAS solid dispersions with varying GF 
loadings are shown in Figure 3.1. The sharp Bragg peaks in the diffraction pattern of spray 
dried GF indicate that the sample is highly crystalline. From these data, the overall 
crystallinity and minimum crystal grain size of spray dried GF were estimated to be 90 
vol% overall and 50 nm, respectively. Conversely, the WAXS patterns of 5, 10, and 50 
wt% GF solid dispersions are broad with no clear Bragg peaks. This is typically attributed 
to fully amorphous drug in the solid dispersion.125,126,127 The practical lower limit of crystal 
detection for laboratory-scale WAXS experiments, however, is approximately 5 vol% 
overall.60 This reported detection limit is corroborated by our WAXS study of a physical 
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mixture of 5 vol% GF and 95 vol% hydroxypropyl methylcellulose (Figure 3.2). Therefore, 
these diffraction patterns only confirm that the 5, 10, and 50 wt% GF solid dispersions have 
an overall crystallinity lower than 5 vol%. Consistent with these observations, the WAXS 
diffraction pattern of a physical mixture of 3 vol% spray dried GF and 97 vol% spray dried 
HPMCAS showed no clear Bragg peaks, even though the WAXS diffraction pattern of 
spray dried GF shows that it is mostly crystalline. Thus, WAXS can detect crystals in the 
spray dried GF, but cannot conclusively establish the complete absence of crystals in the 
GF/HPMCAS solid dispersions. 
 
 
Figure 3.1. WAXS of solid dispersions with varying GF loading. Curves were vertically 
shifted for clarity. Spray dried GF (orange curve) has sharp Bragg peaks, indicating the 
presence of crystal domains. Spray dried HPMCAS, and 5, 10, and 50 wt% GF solid 
dispersions (teal, blue, pink, and purple curves, respectively) do not exhibit Bragg peaks. 
The physical mixture of 3 vol% spray dried GF in spray dried HPMCAS (red curve) also 
does not exhibit Bragg peaks. 
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Figure 3.2. WAXS of the physical mixture of 5 vol% GF and 95 vol% hydroxypropyl 
methylcellulose.The broad Bragg peaks confirm that the lower limit of detection for our 
WAXS studies is ~ 5 vol%. 
 
3.3.2 MDSC of solid dispersions 
 Figure 3.3 shows the modulated differential scanning calorimetry (MDSC) heat 
flow curves for 5, 10, and 50 wt% GF solid dispersion samples. In MDSC the total heat 
flow curve mimics the conventional DSC heat curve, the reversing heat curve accounts for 
changes in the heat capacity of the sample, and the non-reversing heat curve catalogs all 
other thermal events.128 The Tg values of the solid dispersions correspond to the inflection 
point of the increase in the reversing heat flow curves. The 5, 10, and 50 wt% GF solid 
dispersions each only exhibit single Tg values at 110, 100, and 84 °C, respectively, 
suggesting that GF is molecularly dispersed throughout the polymer matrix in the solid 
dispersions.  
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Figure 3.3. Modulated DSC heat flow curves of GF solid dispersions. Data were 
recorded upon first heating using an average temperature heating rate of 1 °C/min, a 
temperature modulation amplitude of 1 °C, and a temperature modulation period of 40 
s. The reported Tgs, Tcs, and ΔHcs represent the average of three DSC experiments, while 
the error bars represent the standard deviation. Curves were vertically shifted for clarity. 
(a) 50 wt% GF solid dispersion exhibits crystallization over a temperature range of 118 
to 131 °C, while (b) 10 wt% GF solid dispersion displays crystallization over a 
temperature range of 109 to 136 °C. (c) 5 wt% GF solid dispersion does not show 
crystallization of the GF. 
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The total and non-reversing heat flow curves of the 50 wt% GF solid dispersion 
feature a sharp exothermic peak that is attributed to crystallization of GF (Figure 3.3a), 
with Tc range and ΔHc of 118 to 131 °C and 79 J/gGF, respectively. From the MDSC data, 
the degree of crystallinity was estimated by taking the ratio of ΔHc of the solid dispersion 
to the ΔHmelting of pure GF.  This ratio corresponds to wt%. To convert wt% to vol%, we 
assumed that all the GF in the solid dispersion was initially non-crystalline (as justified by 
the TEM analysis) and that the density of amorphous GF is 5% less than the density of 
crystalline GF, a typical value for APIs.129,130,131 The overall crystallinity of the entire 50 
wt% GF solid dispersion after MDSC analysis was approximately 40 vol%. Furthermore, 
the reversing heat flow curve exhibits a decrease that coincides with Tc. This decrease was 
attributed to the expectation that crystalline GF should have a lower heat capacity than 
amorphous GF. The total and non-reversing heat flow curves of 10 wt% GF solid 
dispersion feature a broad crystallization peak with a Tc range of 109 to 136 °C (Figure 
3.3b). The crystallinity of the entire 10 wt% GF solid dispersion after MDSC analysis was 
estimated to be approximately 5 vol% overall. In contrast to the higher GF loading solid 
dispersions, the 5 wt% GF solid dispersion does not exhibit a crystallization peak in its 
total and non-reversing heat flow curves (Figure 3.3c). 
 The 5 and 10 wt% GF solid dispersions also exhibit a broad endothermic peak 
around 40 °C in both total and non-reversing heat flow curves. This peak, which appears 
in several other studies,132,133,134 has been attributed to evaporation of bound water,135 but 
we are not aware of any direct evidence that supports this hypothesis. Although the origin 
of this peak is ambiguous, annealing the sample at 80 °C prior to the full MDSC scan does 
not affect the Tg or crystallization of the solid dispersion (Figure 3.4). In summary, the 
MDSC data suggest the GF in the 10 and 50 wt% GF solid dispersions can crystallize upon 
heating, while the 5 wt% GF solid dispersion does not show any crystallization behavior. 
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Figure 3.4. Modulated DSC heat flow curves of 10 wt% GF solid dispersion. When the 
solid dispersion was initially heated to 80 °C (solid lines), total and non-reversing heat 
curves exhibited an endothermic peak from 5 – 80 °C. After cooling the solid dispersion 
to 0 °C and then heating it to 150 °C, the endothermic peak disappeared. The Tg, Tc, and 
ΔHc exhibited upon second heating were consistent with previously recorded values. 
 
3.3.3 TEM of spray dried GF 
 Figure 3.5 shows TEM analysis of a spray dried GF particle. The ill-defined 
morphology of the spray dried GF particle observed in bright-field TEM (Figure 3.5a) is 
consistent with the scanning electron microscopy data (Appendix A.1). The presence of 
sharp diffraction spots in the electron diffraction pattern confirms that the observed particle 
is crystalline (Figure 3.5b). Furthermore, the indices of the 1-D intensity profile of the 
electron diffraction pattern match the indices of the WAXS diffraction pattern of bulk spray 
dried GF (Figure 3.5d), verifying that the particle is composed of GF crystals. Particles that 
produce fewer diffraction spots were also indexed to verify the presence of GF crystals 
(see Appendix A.2). Dark-field TEM of the particle provides real-space information about 
the GF crystals (Figure 3.5c); the intensely white regions correspond to the crystal domains 
of the particle that produce the diffraction pattern. The circle on Figure 3.5b (and all 
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subsequent diffraction patterns) indicates the location of the objective aperture during the 
dark field image acquisition. 
 
 
Figure 3.5. (a) Bright-field TEM of a spray dried GF particle. (b) Electron diffraction 
pattern of the spray dried GF particle in (a). The scale bar is the scattering vector. The 
value in the lower right-hand corner is the cumulative electron dose. (c) Dark-field TEM 
of the particle identifies the domains that produce the reflections encircled in (b). (d) The 
1-D intensity profile of the electron diffraction pattern matches the WAXS diffraction 
pattern of bulk spray dried GF. Curves were shifted for clarity. 
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Figure 3.6 shows the TEM analysis of the physical mixture of 3 vol% spray dried 
GF and 97% vol% spray dried HPMCAS. Unlike WAXS, TEM identified GF crystals 
throughout the physical mixture, as evidenced by the electron diffraction pattern, dark-field 
image, and diffraction pattern indices of selected particles in the sample. This analysis 
demonstrates the improved crystal detection sensitivity of TEM over WAXS. 
 
 
Figure 3.6. (a) Bright-field TEM of particles in a 3 vol% spray dried GF in spray dried 
HPMCAS physical mixture. The (b) electron diffraction pattern and (c) dark-field TEM 
of the particles confirm the presence of crystals in the ROI, while (d) the peak positions 
of the electron diffraction pattern 1-D intensity profile coincide with the peaks of the 
WAXS diffraction pattern of spray dried GF. The curves in (d) were vertically shifted 
for clarity. 
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3.3.4 TEM analysis of solid dispersions 
 We examined GF/HPMCAS solid dispersions using TEM to further evaluate the 
crystallinity and to complement the WAXS studies. With TEM we did not detect GF 
crystals in any of the solid dispersions (Figure 3.7), corroborating the WAXS results. 
Annealing of GF solid dispersions on a temperature-controlled sample stage during in situ 
WAXS analysis was performed to induce GF crystallization. Following in situ WAXS, the 
annealed samples were studied by TEM. Figure 3.8a features the in situ WAXS analysis 
of a 50 wt% GF solid dispersion. While the WAXS diffraction pattern of the solid 
dispersion is initially smooth, sharp Bragg peaks appear upon annealing, confirming the 
growth of GF crystals. Based on the WAXS diffraction pattern, the overall crystallinity and 
minimum crystal grain size after annealing were estimated to be 40 vol% (consistent with 
the MDSC results) and 40 nm, respectively. TEM analysis of the post-annealed in situ 
WAXS sample (Figures 3.8b, 3.8c, and 3.8d) further verified the presence of GF crystals.  
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Figure 3.7. Bright-field TEM images of (a) 5, (b) 10, and (c) 50 wt% GF solid dispersion 
particles. The corresponding electron diffraction patterns of (d) 5, (e) 10, and (f) 50 wt% 
GF solid dispersion particles do not exhibit sharp diffraction spots, indicating the GF in 
the particles is fully amorphous. 
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Figure 3.8. (a) In situ WAXS of 50 wt% GF solid dispersion before and after annealing 
at 130 °C. (b) Bright-field TEM, (c) electron diffraction, and (d) dark-field TEM provide 
direct observation of crystals in the post-annealed in situ WAXS sample. The dark-field 
TEM image in (d) is sampled from the circled diffraction spots in (c). 
 
Figure 3.9a presents the in situ WAXS analysis of 5 wt% GF solid dispersion. 
Consistent with the MDSC analysis, no clear Bragg peaks developed during annealing. 
Yet, TEM analysis of the post-annealed in situ WAXS sample (Figures 3.9b, 3.9c, and 
3.9d) uncovered GF crystals in the specimen. We also analyzed the data from an annealed 
10 wt% GF solid dispersion (Figure 3.10) and were able to uncover GF crystals in that 
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sample as well. These results demonstrate that TEM has superior crystal detection 
sensitivity as compared to both WAXS and MDSC. 
 
 
Figure 3.9. (a) In situ WAXS of 5 wt% GF solid dispersion before and after annealing 
at 140 °C. Similar to the modulated DSC results, the diffraction patterns of the sample 
during annealing do not show signs of crystallinity. (b) Bright-field TEM, (c) electron 
diffraction, and (d) dark-field TEM reveal that some particles in the post-annealed in situ 
WAXS sample contained GF crystals. 
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Figure 3.10 (a) In situ WAXS of 10 wt% GF solid dispersion before and after annealing 
at 140 °C. The diffraction patterns of the sample during annealing do not show signs of 
crystallinity, disagreeing with the modulated DSC results. (b) Bright-field TEM, (c) 
electron diffraction, and (d) dark-field TEM confirm that some particles in the post-
annealing in situ WAXS sample are crystalline. 
 
To further explore the utility of TEM for studying solid dispersions, a TEM sample 
of 50 wt% GF solid dispersion was thermally annealed in an oven to induce the growth of 
GF crystals. Though some particles did not exhibit crystallization and instead formed 
droplets (Figure 3.11), GF crystals were detected. Figure 3.12 features a narrow (~ 300 nm 
wide) GF crystal that grew from the remnants of a solid dispersion particle. Large GF 
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crystals (~ 30 µm long) were also observed (Figure 3.13). This analysis of the in situ growth 
of GF crystals suggests that the mechanism of crystal growth in a solid dispersion could be 
studied by TEM. 
 
 
Figure 3.11. (a) Bright-field TEM image and (b) electron diffraction pattern of droplet 
observed in the post-annealed TEM sample of 50 wt% GF solid dispersion. Lack of clear 
diffraction spots indicates the droplet is amorphous. 
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Figure 3.12. (a) Bright-field TEM of 50 wt% GF solid dispersion that was annealed on 
a TEM grid at 130 °C for 12 hrs. The circled region is captured at a higher magnification 
in (b). The (c) electron diffraction pattern and (d) dark-field TEM confirm the 
aforementioned region is crystalline. 
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Figure 3.13. (a) Bright-field TEM of a large crystal (30 µm long) in the post-annealed 
TEM sample of 50 wt% GF solid dispersion. The circled region is magnified in (b). The 
(c) electron diffraction pattern and (d) dark-field TEM image confirm the crystal is GF. 
 
3.4 Discussion 
 TEM offers substantial advantages over WAXS, MDSC, and other microscopy 
techniques for detecting crystals in solid dispersions. First, as demonstrated by the physical 
mixtures and solid dispersions of GF and HPMCAS, TEM achieves significantly improved 
crystal detection sensitivity. Second, TEM offers nanoscale spatial resolution. Unlike 
optical microscopy techniques, TEM can detect crystals that are smaller than the 
diffraction-barrier of visible light.66 Electron diffraction patterns have been recorded from 
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nanoparticles as small as 5 nm.136 This spatial resolution allows for single-particle 
screening of drug crystals. Additionally, because organic molecules typically have a critical 
nucleation diameter of ~ 10 to 20 nm,5 I expect that any drug crystal in a solid dispersion 
should be large enough to produce a distinguishable electron diffraction signal. Third, TEM 
can identify drug crystals in a wide variety of drug-excipient pairs. Since electron 
diffraction patterns provide crystal structure information, drug crystals in a solid dispersion 
may be unambiguously identified and located. Fourth, TEM offers fast and facile data 
collection. Image and diffraction pattern acquisition take seconds. TEM grids may hold 
thousands of particles; assuming the particles that stick to the grid are representative of the 
entire ensemble, a statistically significant amount of particles may be sampled. 
 Beam damage, however, is a major challenge for using TEM to study solid 
dispersions. GF, like most organic materials,137 is sensitive to the electron beam of a 
transmission electron microscope; exposure to the beam ultimately destroys GF crystals 
(see Appendix A.3). Therefore, a low electron dose must be used to preserve any possible 
drug crystals. Nevertheless, when paired with other techniques, TEM analysis offers 
complementary information about the structural and thermodynamic properties of solid 
dispersions. For GF/HPMCAS solid dispersions, our TEM study of the post-annealed in 
situ WAXS samples suggests that the equilibrium solubility of GF in AFFINISOL™ 126 G 
HPMCAS is less than 5 wt%. I also performed preliminary FT-IR studies to further probe 
the specific chemical interactions between GF and HPMCAS (see Appendix A.4).  
 Furthermore, TEM allowed observation of the diverse structures – i.e., droplets 
(Figure 3.11) and GF crystals – that developed during the annealing of the TEM sample of 
50 wt% GF solid dispersion. We speculate that the structural diversity is caused by 
heterogeneous distribution of solid dispersion particles throughout the TEM grid. 
Presumably, when the TEM sample was annealed above the Tg of 50 wt% GF solid 
dispersion, isolated particles formed small droplets, while particles that touched each other 
or were agglomerated formed large droplets. The GF in the large droplets should be more 
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likely to nucleate. A similar mechanism was observed for the nucleation of poly(ethylene 
oxide) crystals from droplets on an isotactic polystyrene substrate.138 Still, more studies 
must be performed to determine how the structures in this system developed. 
 While the broader utility of this methodology hinges on the capacity to estimate the 
degree of crystallinity of a solid dispersion, quantification may be challenging. Prolonged 
electron beam exposure eradicates API crystals, and crystals with orientation that does not 
satisfy Bragg's law do not exhibit a diffraction signal. Thus, electron diffraction and dark 
field imaging may capture only a fraction of crystals within a sampling area. Nevertheless, 
the strength of this TEM approach is that it probes crystallinity at the local level. 
Information obtained by TEM is complementary to bulk crystal detection techniques and 
may provide deep insight into the growth mechanism of API crystals in a solid dispersion. 
 
3.5 Conclusion 
 We explored the utility of TEM for characterizing crystallinity and structure of 
solid dispersions. TEM achieves nanoscale spatial resolution and allows for unambiguous 
identification of drug crystals. Using TEM, we detected GF crystals in annealed solid 
dispersions, even in cases where WAXS and MDSC failed to detect crystals. Based on our 
annealing studies, we posit that the solubility of GF in HPMCAS is below 5 wt%, 
suggesting that GF has poor affinity for HPMCAS.  The in situ growth of GF crystals in a 
TEM sample of 50 wt% GF solid dispersion was also achieved. Due to the high spatial 
resolution and sensitivity, TEM is a powerful and complementary tool for evaluating solid 
dispersions and potentially other nanoengineered pharmaceutical materials. 
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Chapter 4: Energy-dispersive X-ray spectroscopy of solid 
dispersions 
 
4.1 Introduction 
 Solid dispersions (SDs) are designed so that the active pharmaceutical ingredient 
(API) and polymer excipient form a homogeneous material. However, standard techniques 
for characterizing SD miscibility, such as differential scanning calorimetry, cannot confirm 
if the two species intimately mix at the nanoscale (see Appendix B). To overcome this 
limitation, I explored the use of energy-dispersive X-ray spectroscopy (EDS) to evaluate 
spatial distribution of the API griseofulvin (GF) within a HPMCAS SD. First, simulations 
of the scanning transmission electron microscopy (STEM) beam trajectory through GF are 
performed to predict the spatial resolution of the technique. Then, X-ray spectrum maps of 
GF SDs are collected to demonstrate that spatial distribution can be evaluated. Finally, 
EDS spectra are quantitatively analyzed to determine if the concentration sensitivity of the 
technique is sufficient for detecting phase separation in SDs. 
 
4.2 Experimental details 
4.2.1 Materials 
 Griseofulvin (GF) (Sigma-Aldrich, 97+%) and tetrahydrofuran (Acros Organics, 
99.9% stabilized with BHT) were used as received. Hydroxypropyl methylcellulose acetate 
succinate (HPMCAS) (AFFINISOL™ HPMCAS 126G, 14 wt% acetate, 6 wt% succinate, 
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The Dow Chemical Company) was dried at reduced pressure at 70 °C for at least 12 h prior 
to use. 
 
4.2.2 Preparation of solid dispersions by spray drying  
 Solid dispersions (SDs) with GF loadings of 1, 5, 10, 50 wt%, spray dried GF, and 
spray dried HPMCAS were used in this study. To prepare each sample, GF and HPMCAS 
were first dissolved in tetrahydrofuran to form a 2 wt% solids solution. The precursor 
solution was then sprayed by a mini spray dryer (Bend Research) using a nitrogen flow 
rate of 12.8 L/min, inlet temperature of 68 °C, and solution flow rate of 0.65 mL/min. The 
outlet temperature, which was not controlled, fluctuated between 24–27 °C. The solid 
dispersion was collected from filter paper set at the outlet of the spray dryer, dried under 
reduced pressure at ambient temperature for at least 12 h, and stored in a desiccator under 
reduced pressure at ambient temperature until use. 
 
4.2.3 STEM electron beam trajectory simulations 
 Monte-Carlo simulations of the scanning transmission electron microscopy 
(STEM) electron beam trajectory through a sample of GF was performed using the 
software CASINO v3.2.139 106 electrons with an accelerating voltage of 300 kV were 
simulated, while the initial electron beam diameter was set to 5 nm. The simulated electron 
trajectory data were analyzed using custom-made Matlab™ (version R2012a) scripts. 
 
4.2.4 STEM EDS sample preparation and instrumentation 
 TEM samples were prepared by spreading SD powder onto a TEM grid with a lacey 
carbon support film. STEM EDS measurements were performed using a FEI Tecnai G2 
F30 transmission electron microscope at an accelerating voltage of 300 kV. Spectra were 
acquired using 10 s collection times. Spectrum map data were recorded by collecting EDS 
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spectra from several spots, separated by 10 nm each, in a region-of-interest. Spectra maps 
were analyzed using ImageJ. 
 
4.3 Results and discussion 
4.3.1 Simulations of STEM electron beam trajectory 
 Because the expected critical nucleation size for an API crystal is ~ 10 nm,5 phase 
separation between API and excipient is posited to occur on a similar length scale. To 
determine if EDS can resolve features at this spatial resolution, the trajectory of the incident 
electrons passing through a TEM sample of GF were modeled. Using the software 
CASINO v3.2,139 the trajectories of 106 incident electrons with an energy of 300 kV were 
simulated (Figure 4.1A). As the electrons penetrated deeper into the sample, they scattered 
from C, O, and Cl atoms of GF, causing the electron beam diameter (defined as the full-
width half-maximum (FWHM) of the incident electron radial distribution) to spread. As 
seen in Figure 4.1B and Table 4.1, the electron beam diameter was ~ 10 nm at sample 
depths below 300 nm (approximately the upper end of thickness for TEM samples). This 
suggested EDS can achieve a sufficient spatial resolution for resolving phase separated 
domains in a SD. 
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Figure 4.1. (A) Simulated trajectories of 106 300 kV incident electrons traveling through 
a GF sample. (B) Spatial distribution of electrons at various sample depths. 𝑟B is the 
distance of the electron from the beam center, while 𝜌B\`4 is the fraction of electrons at a 
particular distance. The initial electron beam diameter was 5 nm. 
 
Table 4.1. Full-width half-maximum (FWHM) of incident electrons at various sample 
depths. 
Sample depth [nm] FWHM [nm] 
0 5 
100 6 
200 8 
300 12 
400 16 
500 21 
1000 52 
 
4.3.2 Elemental spectrum maps of griseofulvin and HPMCAS 
Figure 4.2 compares experimental EDS spectra of spray dried HPMCAS and GF 
particles. The spectra, normalized by the total area under the curve, contained peaks 
representative of the constituent atoms of each molecule. While HPMCAS and GF are both 
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comprise C and O atoms, only GF contained Cl atoms. The Cl peaks in the GF EDS spectra 
served as a signal that qualitatively distinguished API from excipient. 
 
 
Figure 4.2. Comparison of EDS spectra for HPMCAS and GF. Inset is a magnification 
of the Cl peaks. 
 
 EDS spectrum maps of the Cl Ka peak enabled evaluation of the spatial distribution 
of GF. To create a spectrum map, EDS spectra were collected from discrete spots (arranged 
in a grid like manner and separated by 10 nm) in a region-of-interest. The C, O, and Cl Ka 
peaks of each spectra were integrated and visualized in a spectrum map (each pixel 
represents a single spectrum). Figure 4.3 features elemental spectrum maps of a spray dried 
GF particle adhered to the lacy carbon support film of the TEM grid. Both the particle and 
support film are seen in the C Ka map, but only the particle is detected in O and Cl Ka 
maps. Cl maps of spray dried HPMCAS (Figure 4.4) showed that the particles completely 
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disappeared, thereby demonstrating that Cl correlated with the presence of GF and not 
polymer. 
 
 
Figure 4.3. HAADF TEM image (middle-top) and elemental maps of a spray dried GF 
particle. The spatial distribution of C, O, and Cl may be isolated. 
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Figure 4.4. (A) HAADF TEM image and (B) Cl Ka map of a spray dried HPMCAS 
particle. The particle cannot be seen in the Cl map. 
 
 EDS characterization of 10 wt% GF SDs showed that Cl maps recreated the 
particles.  As seen in Figure 4.5, the Cl signal is isolated to the particle, confirming GF can 
be detected in the HPMCAS matrix of the SD. Although the uniform Cl signal across the 
particle implied the spatial distribution of GF was homogeneous, further analyses were 
needed to evaluate the concentration resolution of EDS. 
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Figure 4.5. (A) HAADF TEM image and (B) Cl Ka map of a 10 wt% GF SD particle. 
The particle is recreated in the Cl map. 
 
4.3.3 Quantification of EDS spectra 
The concentration ratio of two distinct elements in a region-of-interest may be 
quantified by Equations 2.1 and 2.2, which are analogous to Beer’s law, although 𝑘cd is 
dependent on the TEM sample and microscope operating parameters. Using these 
equations, theoretical EDS spectrum for EDS were calculated. Comparison between 
theoretical and experimental spectra revealed spray dried GF emitted Cl and O signals that 
have intensities consistent with the predictions, but the C signal intensity was much 
stronger than expected (Figure 4.6 and Table 4.2). This deviation from theory could be the 
result of two distinct phenomena. (i) Excess C X-rays were emitted by the TEM grid itself. 
Although the electron beam was localized on the particle, spurious electrons or X-rays 
emitted from the sample may have excited electrons in the lacey carbon support film. (ii) 
The Cl and O X-rays may be absorbed by the particles themselves. Absorption is especially 
likely to occur in very thick samples.108 
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Figure 4.6. (A) HAADF TEM image of spray dried GF particles. An EDS spectrum was 
collected from the spot marked by the red X. (B) Comparison of theoretical and 
experimental EDS spectra for GF (same data as Figure 4.2). Inset is a magnification of 
the Cl peaks. Spectra were normalized by the height of the Cl Ka peak. 
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Table 4.2. Comparison of theoretical and experimental EDS spectrum peak intensities for 
GF. 
A/B Theo. 𝑰𝑨/𝑰𝑩 for pure GF Exp. 𝑰𝑨/𝑰𝑩 for pure GF 
Cl Ka / C Ka 0.2 0.07 
Cl Ka / O Ka 0.6 0.4 
Cl Ka / Cl Kb 10 5 
 
To probe the influence of thickness, EDS spectra were collected from spray dried 
GF particles with thicknesses varying from 100–1000 nm (Figure 4.7A and Table 4.3). 
Although the particles were homogeneous (they only contained GF), the peak intensity 
deviation from the theory increased as the thickness decreased. Deterioration of both 𝐼£_	¤O/𝐼£	¤O and 𝐼£_	¤O/𝐼¥	¤O ratios, rather than just the 𝐼£_	¤O/𝐼£	¤O ratio, suggested X-rays 
emitted by the lacey carbon support film were not the only reason for the deviation from 
theory. Furthermore, the measured peak ratios for spray dried GF SDs were identical 
between drug loadings of 1 and 50 wt% (Figure 4.7B and Table 4.4). 
 
 
Figure 4.7. (A) EDS spectra for spray dried GF particles with different thicknesses. (B) 
EDS spectra for SD particles with a thickness of 300 nm and varying GF loading. Insets 
for both plots are magnifications of the Cl peaks. All spectra were normalized by the 
total area under the curve. 
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Table 4.3. Measured peak ratio intensities for spray dried GF particles with varying 
thickness. The theoretical values for 𝐼£_	¤O/𝐼£	¤O and 𝐼£_	¤O/𝐼¥	¤O are 0.2 and 0.6, 
respectively. 
Spray dried GF  
particle thickness [nm] 
Exp.  𝑰𝑪𝒍	𝑲𝜶/𝑰𝑪	𝑲𝜶 Exp.  𝑰𝑪𝒍	𝑲𝜶/𝑰𝑶	𝑲𝜶  
1000 0.07 0.4 
500 0.05 0.3 
300 0.02 0.1 
200 0.02 0.2 
100 0.01 0.1 
 
Table 4.4. Measured peak ratio intensities for 300 nm thick GF SD particle with varying 
drug loading. 
GF loading  
[wt%] 
Theo.  𝑰𝑪𝒍	𝑲𝜶/𝑰𝑪	𝑲𝜶 Exp.  𝑰𝑪𝒍	𝑲𝜶/𝑰𝑪	𝑲𝜶 Theo.  𝑰𝑪𝒍	𝑲𝜶/𝑰𝑶	𝑲𝜶 Exp.  𝑰𝑪𝒍	𝑲𝜶/𝑰𝑶	𝑲𝜶  
100 0.2 0.02 0.6 0.1 
50 0.1 0.007 0.2 0.04 
10 0.01 0.004 0.02 0.05 
5 0.0006 0.004 0.0005 0.05 
1 7×10-6 0.004 4×10-6 0.04 
0 0 0 0 0 
 
These observations showed that the measured Cl signal in the EDS spectra only 
provided qualitative, not quantitative, information regarding the spatial distribution of GF 
SDs. Therefore, EDS likely cannot be used to detect phase separated domains in SDs. The 
insufficient concentration resolution presumably resulted due to low X-ray emission from 
GF. Not only is ionization of the Cl atom rare, but the probability that ionization produces 
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an X-ray is also miniscule. However, the signal intensity of photons emitted from GF could 
possibly be increased by using a technique that only probes ionization and not X-ray 
emission, such as electron energy-loss spectroscopy. Exploration of electron energy-loss 
spectroscopy is discussed in Chapter 5. While EDS is ultimately unsuitable for 
characterizing GF SDs, the high spatial resolution of the technique makes it potentially 
useful for characterizing soft matter systems that involve higher concentrations of 
heteroatoms. 
 
4.4 Conclusions 
 Energy-dispersive X-ray spectroscopy was explored as a tool for characterizing the 
spatial distribution of API and polymer in a solid dispersion. Simulations of the electron 
beam trajectory through a griseofulvin sample predicted that the technique could achieve 
a spatial resolution of ~ 10 nm. Elemental spectrum maps demonstrated that the spatial 
distribution of GF in a SD particle could be evaluated. Unfortunately, quantitative analysis 
of EDS spectra from GF showed that the concentration resolution of the technique was not 
sufficient for detecting phase separation between GF and HPMCAS. 
 
 †
Reproduced and modified with permission from Ricarte, R.G.; Lodge, T.P.; Hillmyer, M.A. Langmuir 
2016, 32, 7411–7419. 
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Chapter 5: Nanoscale concentration quantification of 
pharmaceutical actives in amorphous polymer matrices by 
electron energy-loss spectroscopy† 
 
 
5.1 Introduction 
 As discussed in Chapter 4, nanoscale characterization is needed to elucidate the 
spatial distribution of drug and polymer within a solid dispersion (SD). While energy-
dispersive X-ray spectroscopy (EDS) can isolate drug and polymer within high spatial 
resolution, it cannot identify phase separation in SDs due to the poor signal of the X-ray 
spectra. An alternate technique, electron energy-loss spectroscopy (EELS), achieves a 
stronger signal-to-noise ratio than EDS because it relies on the collection of electrons that 
pass through the TEM sample, rather than X-rays. In this chapter, we demonstrate the use 
of EELS to measure the local concentration of drug and polymer throughout various SDs. 
We first use EELS on an SD system composed of the model polymer hydroxypropyl 
methylcellulose acetate succinate (HPMCAS),41 and the model API phenytoin, which has 
a strong tendency to crystallize. The local concentration of phenytoin within the HPMCAS 
matrix can be quantified with high accuracy and sub-100 nm spatial resolution by using a 
multiple least-squares analysis algorithm and reference spectra from the individual 
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components. We then extend this technique to other APIs and propose other small 
molecule/polymer blend systems that may be suitable for this method of analysis. 
 
5.2 Experimental details 
5.2.1 Materials  
Phenytoin, carbamazepine, naproxen, griseofulvin, itraconazole (Sigma-Aldrich), 
and tetrahydrofuran (Acros Organics, 99.9%, stabilized with BHT) were used as received. 
Hydroxypropyl methylcellulose acetate succinate (HPMCAS) (AFFINISOLTM 126 G, 12 
wt% acetate, 7 wt% succinate, The Dow Chemical Company) was dried prior to use by 
heating at 70 °C under reduced pressure for at least 12 h. 200-mesh TEM grids with an 
ultrathin (nominally 3-4 nm) C support film (Electron Microscopy Sciences) were used to 
prepare samples for EELS analysis. 
 
5.2.2 Preparation of SDs by spin coating  
Spin-coated SDs of 10, 25, and 50 wt% drug, spin-coated drug, and spin-coated 
HPMCAS were used for this study. The appropriate amounts of drug and HPMCAS were 
dissolved in tetrahydrofuran to create a precursor solution with a total solids loading of 2 
wt%. A ~ 10 µL drop of the solution was passed through a 0.2 µm PTFE syringe filter and 
placed onto a 200-mesh copper TEM grid that was supported by a 1 cm x 1 cm silica wafer. 
The TEM grids had an ultrathin amorphous carbon film to uphold the SD. The TEM 
samples were spun at 2500–3000 rpm for 1 min, dried under reduced pressure at ambient 
temperature for at least 12 h, and stored in a desiccator under reduced pressure at ambient 
temperature until use.  
 
5.2.3 High-angle annular dark-field scanning transmission electron microscopy and 
electron energy-loss spectroscopy  
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A FEI Tecnai G2 F30 cryogenic transmission electron microscope at an 
accelerating voltage of 300 kV was used to collect high-angle annular dark-field scanning 
TEM images (HAADF STEM) and electron energy-loss spectroscopy (EELS) data. The 
microscope was equipped with a HAADF detector (inner and outer angles of 50 and 200 
mrad, respectively) and a post-column Gatan Image Filter. The energy distribution of the 
electron beam, determined by the full-width at half maximum of the zero-loss peak, was 
0.9 eV. To minimize radiation damage of the spin-coated SD TEM samples, regions of 
interest were surveyed in conventional bright-field TEM at a low magnification (9400×) 
using an electron dose rate of ≲ 10 e–/nm2s. At higher magnifications (40,000× and above), 
HAADF STEM image focusing and EELS spectrum alignment were performed on a 
sacrificial area that was far removed from the desired regions of interest. EELS spectra 
were then collected from the regions of interest by using "Focus" mode, in which the beam 
was rastered over an area of chosen size for an acquisition time of 10 s. The collection area 
size was varied among 200 nm × 200 nm, 100 nm × 100 nm, and 50 nm × 50 nm; the 
electron dosages for each collection area size were 2800, 11000, and 46000 e–/nm2, 
respectively. For each sample, EELS spectra were collected from at least 50 different 
regions of interest on the TEM grid. The beam was blocked before and after spectrum 
acquisitions to prevent damage of the sample. HAADF STEM images were collected after 
EELS spectra collection. Acquisition of conventional TEM EELS spectra is described in 
the Appendix C.2. 
 
5.2.4 Quantification of drug concentration in spin-coated SDs from EELS spectra  
To extract the zero-loss and low-loss EELS spectra from the raw EELS spectrum, 
the Fourier-log deconvolution routine in the Gatan Digital Micrograph software was used. 
The reflected tail zero-loss peak identification and modifier were chosen for the 
deconvolution. For each deconvoluted low-loss spectrum, the data below 3.5 eV and above 
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50.0 eV were removed and the contribution from the amorphous carbon film of the TEM 
grid was subtracted (see Appendix C.3). The intensity of each deconvoluted low-loss EELS 
spectrum was normalized by the integrated intensity of the spectrum. Average reference 
spectra of pure drugs and HPMCAS were calculated by summing at least 50 truncated 
spectra collected from each material and dividing the sum by the total integrated intensity. 
Reference spectra were created for different EELS spectra collection area sizes. 
 A multiple least-squares (MLS) analysis was used to quantify the concentration of 
a drug from the deconvoluted low-loss EELS spectrum. This analysis, which assumes that 
the experimental EELS spectrum of the SD is a linear combination of pure drug and 
HPMCAS spectra, may be described by: 
 
∑
i
iiSD SaS =  (5.1) 
 
where SSD is the predicted SD EELS spectrum (in units of normalized intensity), i is the 
index of each component, ia  is a fitting coefficient, and Si is the reference spectra of the 
pure drug or HPMCAS. ia  is equal to: 
 
𝑎B = 𝑤B𝜉B 𝑀B𝑤B𝜉B 𝑀BB  (5.2) 
 
where iw  is the weight fraction of the ith species, iξ  is the inelastic scattering cross section, 
and iM  is the molecular mass of the drug molecule or average HPMCAS substituted 
anhydroglucose unit. LENZPLUS was used to calculate iξ  for various drugs and HPMCAS 
(see Table C.1).109 For the deconvoluted low-loss EELS spectra of the drug:HPMCAS SDs, 
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MLS fitting was only performed on the range between 3.5 and 9.5 eV, which contains the 
π–π* transition peak, because this range exhibited the largest contrast between the drug 
and HPMCAS spectra. All MLS analysis calculations were performed using custom-made 
MATLAB (version R2012a) scripts. 
 
5.2.5 Annealing of 25 wt% phenytoin spin-coated SD TEM sample  
A 25 wt% phenytoin spin-coated SD TEM sample was annealed using a Discovery 
differential scanning calorimeter (TA Instruments). First, the TEM sample was placed 
inside a TzeroTM aluminum pan with a standard lid. Then, while immersed under nitrogen 
gas flow with a rate of 50 mL/min, the sample pan was heated from 0–160 °C using the 
following modulated differential scanning calorimetry (DSC) parameters: average 
temperature heating rate = 1 °C/min, temperature modulation amplitude = 1 °C, 
temperature modulation period = 40 s. Modulated DSC mode was used to mimic an 
experiment on the 25 wt% phenytoin spray-dried dispersion sample (see Appendix C.4). 
 
5.3 Results and discussion 
5.3.1 EELS of HPMCAS and phenytoin  
 Figure 5.1A shows a high-angle annular dark-field (HAADF) STEM image of a 
spin-coated HPMCAS film. While TEM imaging does not provide much information about 
this uniform HPMCAS film, the raw EELS spectrum of HPMCAS in Figure 5.1C reveals 
the electronic fingerprint. The peak at 0 eV is caused by electrons that undergo elastic 
scattering or no scattering, and is referred to as the zero-loss peak.108 Created by 
interactions between the incident electrons of the beam and the valence shell electrons of 
the HPMCAS, a broad plasmon peak at 25 eV is commonly observed in molecules that 
contain a high fraction of carbon atoms.140,141 Figure 5.1B displays a HAADF STEM image 
of a spin-coated phenytoin film. The film has holes and a jagged surface texture, 
presumably due to crystallization of phenytoin during the spin-coating process. The raw 
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EELS spectrum of phenytoin in Figure 5.1D not only contains the zero-loss and plasmon 
peaks, but also has a sharp π–π* transition peak at 7.5 eV. Unlike conventional TEM 
imaging, we can use this spectroscopic signal to distinguish between HPMCAS and 
phenytoin. 
 
 
Figure 5.1. High-angle annular dark-field (HAADF) STEM image of spin-coated (A) 
HPMCAS and (B) phenytoin films. The outlined regions are the areas from which EELS 
spectra were collected. EELS spectra and molecular structures of (C) HPMCAS and (D) 
phenytoin. The pictured structure of HPMCAS is merely illustrative; it does not 
represent the actual substitution pattern The y-axis is the intensity (I) and the x-axis is 
the energy-loss exhibited by a particular electron (ΔE). The HPMCAS spectrum only has 
the zero-loss and plasmon peaks, while the phenytoin spectrum contains the zero-loss, 
plasmon, and π–π* transition peaks.  
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5.3.2 Quantification of phenytoin concentration for spin-coated HPMCAS and phenytoin 
 Figure 5.2 shows the histograms of the measured phenytoin concentrations from 
STEM EELS for spin-coated HPMCAS and phenytoin. The average measured 
concentrations are consistent with the expected concentrations (0 and 100 wt% for 
HPMCAS and phenytoin, respectively) and the standard deviations of the measured 
concentrations match the values we observed for the phenytoin:HPMCAS SDs. 
 
 
Figure 5.2. Histograms of measured concentrations for (A) spin-coated HPMCAS and 
(B) spin-coated phenytoin. 
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5.3.3 EELS of spin-coated SDs with varying phenytoin concentration 
 Figure 5.4 presents HAADF STEM images of spin-coated SDs with different 
loadings of phenytoin (10, 25, and 50 wt% drug). The square marks in the images, spots 
from where EELS spectra were collected, are artifacts of beam damage (see Appendix C.1 
for bright-field TEM images of the SDs). Although the concentration of phenytoin varies 
significantly, TEM imaging cannot distinguish amongst these films and shows no features 
that signal the presence of HPMCAS or phenytoin, due to the small difference in electron 
density of the two species. 
 
 
Figure 5.3. HAADF STEM images of (A) 10, (B) 25, and (C) 50 wt% phenytoin spin-
coated dispersion films. TEM imaging cannot distinguish among these films. The square 
marks, caused by radiation damage, were areas from which EELS spectra were collected. 
 
EELS, however, can distinguish among solid dispersions with different phenytoin 
loadings. Figure 5.4 contains experimental and predicted spectra, as calculated by Eqn. 1, 
for spin-coated SDs of varying phenytoin concentration. The spectra show that the intensity 
of the π–π* transition peak in the EELS spectrum increases as the phenytoin concentration 
increases. Furthermore, the shape of each experimental spectrum qualitatively matches the 
shape of its corresponding predicted spectrum (no fitting was performed in this step). This 
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agreement not only corroborates the assumptions required for the MLS analysis (as 
described in the Section 5.2.4), but also allows for phenytoin concentration quantification. 
 
 
Figure 5.4. Comparison of experimental and predicted EELS spectra for 10, 25, and 50 
wt% phenytoin (PHY) spin-coated dispersions. The y-axis is the normalized spectrum 
intensity (Normalized I) and the x-axis is the energy-loss of each electron (ΔE). The 
HPMCAS and phenytoin spectra are each averages of 50 spectra. The representative 
experimental spectra qualitatively match the predicted spectra. 
 
5.3.4 Quantification of phenytoin concentration in spin-coated SDs 
 For the 10, 25, and 50 wt% phenytoin spin-coated SDs, EELS spectra from 50 
different regions on each film were evaluated. The spectra were acquired using a collection 
area size of 200 nm × 200 nm, and the aforementioned MLS model was used to calculate 
the phenytoin concentration. Histograms of the calculated phenytoin concentrations from 
50 different regions for each SD show that the average calculated concentrations match the 
nominal concentrations (Figure 5.5), suggesting that the use of the MLS analysis is valid 
for the phenytoin:HPMCAS system. Furthermore, the concentration histograms are 
monomodal and exhibit a standard deviation of 4–5 wt%, much larger than the error 
expected due to spectrum noise,112 but consistent with the experimental error reported in 
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the literature (~ 4 wt% for measurements of water and biomacromolecule concentrations 
in biological cryosections).142,143 We posit that the major source of this error is random 
experimental uncertainty. In particular, the subtraction of the contribution of the 
amorphous carbon support film from the deconvoluted low-loss EELS spectrum may create 
an uncertainty of ~ 4 wt% (see Appendix C.3 for further discussion of this point). Statistical 
fluctuations in the local concentration of drug and polymer may also cause the measured 
concentration to deviate from bulk concentration. These fluctuations, due in part to chain 
connectivity, are assumed to occur on a length scale of approximately the Kuhn length (~ 
10–20 nm for cellulosic polymers).71,72,73,144,145 Therefore, given that the EELS spectra 
collection area size used was 200 nm × 200 nm and thus much larger than the Kuhn length 
of a cellulosic polymer, such concentration fluctuations likely have little influence on the 
calculated concentration uncertainty. Based on these factors, we assume that 4 wt% is the 
minimum calculated concentration error for SD samples that are supported by an 
amorphous carbon film. Hence, we interpret the histograms to be strong evidence that for 
drug loadings of 10–50 wt% the phenytoin and HPMCAS in the SDs are intimately mixed 
at a length scale of 200 nm. This result, which supports studies that suggest that HPMCAS 
intimately mixes with phenytoin up to a drug loading of at least 50 wt%,25,42 implies that 
HPMCAS is an effective excipient for stabilizing glassy phenytoin. 
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Figure 5.5. Histograms of measured concentrations, as calculated by the EELS MLS 
noise-weighted algorithm, for 50 spots in (A) 10, (B) 25, and (C) 50 wt% spin-coated 
SDs. The average measured concentrations agree with the nominal phenytoin loadings 
of the dispersions. 
 
These data, however, do not conclusively rule out phase separation in 
phenytoin:HPMCAS SDs, as phase separated domains of phenytoin or HPMCAS could be 
smaller than 100 nm in size. To further investigate the possibility of phase separation in 
the phenytoin:HPMCAS spin-coated SDs, we also quantified the phenytoin concentration 
from EELS spectra that were acquired from much smaller collection area sizes of 100 nm 
× 100 nm and 50 nm × 50 nm. Figure 5.5 features the phenytoin and HPMCAS EELS 
spectra for collection area sizes of 200 nm x 200 nm, 100 nm x 100 nm, and 50 nm x 50 
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nm. The electron dosage for these collection area sizes was 2800, 11000, and 46000 e-/nm2, 
respectively. For phenytoin, the intensity of the π–π* transition peak intensity decreases as 
the collection area size decreases. Conversely, the π–π* region in the HPMCAS spectrum 
increases in intensity as the collection area size decreases. These changes in the spectra 
may be caused by the increase in electron dosage at smaller collection area sizes. When 
exposed to radiation, aromatic rings can break to create aliphatic crosslinks, thereby 
eliminating a π-bond from the molecule, while saturated C-H bonds can cleave to form an 
unsaturated C=C bond.146 Further experiments are needed to fully understand the influence 
of electron beam damage on the phenytoin and HPMCAS spectra. 
 
 
Figure 5.6. Phenytoin and HPMCAS EELS spectra for various collection area sizes. 
Each spectrum is an average of at least 50 experimental spectra. For phenytoin, the π–
π* transition peak intensity decreases as the collection area decreases. For HPMCAS, 
the π–π* transition region slightly increases in intensity as the collection area decreases. 
 
As an example, Figures 5.6 compares the concentration histograms of a 25 wt% 
phenytoin spin-coated dispersion for different collection area sizes (the 10 and 50 wt% 
phenytoin spin-coated SDs analyses are located in the Figures 5.7 and 5.8, respectively). 
At smaller collection area sizes, the average calculated concentrations still match the 
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nominal drug loadings, but the standard deviation of the calculated concentrations 
increased. The monomodal calculated concentration histograms again suggest that 
phenytoin and HPMCAS are not phase separated. The increase in the concentration 
variance may possibly be caused by two separate factors. First, the influence of statistical 
fluctuations in local drug and polymer concentration should increase as the collection area 
decreases. The smallest collection area size probed in this experiment (50 nm × 50 nm) is 
only 2–3 times larger than the expected length scale of concentration fluctuations for 
phenytoin:HPMCAS SDs. Second, the increase in electron dosage may damage the SD in 
a way that skews the calculated concentration. Electron irradiation causes irreversible 
chemical changes to soft materials via incipient radical formation. These chemical changes 
would likely corrupt the shape of the measured EELS spectra and shift the calculated 
concentration away from the concentration of the pristine material.146,147,148 Further studies 
are required to resolve the role of these processes. Nevertheless, these studies show that 
TEM and EELS can overcome the spatial resolution barriers that inhibit other imaging 
techniques. 
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Figure 5.6. Histograms of measured concentrations, as calculated by the EELS MLS 
noise-weighted algorithm, for 50 spots in (A) 10, (B) 25, and (C) 50 wt% spin-coated 
SDs. The average measured concentrations agree with the nominal phenytoin loadings 
of the dispersions. 
 
 
Figure 5.7. Histograms of measured concentrations from 50 spots on a 10 wt% 
phenytoin spin-coated SD. The EELS spectrum collection area sizes are (A) 200 nm × 
200 nm, (B) 100 nm × 100 nm, and (C) 50 nm × 50 nm. 
 
 
 
Figure 5.8. Histograms of measured concentrations from 50 spots on a 50 wt% 
phenytoin spin-coated SD. The EELS spectrum collection area sizes are (A) 200 nm × 
200 nm, (B) 100 nm × 100 nm, and (C) 50 nm × 50 nm. 
 
5.3.5 EELS of an annealed 25 wt% phenytoin spin-coated SD 
 To further demonstrate the sub-100 nm spatial resolution of EELS, we collected 
spectra from a 25 wt% phenytoin spin-coated SD that was heated to 140 °C, which is above 
the crystallization temperature of the 25 wt% phenytoin spray-dried SD (Appendix C.4). 
Unlike the virgin sample, the annealed SD exhibits non-uniform topology and 
nanostructures. For the region captured in Figure 5.9A, EELS spectra were collected from 
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regions "X" and "Y". Though "X" and "Y" were only separated by less than 50 nm, the 
phenytoin concentrations of the two regions were substantially different (Figure 5.9B). "X" 
is likely a region of crystalline phenytoin, while "Y" is likely a region of amorphous 
phenytoin and HPMCAS. A lower magnification HAADF TEM image of the region is 
given in Figure 5.10. By using EELS, we may directly elucidate the composition of the 
nanostructures in the sample with high spatial resolution.  
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Figure 5.9. (A) HAADF STEM image of a 25 wt% phenytoin spin-coated dispersion 
film that was annealed to 140 °C. EELS spectra were collected from the regions "X" and 
"Y". (B) EELS spectra from regions "X" and "Y". Though the regions are separated by 
less than 50 nm, the phenytoin concentrations in these two regions are drastically 
different. Phenytoin (PHY) and HPMCAS EELS spectra are shown for comparison. 
 
 
Figure 5.10. Low magnification HAADF TEM image of annealed 25 wt% phenytoin 
SD. 
 
5.3.6 Application of EELS for detecting other aromatic-ring containing drug molecules 
 The use of the EELS MLS analysis should be useful for SDs containing not only 
phenytoin, but also other APIs. To further test the versatility of this strategy, we collected 
EELS spectra from four other drug molecules containing aromatic motifs: carbamazepine, 
naproxen, itraconazole, and griseofulvin. As seen in Figure 7, each drug exhibits a unique 
π–π* transition peak in the EELS spectrum. The intensity and breadth of the π–π* transition 
peak is intimately tied to molecular structure.149  
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Figure 5.11. (A) Molecular structures of carbamazepine, naproxen, itraconazole, and 
griseofulvin. (B) Conventional TEM EELS spectra of the four additional APIs. Each 
spectrum is the average of at least 50 experimental spectra. The molecules, which all 
contain aromatic rings, each exhibit a unique EELS spectrum. Phenytoin and HPMCAS, 
the dashed lines, are included for comparison. 
 
To probe the accuracy and precision of the concentration quantification for different 
molecules, we analyzed EELS spectra from SDs that contained 10 wt% of carbamazepine, 
naproxen, itraconazole, or griseofulvin (Figure 5.12). The concentration quantification was 
accurate and precise for the SDs that had carbamazepine or naproxen (molecules that 
exhibit a relatively strong π–π* transition signal), but was both inaccurate and imprecise 
for the SDs that had itraconazole or griseofulvin (molecules that exhibited a relatively weak 
π–π* transition signal). This observation implies that the reliability of the MLS analysis is 
contingent on the strength of the associated π–π* transition peak relative to the HPMCAS 
EELS spectrum. Furthermore, this result supports the finding of Yakovlev et al. that the 
uncertainty of the concentration calculated by the EELS MLS analysis is inversely related 
to the difference between the pure species spectra.112  
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Figure 5.12. Histograms of measured concentrations from 50 spots for 10 wt% drug 
solid dispersions featuring HPMCAS as the excipient and either (A) carbamazepine, (B) 
naproxen, (C) itraconazole, or (D) griseofulvin as the drug. The ELS MLS analysis is 
accurate and precise for carbamazepine and naproxen, which have strong π–π* transition 
peaks, while the analysis is inaccurate and imprecise for itraconazole and griseofulvin, 
which have weak π–π* transition peaks. 
 
The findings in this work suggest that EELS will be a useful tool for resolving many 
questions regarding SD design. This technique may potentially be used to characterize with 
sub-100 nm the miscibility of a single API in various non-aromatic excipients (e.g., 
Soluplus®, Eudragit®, other cellulose derivatives)54,150 and to elucidate the relationship 
between API spatial distribution and SD performance. Potentially, the influence of 
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temperature and humidity on the API nanoscale spatial distribution may also be evaluated 
by EELS. Furthermore, the EELS MLS analysis described in this work could be 
generalized for binary blends in which one component has a relatively strong π–π* 
transition signal and the other component does not. Many soft materials fit this criterion. 
For example, many polymer binary blends and block polymers commonly have an aromatic 
component and a non-aromatic component. Many of these aromatic polymers – such as 
poly(styrene), poly(2-vinylpyridine), and polycarbonate – exhibit strong π–π* transition 
signals.112,149,151,152 Materials that contain an encapsulated fluorophore are also excellent 
candidates for this analysis. Fluorophores, typically polycyclic aromatic hydrocarbons, 
exhibit sharp π–π* transition signals.153 The transparency and flexibility of the EELS MLS 
analysis suggest it may be useful for characterizing a wide variety of systems. 
 The main challenge that prevents the use of EELS MLS analysis as a routine 
characterization tool for soft materials is electron beam damage. Extended irradiation of 
the sample materials may cause structural changes or non-linear phenomenon to occur, 
thereby compromising the linearity assumption of the MLS analysis. The effect of beam 
damage may be diminished by using reference spectra of the pure species components that 
were collected at the same conditions as the blend materials (as was done in this work).148 
Also, the rate of beam damage can be reduced by cooling the sample to cryogenic 
conditions.112 By minimizing the influence of electron beam damage and other random 
experimental uncertainty, the accuracy and precision of the EELS MLS analysis may be 
improved.  
 
5.4 Conclusions 
 We demonstrated EELS characterization of SDs. The technique may be used to 
quantify the local concentration of drug throughout the polymer matrix with high accuracy 
and sub-100 nm resolution. Analysis of phenytoin:HPMCAS SDs suggests the drug and 
polymer are intimately mixed throughout the dispersion, even at high drug loadings. 
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Furthermore, we established the utility of EELS for characterizing other drug molecules. 
EELS is therefore a potentially powerful and complementary tool for evaluating the spatial 
distribution and structure-property relationships of a wide variety of small molecule-
polymer blends. 
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Chapter 6: Direct observation of nanostructures during 
dissolution of polymer/drug particles 
 
 
6.1 Introduction 
 The use of a solid dispersion (SDs) may significantly enhance the apparent 
solubility of a pharmaceutical drug, but the role of the polymer excipient is poorly 
understood. For example, hydroxypropyl methylcellulose acetate succinate (HPMCAS, 
Scheme 6.1) is an effective excipient for some drugs, but it is not a panacea. To address 
this ambiguity, the work in this chapter elucidates the influence of polymer and drug on 
SD dissolution in phosphate buffered saline by directly evaluating nanostructures in 
solution. First, aqueous solution behavior of HPMCAS, a polymer considered to be one of 
the most effective excipients, is characterized. Then, dissolution of HPMCAS SDs, 
containing either phenytoin or probucol (Scheme 6.1) as the API, is investigated. Although 
both of these drugs have poor aqueous solubility, phenytoin and probucol have very 
disparate physical properties (see Figure D.1). Using a combination of cryogenic 
transmission electron microscopy, small-angle X-ray scattering, and electron diffraction, a 
direct correlation between SD dissolution profiles and the presence of nanoparticles, <100 
nm in size, was revealed. Finally, the repercussions and potential universality of these 
discoveries are discussed. 
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Scheme 6.1. Chemical structures of hydroxypropyl methylcellulose acetate succinate 
(HPMCAS), phenytoin, and probucol. The pictured structure of HPMCAS is merely 
illustrative and not representative of the actual substitution pattern. 
 
 
6.2 Experimental Section 
6.2.1 Materials  
Phenytoin, probucol (Sigma-Aldrich), and tetrahydrofuran (Acros Organics, 
99.9%, stabilized with BHT) were used as received. Hydroxypropyl methylcellulose 
acetate succinate (AFFINISOLTM HPMCAS 912 G, 10 wt% acetate, 11 wt% succinate, 
reported Mn, Mw, and Đ of 60 kg/mol, 140 kg/mol, and 2.4, respectively, The Dow 
Chemical Company) was dried prior to use for 12 h under reduced pressure at a temperature 
of 70 °C. Phosphate buffered saline (PBS, pH = 6.5) was prepared using Milli-Q water, 20 
mM sodium phosphate dibasic heptahydrate (Fisher, 98%), 47 mM potassium phosphate 
monobasic (J.T. Baker, ³ 99%), and 82 mM sodium chloride (Fisher, ³ 99%). 
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6.2.2 Preparation of SDs by spray drying 
Spray dried SDs of 3.2, 10, 25, and 50 wt% phenytoin or 10, 25, and 50 wt% 
probucol, and HPMCAS were studied in this work. Specified amounts of drug and 
HPMCAS were dissolved in tetrahydrofuran to form a 2 wt% solution. The precursor 
solution was then spray dried by a mini spray dryer (Bend Research) using a nitrogen flow 
rate of 12.8 standard liters per min, an inlet temperature of 68 °C, and a solution flow rate 
of 0.65 mL/min. The outlet temperature, which was not controlled, fluctuated between 24 
and 27 °C. SD powder was recovered from filter paper placed in the outlet of the spray 
dryer, subsequently dried under reduced pressure at ambient temperature for at least 12 h, 
and stored in a desiccator under reduced pressure at ambient temperature until use. SD 
morphology was characterized by scanning electron microscopy. All SDs were determined 
to be homogenous and fully amorphous materials within the detection limits of wide-angle 
X-ray scattering and modulated differential scanning calorimetry (see Figures D.4 and 
D.5). 
 
6.2.3 Dynamic light scattering (DLS) 
Samples were prepared by directly dissolving HPMCAS in PBS or tetrahydrofuran 
and passing the solutions through 0.2 µm filters (GHP and PTFE for PBS and 
tetrahydrofuran, respectively) into clean glass tubes. DLS was conducted on a Brookhaven 
BI-200SM light scattering instrument with a wavelength of 637 nm, laser power of 30 mW, 
and an avalanche photodiode detector with a 200 µm pinhole. Measurements were made at 
11 angles ranging from 30–120°. 
 
6.2.4 Static light scattering (SLS) 
To prepare samples for SLS, HPMCAS was dissolved in tetrahydrofuran to form a 
2 wt% HPMCAS solution, successively passed through 0.45 and 0.25 µm PTFE filters, 
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and spray dried. The resulting dried polymer was dissolved in PBS to form a 0.25 mg/mL 
HPMCAS stock solution. Aliquots of the stock solution were diluted to form 11 additional 
SLS samples that had concentrations ranging from 0.010–0.235 mg/mL. SLS 
measurements were performed using the Brookhaven BI-200SM light scattering 
instrument described above. The pinhole size was set to 1 mm and measurements were 
made at 13 angles ranging from 30–102°. 
 
6.2.5 Microcentrifuge dissolution and solubility assays 
 For each dissolution measurement, a SD was loaded into a 1.5 mL microcentrifuge 
tube. PBS was added to the SD at 37 °C to achieve the desired targeted drug concentration 
(e.g., to obtain 1000 µg/mL of phenytoin, 1.2 mL of PBS was added to 12 mg of 10 wt% 
phenytoin SD). Dissolution media were vortexed for 1 min and placed in an isothermal 
aluminum microcentrifuge tube holder held at 37 °C. At 4, 10, 20, 40, 90, 180, and 360 
min, the dissolution media was centrifuged at 13000 g for 1 min, a 50 µL aliquot of the 
supernatant was collected and subsequently diluted by 350 µL of methanol, and the 
remaining dissolution medium was re-vortexed for 30 s and returned to the microcentrifuge 
tube holder. During aliquot collection, the samples are typically outside the 37 °C sample 
holder for ~ 2 min. For solubility measurements, 4 mg of crystalline drug (phenytoin or 
probucol) was loaded into a 1.5 mL microcentrifuge tube with a small stir bar and covered 
with 1 mL solution of HPMCAS dissolved in PBS. The sample was sealed with ParafilmTM, 
vortexed for 1 min, placed in a sand bath heated to 37 °C, and stirred for 72 hrs. Then, the 
solubility media were centrifuged at 13000 g for 1 min. 50 µL aliquots of the supernatant 
were collected, passed through a 0.25 µm GHP filter, and diluted by 350 µL of methanol. 
Diluted aliquots for both measurements were analyzed by high-performance liquid 
chromatography using an Agilent 1260 liquid chromatograph system with multi-
wavelength UV-vis detection and a reversed-phase EC-C18 column (Poroshell 120, 4.6 × 
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50 mm, particle size 2.7 µm, Agilent). The mobile phase was 45:55 and 96:4 (v/v) 
MeCN/H2O for SDs containing phenytoin and probucol, respectively. For both drugs, 
calibration curves ranging from 10–1000 µg/mL were developed. All dissolution and 
solubility measurements were repeated in triplicate. 
 
6.2.6 Cryogenic transmission electron microscopy (Cryo-TEM)  
Samples of vitrified SD dissolution media were made using an FEI Vitrobot Mark 
III automated vitrification device. Glow discharge was applied to a 200-mesh copper TEM 
grid with a lacey carbon support film to increase the surface energy of the grid. The grid 
was then placed into the sample chamber of the Vitrobot, which had a relative humidity 
and temperature of 100% and 26 °C, respectively. SD dissolution was initiated using the 
method described previously. After centrifugation of dissolution media at various time 
points, a 2 µL aliquot of the supernatant was collected and deposited onto the 
aforementioned TEM grid. The grid was then immediately plunged into a pool of liquid 
ethane to vitrify the dissolution media. Vitrified samples were stored at cryogenic 
temperature until imaging. Cryo-TEM imaging and electron diffraction were executed 
using a FEI Tecnai Spirit BioTWIN transmission electron microscope with an accelerating 
voltage of 120 kV. During imaging, the sample was maintained between –179 and –175 
°C. Electron diffraction patterns of dissolution media structures were collected using low-
dose conditions. Briefly, a region of interest (ROI) was identified in bright-field TEM at 
low magnification (4700×) using an electron dose rate of ≲ 10 e–/nm2s. Higher 
magnification (49000×) alignments were made on an area far removed from the desired 
ROI. To reduce the size of the sampled ROI, a selected-area aperture with an area of ~ 1 
µm2 was inserted into the electron beam path. Electron diffraction patterns were recorded 
using an electron dose rate of ~ 150 e–/nm2s and indexed using the DiffTools plug-in for 
Gatan DigitalMicrographTM.115 
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6.2.7 Small-angle X-ray scattering (SAXS)  
SAXS experiments were conducted at DND-CAT (beamline 5-ID-D) at the 
Advanced Photon Source in Argonne National Laboratory (Argonne, IL). The sample-to-
detector distance was 8.5 m. Dissolution media samples were generated by loading SDs 
into 20 mL scintillation vials and adding PBS at 37 °C to achieve the desired targeted drug 
concentration. The vials were vortexed for 1 min and heated in an aluminum vial holder at 
37 °C. At 4, 10, 20, 40, 90, 180, and 360 min, the vials were vortexed to remix the 
dissolution media. At each time point, approximately 0.1 mL of dissolution media was 
collected and injected into a 1.5 mm quartz capillary. The remaining solution was replaced 
into the vial holder and held at 37 °C. The aliquot capillary was immediately placed in a 
multi-capillary heating stage set to 37 °C. After closing the hutch door (a process that takes 
~ 2 min), 2D SAXS scattering patterns of the aliquots were recorded and subsequently 
integrated to create 1D intensity (arbitrary units) vs. q patterns. SAXS patterns were 
analyzed using custom-made MATLAB (version R2012a) scripts. Background was 
removed from the SAXS patterns by subtracting a high q baseline and a PBS reference 
pattern.  
 
6.3 Results 
6.3.1 Characterization of HPMCAS solutions 
 The 912 G grade of HPMCAS (roughly equal weight fractions of acetate and 
succinate substituents) was chosen as the model excipient to balance hydrophobicity and 
aqueous solubility. Figure 6.1A shows the hydrodynamic radius (Rh) distribution, as 
calculated by REPES of the DLS data, for 9 mg/mL of HPMCAS dissolved in PBS. The 
peaks around 10 nm are consistent with the expected Rh of linear HPMCAS chains with a 
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molecular weight ~ 105 g/mol. There was also a peak around 100 nm. The collected second-
order auto correlation functions, (𝑔:), were also fit to a double exponential model: 
 
𝑔: 𝑞, 𝑡 = 𝛽 𝑔E 𝑞, 𝑡 : + 𝐵𝐺 (6.1) 
𝑔E 𝑞, 𝑡 = 𝑓 exp −ΓE𝑡 + 1 − 𝑓 exp−Γ:𝑡 (6.2) 
 𝛽 is the spatial coherence factor, 𝑔E is the first-order auto correlation function, 𝐵𝐺 is the 
background, 𝑓 is the fractional intensity of the first mode, 𝑡 is time, ΓE is the decay rate of 
the first mode, and Γ: is the decay rate of the second mode. The double exponential fits 
(featured in Figure 6.2A) agrees with the REPES analysis, although the systematic error in 
the residuals suggests that this simplified model is not completely appropriate (see Figure 
6.2B). The linear relationship between Γ for both modes and the square of the scattering 
vector (𝑞) verifies the relaxations are diffusive (Figure 6.2C). Table 6.1 contains the values 
for all fitted parameters.  
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Figure 6.1. (A) Hydrodynamic radius distribution of HPMCAS in PBS buffer at 37 °C. 
The distribution was calculated by performing a REPES analysis on the 90° 
autocorrelation function measured by DLS. (B) Berry-modified Zimm plot of HPMCAS 
in PBS at 37 °C. The open black circles are the measured data, while the green and blue 
lines are the zero-angle and zero-concentration extrapolations, respectively. (C) Second 
virial coefficient, A2, and ceff of HPMCAS in PBS for various temperatures. PBS is a 
poor solvent for HPMCAS at 25 and 37 °C. (D) Molecular weight, Mw, and radius of 
gyration, Rg, of HPMCAS in PBS. 
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Figure 6.2. Additional DLS data of 9 mg/mL of HPMCAS in PBS at 37°C. (A) 
Comparison of autocorrelation functions versus double exponential fit. (B) Double 
exponential fit residuals. (C) Decay rate (Γ) versus 𝑞: for both modes of double 
exponential fit. 
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Table 6.1. Fitted parameters from double exponential fit of second-order autocorrelation 
functions for 9 mg/mL HPMCAS in PBS at 37°C. 
 
Angle [°] B β f Γ1 [1/s] Γ2 [1/s] 
30 1.0004 0.56 0.90 49 720 
35 1.004 0.50 0.89 73 1000 
40 1.0038 0.52 0.90 100 1600 
45 1.0021 0.53 0.90 130 2100 
50 1.0025 0.53 0.90 160 2500 
55 1.0003 0.53 0.89 200 2900 
60 1.0025 0.53 0.88 240 3400 
75 1.0006 0.52 0.86 380 4900 
90 0.9996 0.49 0.84 540 6800 
105 1.0006 0.45 0.82 710 8200 
120 1.001 0.40 0.81 920 11000 
 
As light scattering is more sensitive to larger objects, the numerical fraction of the 
larger structure is likely quite low.5 While several reports have suggested that the 
amphilicity of HPMCAS causes it to form aggregates or a gel in solution,41,42,49,154 no 
evidence of aggregates was observed using cryo-TEM for solutions of HPMCAS in PBS 
(Figure 6.3). Alternately, during synthesis of HPMCAS the acetate and succinate moieties 
not only add to the hydroxyl groups on the anhydroglucose backbone of HPMCAS, but 
also react with the hydroxypropyl substituent to form oligomeric side chains. Succinic 
anhydride may also induce chain coupling.45,155 To distinguish between aggregates and 
cross-linked chains, we compared the Rh distribution of HPMCAS dissolved in PBS to that 
in tetrahydrofuran at 25 °C (Figure 6.4). Despite the different solvents, the Rh distributions 
are nearly identical. The persistence of the slower mode suggests that the 100 nm structure 
primarily reflects a low concentration of covalently-linked HPMCAS chains. 
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Figure 6.3. Cryo-TEM of 9 mg/mL HPMCAS in PBS solution. The red arrow points to 
an ice crystal artifact. 
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Figure 6.4. (A) REPES analysis and (B) double exponential fit analysis for 8 mg/mL of 
HPMCAS in PBS at 25 °C. (C) REPES analysis and (D) double exponential fit analysis 
for 8 mg/mL of HPMCAS in tetrahydrofuran at 25 °C. 
 
To further probe the solution behavior of HPMCAS, SLS was performed on dilute 
solutions (≤0.25 mg/mL) in PBS. Static light scattering (SLS) data were fit to the Berry-
modified Zimm equation:119 
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𝐾𝑐𝑅 = 1𝑀E : 1 + 𝑞:𝑅𝑔:6 +⋯ + 2𝐴:𝑐 + ⋯ (6.3) 
 𝑅 is the Rayleigh ratio, 𝐾 is the optical constant, 𝑐 is concentration (g/mL), 𝐴: is the 
second virial coefficient, 𝑀 is weight-average molecular weight of the polymer, 𝑞 is the 
scattering vector, and 𝑅@ is the radius of gyration of the polymer in solution. Figure 6.1B, 
6.5A, and 6.5B are the Berry-modified Zimm plots for the solutions at 37 °C, 25, and 50 
°C, respectively. Figures 6.5C-E magnify the zero-concentration extrapolation lines at 25, 
37, and 50°C. The zero-angle and zero-concentration extrapolations were used to estimate 
the second virial coefficient, A2, weight-average molecular weight, Mw, and radius of 
gyration, Rg. An effective interaction parameter, ceff, was calculated by 
 
𝜒;<< = 12 −𝑀P:𝑉𝐴:𝑉/:  (6.4) 
 𝑀P is the polymer repeat unit molecular weight, 𝑉  is the solvent molar volume, 𝑉/ is the 
polymer average repeat unit molar volume. Based on the temperature dependence of A2 
and ceff, HPMCAS dissolved in PBS displays an upper critical solution temperature phase 
diagram (Figure 6.1C). At 25 and 37 °C, PBS is a poor solvent for HPMCAS, indicating 
there is a thermodynamic driving force for HPMCAS to preferentially interact with itself 
(and/or possibly other species) rather than with water molecules. At 50 °C, PBS is 
approximately a theta solvent for HPMCAS.5 Both Mw and Rg are essentially invariant with 
temperature (Figure 6.1D). The measured Rg is consistent with the 100 nm mode observed 
by DLS, and given the observation of 100 nm structures in different solvents, temperatures, 
and across orders of magnitude in concentration, strongly suggests that HPMCAS solutions 
contain species resulting from chain coupling.  
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Figure 6.5. Berry-modified Zimm plots of HPMCAS in PBS at (A) 25 and (B) 50 °C. 
Zero-concentration extrapolation lines at (C) 25, (D) 37, and (E) 50 °C. 
 
6.3.2 Dissolution of phenytoin and HPMCAS SDs 
 Figure 6.6 features dissolution profiles of phenytoin (PHY) and HPMCAS SDs 
with varying drug loading. The 10 wt% PHY SD dissolution profile plateaus at 600 µg/mL 
and then rapidly decays after 20 min. The 20 wt % PHY SD dissolution profile decays from 
600 µg/mL after 4 min, while the 50 wt% SD dissolution profile stays at a low 
concentration over 6 hours. The observed trends show that PHY, a drug with a strong 
tendency to crystallize (Figure D.1), can be temporarily stabilized in solution by HPMCAS. 
The polymer, however, has minimal influence on the solubility of crystalline PHY (Figure 
6.7), confirming that the dissolution profiles reflect kinetic phenomena. 
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Figure 6.6. Dissolution profiles of PHY:HPMCAS SDs with various drug loadings. 
 
 
Figure 6.7. Measured solubility of crystalline phenytoin in HPMCAS solutions. The 
polymer had minimal influence on the solubility of the crystalline drug. 
 
To further elucidate the dissolution mechanism, PHY:HPMCAS SD dissolution 
media were characterized using both cryo-TEM and small-angle X-ray scattering (SAXS). 
For the 10 wt% PHY SD, cryo-TEM revealed that the dissolution media contained 
nanoparticles that persisted over 90 min, with a constant volumetric average radius of 15 
± 3 nm (Figure 6.8A), much smaller than the large mode structures in HPMCAS solutions 
observed by light scattering and also other previously reported dissolution aggregates.16 
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Figure 6.9 contains additional cryo-TEM images of 10 wt% PHY SD dissolution media. 
These nanoparticles are not detected during the dissolution of spray dried HPMCAS 
particles (Figure 6.10). SAXS further corroborates the presence of nanoparticles in the 
dissolution media (Figure 6.8B). The shoulder in the SAXS patterns between 4–90 min 
confirms the presence of structures ≈ 100 nm in size, while the decaying shoulder intensity 
verifies the gradual disappearance of the structures. SAXS patterns of centrifuged 
dissolution media also display the same trend (Figure 6.11). Additionally, beginning at 20 
min, an upturn in the SAXS pattern emerges at q < 0.3 nm–1. This upturn, coinciding with 
the first time point in which PHY crystals are observed in the dissolution media by optical 
microscopy,156 possibly indicates the onset of PHY crystallization from solution. 
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Figure 6.8. (A) Cryo-TEM image of 10 wt% phenytoin SD dissolution media at 10 min. 
(B) SAXS patterns of 10 wt% phenytoin SD dissolution media at various time points. 
The characteristic shoulder confirmed the presence of a metastable nanostructure in 
solution. (C) Radius of gyration, Rg, estimated by fitting SAXS pattern to Equation 6.5 
using a triaxial ellipsoid form factor. (D) Comparison of dissolution profile and 
estimated ellipsoid scaling parameters. Measured drug concentration directly correlated 
with the presence of nanoparticles in the dissolution media. (E) Low-dose cryo-TEM 
image and (F) electron diffraction pattern of 10 wt% phenytoin dissolution media at 40 
min. Red circle represents position of SAD aperture during acquisition. Lack of sharp 
diffraction spots suggested nanoparticles are amorphous. 
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Figure 6.9. Cryo-TEM images of 10 wt% PHY SD dissolution media at (A) 4, (B) 20, 
(C) 40, and (D) 90 min. 
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Figure 6.10. Characterization of spray dried HPMCAS dissolution media (targeted 
concentration of 9 mg/mL). (A) Cryo-TEM of dissolution media at 4 min. (B) SAXS 
patterns. 
 
 
Figure 6.11. SAXS patterns of centrifuged 10 wt% PHY SD dissolution media. 
 
SAXS patterns may be quantitatively analyzed by fitting the scattering intensity, 𝐼 𝑞 , to an empirical model that is a sum of form factor scattering from nanoparticles (first 
term) and pure HPMCAS (second term): 
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𝐼 𝑞 = 𝑃/ 𝑞 + 𝛽𝑞® + 𝐵𝐺 (6.5) 
𝑃/ 𝑞  is a form factor that describes nanoparticle shape, 𝛽 and 𝛾 are power law constants, 
and 𝐵𝐺 is the background. Because the nanoparticles observed in the cryo-TEM images 
were jagged, a triaxial ellipsoid form factor was used to describe the nanoparticle shape:S157 
 
𝑃;_/ 𝑞 = 2𝜋 𝜀;_/ Φ 𝑞𝑟 𝑎, 𝑏, 𝑐, 𝜃, 𝜑 : sin 𝜃 𝑑𝜃𝑑𝜑± :P  (6.6) 
Φ 𝑥 = 3 sin 𝑥 − 𝑥 cos 𝑥𝑥  (6.7) 
𝑟 𝑎, 𝑏, 𝑐, 𝜃, 𝜑 = 𝑎: sin: 	𝜑 + 𝑏: cos: 𝜑 + 𝑐: cos: 𝜃 (6.8) 
𝑅@ = 𝑎: + 𝑏: + 𝑐:5  (6.9) 
 
 𝜀;_/ is the ellipsoid scattering intensity scaling factor, 𝑞 is the scattering vector, Φ 
is the square root of the hard sphere form factor, 𝑎, 𝑏, and 𝑐 are semi-axes lengths, and 𝑅@ 
is the ellipsoid radius of gyration. Figure 6.12A compares the SAXS patterns to the model 
fits, Figure 6.12B features the extracted semi-axes lengths, and Table 6.2 lists values of all 
fit parameters. From 4 to 90 min, the estimated nanoparticle 𝑅@	increased slightly (Figure 
6.8C). The estimated values of 𝜀;_/, which assess scattering caused solely by the 
nanoparticles, exhibited a trend identical to the dissolution profile (Figure 6.8D). Thus, 
measured drug concentration directly correlates with the presence of nanoparticles in 
solution.  
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Figure 6.12. (A) Comparison of experimental SAXS data versus triaxial ellipsoid form 
factor model fit. (B) Ellipsoid semi-axes lengths extracted from model fitting. SAXS 
pattern for 9 mg/mL HPMCAS solution was fit only to a power law model. 
 
 
 
  
131 
 
Table 6.2. Fitted parameters from triaxial ellipsoid form factor model fit of 10 wt% PHY 
SD dissolution media SAXS patterns. 
 
Time 
[min] 
𝜀;_/ 
[a.u.] 𝑎 𝑏 c 𝛽 𝛾 𝐵𝐺 [a.u.] 
4 7.5 8.5 15 22 0.003 1.2 0.014 
10 8.5 8.8 15 24 0.008 1.2 0.0008 
20 6.6 8.7 16 28 0.005 1.8 0.002 
40 2.0 7.9 17 30 0.006 2.1 0.003 
90 0.5 10 20 30 0.011 1.7 -0.014 
180 0.02 2.1 15 20 0.009 1.9 -0.010 
360 0.02 2 11 20 0.011 1.9 -0.013 
9 mg/mL 
HPMCAS - - - - 0.023 1.3 -0.051 
 
The nanoparticles in the 10 wt% PHY SD dissolution media may also be described 
by a polydisperse sphere form factor: 
 
𝑃 / 𝑞 = 𝜀^/ 𝑝 𝑅 Φ: 𝑞𝑅 𝑑𝑅P  (6.10) 
𝑝 𝑅 = 𝑧·¸EΓ 𝑧 + 1 𝑅·E𝑅`¹@· exp −𝑧𝑅𝑅`¹@  (6.11) 
 𝜀^/ is the polydisperse sphere scattering intensity scaling factor, 𝑝 is the normalized 
Schulz-Zimm distribution,158 𝑅 is the radius, 𝑞 is the scattering vector, Φ is the square root 
of the hard sphere form factor (Equation 6.7), 𝑧 is the Schulz-Zimm distribution width 
parameter, and 𝑅`¹@ is the average radius. Figure 6.13 is a comparison between the SAXS 
patterns and polydisperse sphere form factor model fit, Figure 6.14 shows 𝑅`¹@, 𝑧, and 𝜀^/, and Table 6.3 features values for all fit parameters. Fitting the data to a polydisperse 
sphere form factor gave similar results. 
  
132 
 
 
Figure 6.13. Comparison of experimental SAXS data versus polydisperse sphere form 
factor model fit. SAXS pattern for 9 mg/mL HPMCAS solution was fit only to a power 
law model.  
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Figure 6.14. (A) Average radius (𝑹𝒂𝒗𝒈) and (B) Schulz-Zimm distribution width 
parameter (𝒛) extracted from polydisperse sphere form factor model fit for 10 wt% PHY 
SD dissolution media. (C) Comparison of 10 wt% PHY SD dissolution profile and sphere 
scattering intensity scaling factor (𝜀^/). 
 
 
 
 
 
 
 
  
134 
Table 6.3. Fitted parameters from polydisperse sphere form factor model fit of 10 wt% 
PHY SD dissolution media SAXS patterns. 
Time [min] 𝜀^/;\; [a.u.] 𝑅`¹@ 𝑧 𝛽 𝛾 𝐵𝐺 [a.u.] 
4 11 17 15 0.0036 1.2 0.005 
10 13 17 14 0.0016 1.2 0.009 
20 9.3 18 12 0.0018 2.3 0.006 
40 3 20 8.6 0.0052 2.2 0.003 
90 1.4 27 5.3 0.0063 1.8 -0.002 
180 0.61 20 3.4 0.0021 2.4 0.004 
360 0.047 10 75 0.0089 1.9 -0.005 
9 mg/mL 
HPMCAS - - - 0.023 1.3 -0.051 
 
To determine whether the nanoparticles are crystalline PHY, electron diffraction 
patterns of 10 wt% SD dissolution media were collected under low-dose conditions. While 
electron diffraction patterns of crystalline drug exhibit strong Bragg peaks,159 the absence 
of Bragg peaks in the dissolution media diffraction patterns suggests that the nanoparticles 
are amorphous structures (Figures 6.8E and 6.8F), consistent with observations by Taylor 
et al.16  
The dissolution profiles of SDs with higher PHY loading also correlated with the 
presence of nanoparticles. For the 25 wt% PHY SD, cryo-TEM and SAXS verified that at 
4 min, when the measured PHY concentration was at 600 µg/mL, the dissolution media 
contained nanoparticles with a similar average size as the 10 wt% PHY SD dissolution 
media (Figures 6.15A and 6.16A, respectively). After 10 min, when the PHY concentration 
begins to decrease, the nanoparticles disappeared from solution (Figures 6.15B and 6.15B). 
For the 50 wt% PHY SD, nanoparticles were not detected at any time point (Figures 6.17). 
These results demonstrate that achievement and stabilization of high PHY concentrations 
corresponds to nanoparticle formation. 
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Figure 6.15. Cryo-TEM images of 25 wt% phenytoin dissolution media at (A) 4 min 
and (B) 10 min. 
 
 
Figure 6.16. (A) Comparison of SAXS pattern and triaxial ellipsoid form model fit for 
25 wt% PHY SD dissolution media at 10 min. (B) SAXS patterns of 25 wt% PHY SD 
dissolution media at various time points. 
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Figure 6.17. Characterization of 50 wt% PHY SD dissolution media. (A) Cryo-TEM 
image at 4 min. (B) SAXS patterns at various time points. 
 
The influence of targeted drug concentration on PHY SD dissolution was 
investigated. Figure 6.18A is the dissolution profile for 10 wt% PHY SD with a targeted 
drug concentration of 300 µg/mL. In this case, dissolution of the SD results in lower 
concentrations of both drug and polymer relative to the measurement where 1000 µg/mL 
of drug was targeted. Concentration decreased at 360 min, likely caused by crystallization 
or precipitation of drug from solution. Nanoparticles were not detected in the dissolution 
media by both cryo-TEM and SAXS (Figures 6.18B and 6.18C). Figure 6.18D is the 
dissolution profile for 3.2 wt% PHY SD with a targeted drug concentration of 300 µg/mL. 
While the polymer concentration is much higher, still no nanoparticles were detected by 
cryo-TEM and SAXS (Figures 6.18E and 6.18F). These observations strongly suggest 
nanoparticles only form above some critical PHY concentration. 
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Figure 6.18. Dissolution profiles for PHY SDs with a targeted drug concentration of 300 
µg/mL. (A) Dissolution profile, (B) cryo-TEM of dissolution media at 4 min, and (C) 
SAXS patterns of dissolution media for 10 wt% PHY SD. (D) Dissolution profile, (E) 
cryo-TEM of dissolution media at 4 min, and (F) SAXS patterns of dissolution media 
for 3.2 wt% PHY SD. 
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6.3.3 Dissolution of probucol and HPMCAS SDs 
 Figure 6.19A presents the dissolution profiles of probucol (PRB) and HPMCAS 
SDs. Increased PRB loading decreased the release rate of drug, a trend unlike the behavior 
of PHY SDs, but observed for other API:excipient pairings.94,95,96 Once the concentration 
was relatively high, PRB remained in solution. The lack of a concentration decrease is 
likely related to the relatively weak crystallization tendency of PRB (Figure D.1). 
Measurements of crystalline PRB solubility in HPMCAS solutions (Figure 6.19B) were 
overestimated because the solubility media contained both fully dissolved PRB and 
nanoscale crystals, as confirmed by electron diffraction (Figure 6.19C and 6.19D), that 
passed through the filter. The PRB crystals, initially many microns in size (Figure D.3B), 
were smaller than 200 nm in the solubility media. This shrinking in size qualitatively 
confirmed HPMCAS increased the solubility of crystalline PRB. The poor solvent quality 
of PBS at 37 °C potentially induces HPMCAS and PRB to interact in solution.  
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Figure 6.19. (A) Dissolution profiles of probucol:HPMCAS SDs with various drug 
loadings. (B) Solubility of crystalline probucol in HPMCAS solutions. Measured 
concentrations were overestimates because the solubility media contained both fully 
dissolved and nanocrystalline drug. (C) Low-dose cryo-TEM image and (D) electron 
diffraction pattern of probucol solubility media with 1 mg/mL of HPMCAS. Indexing of 
diffraction spots confirmed particle is crystalline probucol. Zone-axis and electron 
dosage are located in the top-left and bottom-right corners of (D), respectively. 
 
In contrast to the solubility measurements, dissolution profiles of PRB SDs 
correlated with amorphous nanoparticles, not PRB crystals. Cryo-TEM showed the 10 wt% 
PRB SD dissolution media contained spherical nanoparticles that endured for the entire 
dissolution assay (Figures 6.20A and 6.21). The volumetric average radius measured from 
cryo-TEM images at 4, 90, and 360 min were 20 ± 5 nm, 16 ± 4 nm, and 19 ± 4 nm, 
respectively. SAXS patterns of the dissolution media also exhibited a characteristic 
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shoulder (Figure 6.20B), although the low electron density of PRB caused this feature to 
have a weaker intensity than the corresponding feature for 10 wt% PHY SD. The SAXS 
patterns were quantitatively analyzed by fitting the data to Equation 6.5. Because the 
nanoparticles observed in the cryo-TEM images were spherical, a polydisperse sphere form 
factor with a Schulz-Zimm distribution was used to describe the nanoparticle shape (see 
Figure 6.22). From this form factor, the average sphere radius, 𝑅`¹@, Schulz-Zimm 
distribution width parameter, 𝑧, and sphere scattering intensity scaling factor, 𝜀^/;\;, were 
estimated. Table 6.4 lists the extracted values of all fit parameters. The growth of 
nanoparticle size and decrease of dispersity (𝑅`¹@ increased from 20 to 30 nm (6.20C), and 𝑧 increased from 10 to 30 (Figure 6.23B)) may be described by Ostwald ripening models: 
160 
 𝑅`¹@ = 𝑘𝑡 + 𝑅P¿  (6.12) 
 𝑘 is the ripening rate, 𝑡 is time, and 𝑅P is the initial particle size. 𝑛 is the exponent that 
reflects the mechanism of growth. An 𝑛 value of 2 suggests the rate limiting step is 
incorporation of solute into the particle, while a value of 3 indicates growth is diffusion-
limited. Because both exponents describe the data (Table 6.5), the mechanism of growth 
cannot be distinguished. Identical trends between 𝜀^/;\; and dissolution profile 
established that high PRB concentration coincides with nanoparticles in solution. 
Additionally, electron diffraction of the dissolution media strongly suggests the 
nanoparticles are amorphous (Figures 6.20E and 6.20F). Despite the dissimilarity between 
the physical properties of the APIs, the hydrophobicity of both PRB and PHY likely causes 
the APIs to form amorphous nanoparticles with HPMCAS during SD dissolution. 
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Figure 6.20. (A) Cryo-TEM image of 10 wt% probucol SD dissolution media at 4 min. 
(B) SAXS patterns of 10 wt% probucol SD dissolution media at various time points. 
Characteristic shoulder confirmed presence of nanostructures. (C) Average radius of 
gyration, Ravg, of nanoparticles estimated by fitting SAXS patterns to Equation 6.5 using 
a polydisperse sphere form factor with a Schulz-Zimm distribution. (D) Comparison of 
dissolution profile and estimated polydisperse sphere scaling parameters. Measured drug 
concentration directly correlated with the presence of nanoparticles in the dissolution 
media. (E) Low-dose cryo-TEM image and (F) electron diffraction pattern of 10 wt% 
probucol SD dissolution media. Red circle represents position of SAD aperture. Electron 
diffraction patterns suggested nanoparticles are amorphous. 
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Figure 6.21. Cryo-TEM of 10 wt% PRB dissolution media at (A) 90 and (B) 360 min. 
 
 
Figure 6.22. Comparison of SAXS patterns and polydisperse sphere form factor model 
fit for 10 wt% PRB SD dissolution media. SAXS pattern for 9 mg/mL HPMCAS solution 
was fit to a power law model. 
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Table 6.4. Fitted parameters from polydisperse sphere form factor model fit of 10 wt% 
PRB SD dissolution media SAXS patterns. 
Time [min] 𝜀^/;\; [a.u.] 𝑅`¹@ 𝑧 𝛽 𝛾 𝐵𝐺 [a.u.] 
4 1.7 22 7 0.003 1.9 0.012 
10 2.0 21 11 0.008 1.6 0.009 
20 2.0 25 8 0.006 1.7 0.011 
40 2.0 24 12 0.009 1.6 0.006 
90 2.2 25 22 0.011 1.6 0.0002 
180 2.7 28 20 0.016 1.4 -0.012 
360 2.7 31 31 0.011 1.6 -0.008 
9 mg/mL 
HPMCAS - - - 0.020 1.3 -0.043 
 
 
Figure 6.23. (A) Average radius (𝑹𝒂𝒗𝒈) and (B) Schulz-Zimm distribution width 
parameter (𝒛) extracted from polydisperse sphere form factor model fit for 10 wt% PRB 
SD dissolution media. 
 
Table 6.5. Fitted parameters from Ostwald ripening model fit 
of 10 wt% PRB SD dissolution media nanoparticles. 𝑛 𝑘 [nmn/min] 𝑅P [nm] 
2 1.3 23 
3 53 23 
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Cryo-TEM confirms that the lag in the higher PRB loading SD dissolution profiles 
is mirrored by delayed nucleation of nanoparticles. For 25 wt% PRB SD, the dissolution 
media at 4 min is not populated by spherical nanoparticles, but instead contains larger 
structures with ill-defined shapes (Figure 6.24A). These structures are likely disintegrating 
spray dried SD particles. Coinciding with the increase of PRB concentration, over time the 
nanoparticles become more spherical and much larger in size relative to the structures in 
the 10 wt% PRB dissolution media (Figure 6.24B; the volumetric average radius of the 
nanoparticles at 360 min was 70 ± 40 nm). Although the structures are large, electron 
diffraction patterns strongly suggest the nanoparticles are amorphous (Figures 6.24C and 
6.24D). SAXS patterns of the dissolution media display a small shoulder, but the large size 
dispersity of the nanoparticles smears the patterns and obscures quantitative analysis 
(Figure 6.25). The prolonged onset in the 50 wt% PRB dissolution profile also corresponds 
to delayed nanoparticle nucleation, while the higher drug to polymer ratio leads to much 
larger nanoparticle sizes (Figure 6.26; the volumetric average radius of the nanoparticles 
at 360 min is 180 ± 60 nm). While the dissolution behavior for PRB SDs differs greatly 
from PHY SDs, high concentration of PRB still parallels the appearance of nanoparticles 
in the dissolution media.  
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Figure 6.24. 25 wt% probucol SD dissolution media at (A) 4 min and (B) 360 min. (C) 
Low-dose cryo-TEM image and (D) electron diffraction pattern at 360 min. Electron 
diffraction pattern suggested nanoparticles are amorphous. 
 
 
 
  
146 
 
Figure 6.25. SAXS patterns of 25 wt% SD PRB dissolution media. 
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Figure 6.26. Cryo-TEM images of 50 wt% PRB SD dissolution media at (A) 4, (B) 40, 
and (C) 360 min. (D) SAXS patterns of 50 wt% PRB SD dissolution media. 
 
Figure 6.27 exhibits the dissolution profile and nanostructure characterization for 
the 10 wt% PRB SD dissolution at a targeted drug concentration of 300 µg/mL. The 
detection of nanoparticles in the dissolution media suggests the critical nanoparticle 
concentration for PRB is lower than 300 µg/mL. The weak intensity of the shoulder in the 
SAXS patterns prevents quantitative analysis. 
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Figure 6.27. Dissolution profiles for 10 wt% PRB SD with a targeted drug concentration 
of 300 µg/mL. (A) Dissolution profile, (B) cryo-TEM of dissolution media at 360 min, 
and (C) SAXS patterns of dissolution media. 
 
6.4 Discussion 
 This work directly confirms that formation of amorphous nanoparticles is essential 
for achieving and maintaining enhanced solubility of hydrophobic drugs that come from 
SDs. Although PRB and PHY have very different physical properties, dissolution profiles 
of SDs containing these drugs reflected the nanostructure evolution within the dissolution 
medium. Conclusions drawn from this work (and others)16 imply correlation between 
dissolution and nanoparticles applies not only HPMCAS SDs, but possibly many other 
polymeric drug delivery systems. Nanoparticle formation may possibly be a critical step 
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that is neglected by current theoretical models of drug release from polymeric 
matrices.161,99  
These studies also clarify the role of HPMCAS during SD dissolution. Contrary to 
many theories,41,42,154 the colloidal structure of HPMCAS in solution appears to have little 
relevance in the mechanism. Instead, A2 measurements suggest that unfavorable 
interactions between HPMCAS and PBS at 37 °C drive polymer to interact with 
hydrophobic drug. The success of HPMCAS at stabilizing drug in solution seems to be tied 
to crystallization tendency of the API, but electron diffraction of both PHY and PRB SD 
dissolution media suggests the polymer inhibits drug crystallization by impeding 
nucleation, rather than slowing crystal growth. Furthermore, the connection between 
PRB:HPMCAS ratio and ensuing nanoparticle size hints that increased polymer 
concentration leads to lower interfacial tension between API and water, resulting in smaller 
droplets—reminiscent of trends observed for oil:water emulsions stabilized by 
surfactants.162,163 
 This investigation potentially establishes a fundamental criterion for rational SD 
design: API and excipient must form nanostructures to achieve high concentration of drug 
in solution. Screening of excipients for a particular API may be streamlined to focus only 
on polymers that form amorphous nanoparticles with the drug. Thus, nanoscale 
characterization tools—such as the cryo-TEM, electron diffraction, and SAXS assays 
developed for this work—will be essential for identifying optimal formulations. These 
findings also raise deeper questions regarding the SD dissolution mechanism. Although 
nanoparticles can readily form in the dissolution media, the bioavailability of drug in these 
structures is not known. Some theories propose the nanoparticles compensate drug loss, 
resulting from both crystallization and permeation through the gastrointestinal membrane, 
by replenishing the dissolved drug concentration.16 However, the nanoparticles can 
potentially adhere to the mucus lining of the gut, leading to facilitated transport of drug.164 
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Nanoparticle formation itself could possibly lead to enhanced drug efficacy, although more 
studies are needed to clarify this relationship. Moreover, the structure and stability of the 
nanoparticles may also be influenced by the native surfactants in the intestinal fluid.165 
Resolving these questions and other structure-property relationships will likely involve 
even more rigorous nanoscale characterization of SD dissolution. 
  
6.5 Conclusions 
 I investigated the dissolution mechanism for HPMCAS SDs featuring PHY or PRB 
as the API. The poor solvent quality of PBS at 37 °C possibly served as the driving force 
for HPMCAS to interact with drug. Characterization by cryo-TEM and SAXS showed that 
both PHY and PRB SD dissolution directly correlated with the appearance of nanoparticles 
in the dissolution media. Drug identity, loading, and targeted drug concentration were 
critical factors that affected the nanoparticle size, shape, and formation kinetics. The 
relationship between dissolution and nanostructure potentially extends to other 
polymer:drug systems.  
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Chapter 7: Conclusions and suggestions for future directions 
 
 
7.1 Project summary 
 The use of solid dispersions (SDs) can surmount the solubility limitations of many 
pharmaceutical drugs, but the primitive understanding of structure-property relationships 
for these materials inhibits rational SD design. Furthermore, the complexity of some 
excipients, such as hydroxypropyl methylcellulose acetate succinate (HPMCAS), obscures 
elucidation of the polymer:drug interactions. To resolve these uncertainties, I developed 
several novel strategies for characterizing solid dispersions in both the solid-state and 
during dissolution. These tools, which achieved spatial resolutions and sensitivity superior 
to the traditional techniques, probed the nanoscale phenomena that govern SD material 
properties. 
 In Chapter 3, I demonstrated the use of transmission electron microscopy (TEM) to 
evaluate the crystallinity of griseofulvin:HPMCAS SDs. TEM, providing both real-space 
images and electron diffraction patterns, was used to unambiguously detect griseofulvin 
crystals in a physical mixture of spray dried griseofulvin and spray dried HPMCAS that 
had an overall crystallinity of ~ 3 vol%, below the practical lower limit of detection for 
laboratory-scale wide-angle X-ray scattering (WAXS). Using both TEM and WAXS, I did 
not find crystals in griseofulvin:HPMCAS SDs that had drug loadings of 5, 10, and 50 
wt%. I detected griseofulvin crystals in annealed 5 wt% griseofulvin SD using TEM, but 
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did not detect crystals in the same sample using in situ WAXS and modulated differential 
scanning calorimetry, thereby confirming the superior crystal detection sensitivity of TEM. 
I also performed TEM analysis on the in situ growth of griseofulvin crystals in a TEM 
sample of 50 wt% griseofulvin SD. Based on this study, TEM has significant potential for 
characterizing trace levels of crystallinity in SDs. 
In Chapter 4, I tested the use of energy-dispersive X-ray spectroscopy (EDS) for 
mapping the spatial distribution of griseofulvin throughout a SD particle. Based on Monte-
Carlo simulations of the TEM electron beam trajectory through a sample of griseofulvin, 
the spatial resolution of EDS was predicted to be ~ 10 nm, sufficient for detecting phase 
separated domains of drug in the HPMCAS SDs. In the EDS spectrum for spray dried 
griseofulvin, the Cl Ka peak served as a signal that distinguished the drug from HPMCAS. 
By tracking this spectroscopic signature, the spatial distribution of griseofulvin was 
isolated in particles of spray dried griseofulvin and 10 wt% griseofulvin SD. Quantitative 
analysis of EDS spectra for SDs with varying particle size and griseofulvin loading 
revealed that the Cl Ka peak was too weak for calculating drug concentration. The 
inadequate concentration resolution of the technique was attributed to the poor counting 
statistics of the collected X-rays. Based on this deficiency, EDS was judged to be a limited 
tool for characterizing SDs. 
 In Chapter 5, I explored electron energy-loss spectroscopy (EELS) as a tool for 
evaluating the composition of phenytoin:HPMCAS spin-coated SDs. To overcome weak 
elemental signals recorded by EDS, I used the π–π* transition peak in the EELS spectrum 
to detect phenytoin within the HPMCAS matrix of the SD. The phenytoin concentrations 
for SDs with drug loadings of 10, 25, and 50 wt% were calculated using a multiple least-
squares analysis. Measuring the concentration of 50 different regions in each SD, I 
concluded that HPMCAS and phenytoin were intimately mixed at a length scale of 200 nm 
for drug loadings up to 50 wt%. At length scales below 100 nm, the variance of the 
measured drug concentration increased; I speculated that this increase was due to statistical 
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fluctuations in local phenytoin concentration and electron irradiation. I also analyzed an 
annealed 25 wt% phenytoin SD and showed that EELS resolves concentration differences 
between regions less than 50 nm apart. These findings indicated EELS is a powerful tool 
for quantifying, with high accuracy and sub-100 nm spatial resolution, the composition of 
many polymer drug delivery systems. 
 In Chapter 6, I investigated the solution behavior of HPMCAS and dissolution of 
HPMCAS SDs in phosphate buffered saline. Dynamic and static light scattering 
measurements of HPMCAS solutions showed that the polymer formed both 10 and 100 nm 
structures (likely linear and cross-linked polymer chains, respectively) in solvent. Static 
light scattering also revealed phosphate buffered saline at 37 °C and below is a poor solvent 
for HPMCAS, potentially inducing the polymer to interact with itself or other species in 
solution. Characterization of the dissolution of HPMCAS SDs—featuring either phenytoin 
or probucol as the hydrophobic drug—showed that polymer and drug formed amorphous 
nanoparticles (<100 nm in size) in solution. Using a combination of cryogenic transmission 
electron microscopy, small-angle X-ray scattering, and electron diffraction, a direct 
correlation between SD dissolution profiles and nanostructure evolution was discovered 
for both drugs. The size, shape, and lifespan of the nanoparticles were affected by drug 
identity, loading, and targeted concentration. These findings confirm SD dissolution is a 
manifestation of nanoscale phenomena and suggest nanoparticle formation is universal to 
many other polymeric drug delivery systems. 
  
7.2 Future research directions 
 The discoveries discussed in Chapter 6 illuminate critical steps of the SD 
dissolution mechanism. The correlation between solubility enhancement and nanoparticle 
formation may be universal not only to HPMCAS SDs, but other polymer:drug pairings, 
as well. Probucol and phenytoin occupy extreme quadrants of the hydrophobicity vs. 
crystallization tendency phase space (Figure D.1), so the dissolution of SDs featuring 
  
154 
hydrophobic APIs with more modest properties (i.e., a smaller partition coefficient and 
lower free energy of crystallization) should be studied, such as griseofulvin, nifedipine, 
carbamazepine, and ketoprofen. Ionizable APIs—e.g., nilutamide and bifonazole—
possibly exhibit more complex nanoparticle behavior. Furthermore, the influence of 
excipient identity on nanostructure evolution in solution must also be investigated. For 
example, poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide) (poly(NIPAm-co-
DMA)) has recently been identified as an excellent excipient for phenytoin.166 Preliminary 
SAXS characterization of SDs featuring phenytoin and poly(NIPAm-co-DMA) show that 
the dissolution profile corresponds to nanostructural changes in the solution (Appendix 
D.4). HPMC esters of substituted succinates, another outstanding novel excipient for 
phenytoin,57 possibly forms nanoparticles with API. 
 While nanoparticles are potentially ubiquitous to SD systems, the spatial 
distribution of drug and polymer within the structures is not known. To probe the structure, 
alternate techniques must be developed to complement the cryo-TEM and SAXS assays 
discussed in Chapter 6. In particular, small-angle neutron scattering (SANS) contrast 
matching experiments might offer a way to isolate the spatial distribution of drug or 
polymer within the nanoparticles. In this measurement, the SANS intensity is proportional 
to the scattering length density differences between polymer, drug, and solvent.118 Tuning 
the scattering length density of phosphate buffered saline by altering the ratio of H2O to 
D2O may eliminate scattering from either polymer or drug and isolate the other species. 
The resulting scattering profile can then be fit to particular models to extract quantitative 
information regarding the structure or population of nanostructures. To achieve sufficient 
contrast between the isolated species and solvent, the use of deuterated polymer or drug 
will likely be needed. Furthermore, due to the lengthy collection times for SANS (ranges 
from 30 min to hours), this measurement will be limited to polymer:drug pairings that 
exhibit stable dissolution profiles. For formulations that display an unstable dissolution 
profile, more accurate quantitative information regarding the nanoparticle structure or 
  
155 
concentration may be acquired by modifying the SAXS assay to collect absolute intensity 
scattering profiles. Instead of collecting discrete aliquots at various time points, the 
dissolution media can be continuously pumped through a quartz capillary and heated stage. 
Because the background scattering intensity throughout the experiment is constant, time-
resolved absolute intensity scattering patterns may be obtained. The intensity of the SAXS 
patterns may be improved by using APIs that have a large electron density (e.g., 
carbamazepine, naproxen, and itraconazole). The flow-cell equipment for this experiment 
is available at the 5ID-D beamline at the Advanced Photon Source of Argonne National 
Laboratory. To selectively image drug or polymer in dissolution media, energy-filtered 
TEM can possibly be used. Similar to EELS, this technique images electrons that have a 
specific energy. By isolating electronic signatures that correspond to drug or polymer, more 
accurate assignment of phases can be achieved. 
Despite the advances in understanding the HPMCAS SD dissolution mechanism, 
the structure of the polymer in solution is still ambiguous. Light scattering experiments in 
Chapter 6 strongly insinuate HPMCAS solutions contain cross-linked chains, but the data 
are not conclusive. SAXS and SANS scattering patterns of HPMCAS solutions lack a 
plateau regime (Appendix D), suggesting the length scale that dominates the scattering 
intensity is larger than 100 nm. To collect scattering data at much lower q (and 
consequently, larger length scales), ultra-small-angle neutron scattering (USANS) may be 
used. With USANS, the q range is expanded to 0.0003–0.1 nm–1,167 likely sufficient 
observing the Rayleigh and Guinier regimes of the scattering pattern for HPMCAS in 
solvent. The scattering data could potentially be fit to a model to deduce the structure of 
HPMCAS in solution.  
 The suite of analytical tools developed in this dissertation not only clarify nanoscale 
properties of HPMCAS SDs, but also enable the ability to directly characterize the 
relationship between the physical stability of the SD in the solid-state and the ultimate 
dissolution profile. As mentioned in Chapters 1, 3, and 5, small traces of API crystallinity 
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or phase separation are hypothesized to have remarkably detrimental influence on the 
solubility enhancement of an SD formulation. To test this hypothesis, the morphology of 
the SD may be tracked before and during dissolution. Crystallinity and phase separation 
within the SD can be induced (either by heating the material above Tg or exposing it to high 
humidity) and characterized by electron diffraction or EELS. Subsequently, the influence 
of these properties on the resulting dissolution media nanostructure may be studied using 
cryo-TEM and SAXS. 
 The results described in this dissertation show that the structure-property 
relationships of SD materials are complex and only partially understood. Thus, rigorous 
characterization is essential for comprehending these materials and enabling rational SD 
design. 
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Appendix A: Supporting information for detection of 
pharmaceutical drug crystallites in solid dispersions by 
transmission electron microscopy† 
  
A.1 GF/HPMCAS solid dispersion particle morphology 
 Scanning electron microscopy (SEM) analysis of solid dispersions was performed 
by either a Hitachi S-900 or S-4700 field emission gun scanning electron microscope. 
Samples were prepared by spreading solid dispersion with a spatula onto carbon conductive 
tape (Ted Pella Inc.) and coating the sample with 10 nm Au/Pd (60/40 w/w) in a 15 mTorr 
argon atmosphere using a Denton DV-502A high vacuum deposition system. 
 Figure A.1 features SEM images of GF/HPMCAS solid dispersions with varying 
GF loading. As GF loading increased the particles became more spherical. This change in 
morphology occurs because GF diffuses toward the center of the droplet during the spray 
drying process faster than HPMCAS.A1 Spray dried GF particles feature nanoscale grains; 
we posit that these grains are crystalline.  
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Figure A.1. Scanning electron microscopy images of solid dispersion particles. (a) Spray 
dried HPMCAS and (b) 5 and (c) 10 wt% GF solid dispersions exhibit a collapsed sphere 
particle morphology, (d) 50 wt% GF solid dispersion demonstrates a spherical particle 
morphology, and (e) spray dried GF features an ill-defined particle morphology.  
 
 
A.2 Indexing of GF electron diffraction patterns 
 The GF crystal has tetragonal lattice geometry with the following lattice 
parameters: a = 0.9 nm and c = 2.0 nm.A2 d-spacings between crystal planes, d, were 
estimated by: 
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where a and c are lattice parameters, and h, k, and l are Miller indices. Interplanar angles,
φ , were calculated by: 
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where a and c are lattice parameters and hi, ki, and li are the Miller indices of the plane with 
spacing di.A3 Single crystal electron diffraction patterns were indexed in an iterative 
fashion. For each diffraction spot, the distance from the center of the diffraction pattern, R, 
was measured. The ratio of R for any two diffraction spots is related to the ratio of the d-
spacings by 
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 (A.3) 
  
Using this relation, the R ratio and the φ  between various diffraction spot pairs were 
compared to estimate the zone axis of the diffraction.A4 A kinematical diffraction pattern 
simulation of the estimated zone axis was produced using Web Electron Microscopy 
Applications Software.A5 The simulated diffraction pattern was then compared with the 
experimental diffraction pattern to determine the accuracy of the zone axis estimate. Figure 
A.2 features the experimental and simulated diffraction pattern of a GF crystal. 
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Figure A.2. (a) Bright-field TEM image and (b) electron diffraction pattern of GF 
crystal. The kinematical diffraction pattern simulation (blue dots) indicates the electron 
diffraction pattern samples two separate crystal grains. The zone axis of each grain is [3 
3  2 ] (aqua) and [6 6  1] (white), respectively. The {1 1 0} planes (yellow) belong to 
both zone axes. 
 
A.3 Beam Sensitivity of GF crystals 
 To establish the maximum electron dose allowed for preserving GF crystals, 
electron diffraction patterns of ~ 400 nm spray dried GF particles were recorded under 
increasing electron beam exposure at both ambient temperature and –180 °C. At ambient 
temperature, the particle, featured in Figure A.3a, maintained a sufficient diffraction spot 
signal until a dosage of approximately 4000 e–/nm2 (see Supporting Information File 
"GF_beam_exposure_ambient.avi" at http://pubs.acs.org/doi/suppl/10.1021/mp500682x). 
At –180 °C, the particle, featured in Figure A.3b, exhibited a sufficient diffraction spot 
signal up to a dosage of 6000 e–/nm2 (see Supporting Information File 
"GF_beam_exposure_cryo.avi" at http://pubs.acs.org/doi/suppl/10.1021/mp500682x). 
Based on these trends, all subsequent electron diffraction studies were performed at –180 
°C using electron doses less than 6000 e–/nm2.  
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Figure A.3. Bright-field TEM images of spray dried GF particles at (a) ambient 
temperature and (b) –180 °C. GF crystals can withstand a longer electron dose at –180 
°C than ambient temperature. 
 
A.4 Fourier transform infrared (FTIR) spectroscopy of solid dispersions 
 Solid dispersions were analyzed by a Bruker ALPHA Platinum FTIR spectrometer 
outfitted with a platinum attenuated total reflectance sampling module hosting a diamond 
crystal (single bounce). Samples were deposited directly on the diamond crystal plate. 128 
scans were collected from a range of 4000 to 40 cm–1 with a resolution of 4 cm–1. 
 Figure A.4 features FTIR spectra of solid dispersions with varying GF loading. 
Spray dried GF (pure drug) exhibits peaks at 1700 (ketone carbonyl stretching), 1660 
(carbon-carbon double bond stretching), 1610, 1600, and 1580 cm–1 (carbon-carbon single 
bond stretching (in-ring)), while spray dried HPMCAS (pure polymer) exhibits at peak at 
1740 cm–1 (ester carbonyl stretching). The ketone carbonyl stretching and carbon-carbon 
double and single bond stretching peaks for the 5, 10, and 50 wt% GF solid dispersions 
differ slightly from the spray dried GF spectrum. These discrepancies, however, are due to 
the GF in the solid dispersions being mostly amorphous. FTIR spectra of 100% amorphous 
GF, as recorded by Vasanthavada et al., has the same features as the spectra of the solid 
dispersions.6 Furthermore, neither the ester carbonyl stretch from HPMCAS nor the ketone 
carbonyl stretch from GF exhibit dramatic discrepancies from the pure polymer or pure 
amorphous drug spectra, respectively. Based on these spectra, we speculate that GF does 
not have any significant interactions with HPMCAS. 
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Figure A.4. FTIR spectra of solid dispersions with varying GF loading. Curves were 
shifted for clarity. No clear shift of the ketone carbonyl stretch peak was observed 
between the 5, 10, and 50 wt% GF solid dispersions (blue, purple, and pink curves, 
respectively) and the 100% amorphous GF spectra recorded by Vasanthavada et al.A6  
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Appendix B: Supporting information for energy-dispersive X-
ray spectroscopy of solid dispersions 
 
B.1 Modulated differential scanning calorimetry of griseofulvin:hydroxypropyl 
methylcellulose acetate succinate solid dispersions 
 Modulated differential scanning calorimetry was performed on SDs comprised of 
griseofulvin (GF) and hydroxypropyl methylcellulose acetate succinate solid dispersions 
(HPMCAS) in varying ratios (experimental method is described in Chapter 2.5). The pure 
GF glass transition temperature (Tg) was measured after heating the drug above its melting 
point (~220 °C). The reversing heat flow curves of each SD exhibit only a single Tg, 
suggests, but does not conclusively prove, that GF and HPMCAS in intimately mixed in 
each blend. Furthermore, the Tgs of SDs are lower than the Tgs of both HPMCAS and GF. 
More experiments are needed to understand the thermal properties of GF:HPMCAS SDs. 
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Figure B.1. MDSC reversing heat flow curves for GF SDs with varying drug loading, 
spray dried HPMCAS, and spray dried GF. #Conventional DSC trace of molten GF. 
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Appendix C: Supporting information for nanoscale 
concentration quantification of pharmaceutical actives in 
amorphous polymer matrices by electron energy-loss 
spectroscopy† 
 
C.1 Cross-section and mean free path length of inelastic scattering for various species 
 Auto-Zeff and LENZPLUS were used to approximate the effective atomic number 
(Zeff) and inelastic scattering cross-section (x), respectively, of various drugs and the 
average HPMCAS anhydroglucose unit, as seen in Table C1. C1 
 
Table C.1. Zeff, molecular weight, and x for various molecules. 
Molecule name Zeff 
Molecular weight 
[g/mol] 
x x 
[× 10-5 nm-2] 
HPMCAS 
anhydroglucose unit 3.9 252 8.50 
Phenytoin 4.3 252 8.58 
Carbamazepine 4.0 220 8.52 
Naproxen 3.9 230 8.50 
Griseofulvin 4.5 353 8.63 
Itraconazole 4.3 706 8.58 
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The mean free path length of inelastic scattering, 𝜆/, was calculated by: 
 𝜆/ = 2𝑎P𝑚P𝜐:𝐸/ ln 1 + 𝛽: 𝜃:  (C.1) 
 
where oa  is the Bohr radius, om  is the rest mass of an electron, 𝜐 is the velocity of the 
incident electron (modified to account for relativistic effects), pE  is the plasmon energy, 𝛽 is the collection semi-angle, and 𝜃 is the plasmon scattering angle.C1 For the molecules 
explored in this study, 𝜆/ was ~ 165 nm. To simplify the MLS analysis, 165 nm was used 
as  𝜆/ for subsequent concentration calculations. 
 
C.2 Conventional TEM EELS characterization of phenytoin:HPMCAS spin-coated 
solid dispersions 
 Conventional TEM EELS spectra were collected from regions of interest by first 
inserting a 300 nm diameter selected-area aperture into electron beam path to confine the 
collection area size. The electron dosage for each spectrum acquisition was 2500 e-/nm2. 
The beam was blanked before and after spectrum acquisition to minimize beam damage. 
Using diffraction mode, EELS spectra from at least 50 different regions of interest were 
collected from each sample. Bright-field TEM images of each region of interest were 
collected after spectrum acquisition. 
 Figure C.1A is a bright-field TEM image of a spin-coated HPMCAS film. Similar 
to Figure 5.1A, the HPMCAS film is uniform. Figure C.1C is a raw conventional TEM 
EELS spectrum of HPMCAS. This spectrum only exhibits the zero-loss and plasmon 
peaks. Figure C.1B is a bright-field TEM image of a spin-coated phenytoin film. Unlike 
the HPMCAS film, the phenytoin film has a jagged topology. The raw conventional TEM 
EELS spectrum of phenytoin, as seen in Figure C.1D, contains the zero-loss, plasmon, and 
π–π* transition peaks. 
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Figure C.1. Conventional bright-field TEM image of spin-coated (A) HPMCAS and (B) 
phenytoin films. The outlined regions are the areas where EELS spectra were collected. 
Conventional TEM EELS spectra and molecular structures of (C) HPMCAS and (D) 
phenytoin. The y-axis is the intensity (I) and the x-axis is the energy-loss exhibited by a 
particular electron (ΔE). Similar to the STEM EELS spectra, the HPMCAS spectrum 
only has the zero-loss and plasmon peaks, while the phenytoin spectrum has the zero-
loss, plasmon, and π–π* transition peaks. 
 
Figure C.2 features bright-field TEM images of the 10, 25, and 50 wt% phenytoin 
spin-coated SDs. Because each film looks identical, TEM imaging cannot distinguish 
between the SDs. The conventional TEM EELS spectra, however, can distinguish each 
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film. As seen in Figure C.3, the π–π* transition peak intensity increases as the phenytoin 
loading increases. The experimental spectra qualitatively match the predicted spectra. 
 
 
Figure C.2. Bright-field TEM images of (A) 10, (B) 25, and (C) 50 wt% phenytoin spin-
coated dispersion films. TEM imaging cannot distinguish among these films. 
 
 
Figure C.3. Experimental and predicted conventional TEM EELS spectra for 10, 25, 
and 50 wt% phenytoin (PHY) spin-coated dispersions. The representative experimental 
spectra and predicted spectra qualitatively match. 
 
Figure C.4 presents histograms of the measured phenytoin concentrations from 
conventional TEM EELS spectra for the 10, 25, and 50 wt% phenytoin spin-coated SDs. 
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 PHY (Avg. of 50 spectra)
 HPMCAS (Avg. of 50 spectra)
 50 wt% PHY pred.
 50 wt% PHY exp.
 25 wt% PHY pred.
 25 wt% PHY exp.
 10 wt% PHY pred.
 10 wt% PHY exp.
 
 
N
or
m
al
iz
ed
 I
DE [eV]
  
179 
Consistent with the STEM EELS results, the measured concentrations match the nominal 
SD loadings and have standard deviations of 3-6 wt%. 
 
 
Figure C.4. Histogram of measured concentrations from 50 spots by conventional TEM 
EELS spectra, as calculated by the MLS noise-weighted algorithm, for (A) 10, (B) 25, 
and (C) 50 wt% phenytoin spin-coated dispersions. The average measured 
concentrations match the nominal phenytoin loadings of the dispersions. 
 
C.3. Subtraction of amorphous C film contribution of EELS spectra 
 To isolate the single-scattering EELS spectra of phenytoin, HPMCAS, and SDs, 
the contribution of the amorphous C film was subtracted from each deconvoluted low-loss 
EELS spectrum. The reference spectrum of the amorphous C film, as seen in Figure C.5, 
was developed by collecting EELS spectra from ~ 50 different spots on a bare TEM grid 
that was covered with a thin (nominally 3 – 4 nm) amorphous film. The spectra were 
averaged and a quadratic spline was applied to the data set to smooth the curve. The isolated 
single-scattering EELS spectrum of the sample, corrS , was calculated by: 
 𝑆K{\\ = 𝑁\`𝑆\` − 𝑁£𝑆£𝑁\` − 𝑁£  (C.2) 
 
where rawN is number of electrons that scatter from both the SD sample and amorphous C 
film, rawS is the normalized uncorrected deconvoluted low-loss EELS spectrum, CN  is 
the number of electrons that scatter from the amorphous C film only, CS is the normalized 
amorphous C film EELS spectrum. rawN  and CN  are calculated by: 
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𝑁 = 𝑁4{^;𝐴 𝑡𝜆 exp − 𝑡𝜆  (C.3) 
𝑡 = 𝜆/ ln 1 + 𝐼tt𝐼utv  (C.4) 
 
where 𝑁4{^; is the electron dosage, 𝐴 is the EELS spectrum collection area, 𝑡 is the 
thickness of the sampled region of interest, 𝜆/ is the mean free path length of inelastic 
scattering, 𝐼tt is the integrated intensity of the deconvoluted low-loss EELS spectrum, and 𝐼utv is the integrated intensity of the zero-loss peak spectrum. To use Eqn. C3, we assume 
that scattering of the electrons in the sample is described by Poisson statistics.  
 
 
Figure C.5. Raw 10 wt% phenytoin (PHY) spin-coated SD, amorphous C film, and 10 
wt% phenytoin spin-coated SD with C film subtracted EELS spectra. The thickness of 
the amorphous C film was assumed to be 16.5 nm. 
 
Though collection of the amorphous C film EELS spectra was straightforward, 
calculating CN , which is a function of the amorphous C film thickness, is non-trivial. 
While the amorphous C film is nominally 3 – 4 nm thick, the thickness calculated from the 
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EELS spectra is ~ 30 nm. This discrepancy may be caused by the presence of surface 
plasmons in the spectra. For thin samples (≲ 25 nm), a surface plasmon loss is more likely 
to occur than the bulk plasmon loss, thereby violating the Poisson statistic assumption 
required for Eqn. C3 to be valid. This uncertainty of the amorphous C film thickness is 
exacerbated by the addition of the spin-coated SD film. To mitigate this ambiguity, we 
assumed the average thickness of the amorphous C film was one-tenth of the mean free 
path length of inelastic scattering for C (i.e., 16.5 nm). Figure C.5 details the C film 
subtraction from a raw EELS spectrum. While this assumption produces reasonable results, 
variation of the film thickness may skew the calculated concentrations. As seen in Figure 
C.6, the use of different amorphous C film thicknesses alters the calculated phenytoin 
concentration. Based on this analysis, we hypothesize that uncertainty of the film thickness, 
which likely varies by at least 2 nm, is a major influence on the standard deviation of the 
calculated concentration. Further experiments are needed to measure the calculated 
concentration error for SD TEM samples that lack the amorphous C film. 
 
 
Figure C.6. Histograms of measured concentrations from 50 spots on a 10 wt% 
phenytoin spin-coated SD. The EELS spectrum of an amorphous C film with an assumed 
thickness of (A) 16.5 nm, (B) 14.5 nm, or (C) 18.5 nm was subtracted from the SD EELS 
spectra. Small variation in the amorphous C film thickness skews the calculated 
phenytoin concentration by 3–4 wt%. 
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C.4 Modulated differential scanning calorimetry of a 25 wt% phenytoin spray-dried 
dispersion 
 To prepare the 25 wt% phenytoin spray-dried dispersion, the required amounts of 
phenytoin and HPMCAS were first dissolved in tetrahydrofuran to create a solution with a 
total solids loading of 2 wt% This solution was then sprayed by a mini spray dryer (Bend 
Research) using the following process parameters: nitrogen flow rate = 12.8 L/min, inlet 
temperature = 68 °C, solution flow rate = 0.65 mL/min. The outlet temperature was ~ 25 
°C. The spray-dried dispersion was collected from a paper filter in the instrument, 
subsequently dried under reduced pressure at ambient temperature for 12 h, and stored in 
a desiccator under reduced pressure until use.  
 Modulated differential scanning calorimetry (DSC) of the 25 wt% phenytoin spray-
dried dispersion was performed using a Discovery DSC (TA Instruments). The TEM 
sample was put into a TzeroTM aluminum pan with a standard lid. While exposed to a 
nitrogen gas flow with a rate of 50 mL/min, the sample pan was heated from 0–160 °C 
using the following parameters: average temperature heating rate = 1 °C/min, temperature 
modulation amplitude = 1 °C, temperature modulation period = 40 s. Figure C.7 shows the 
modulated DSC heat flow curves for the 25 wt% spray-dried SD. The Tg of the SD, as 
identified by the inflection point in the reversing heat curve, is 79 °C. The exothermic peak 
in the total and non-reversing heat curves is attributed to the crystallization of phenytoin in 
the SD. From this peak, the Tc and ΔHc are 149 °C and 33 J/gPHY, respectively. There is 
also a broad endothermic peak around 50 °C. While the source of this peak is unclear, we 
previously showed that this feature doesn't affect the Tg and Tc.C2  
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Figure C.7. Modulated DSC heat flow curves of a 25 wt% phenytoin spray-dried 
dispersion. Data were recorded during the first heating by using an average heating rate 
of 1 °C/min, a temperature modulation amplitude of 1 °C, and a temperature modulation 
period of 40 s. The reported Tg, Tc, and ΔHc are the average of three DSC runs. Errors 
bars represent the standard deviations. Curves were shifted for clarity. The peak enclosed 
by the black box is caused by the crystallization of phenytoin. 
 
C.5. References
C1Egerton, R. F. Electron Energy-Loss Spectroscopy in the TEM, 3rd ed.; Springer: New 
York, 2011.  
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Appendix D: Supporting Information for direct observation of 
nanostructures during dissolution of polymer/drug particles 
 
D.1 Comparison of physical properties for various active pharmaceutical ingredients 
Figure D.1 compares the octanol-water partition coefficient versus the free energy 
of crystallization (∆𝐺K\]^) at 37 °C for various active pharmaceutical ingredients. ∆𝐺K\]^ 
was calculated using: 
 ∆𝐺K\]^ = −∆𝐻<𝑅 𝑇* − 𝑇𝑇*𝑇  (D.1) 
 ∆𝐻< is the enthalpy of crystallization, 𝑇* is the melting temperature, 𝑇 is the temperature, 
and is the 𝑅 universal gas constant. The properties for phenytoin were obtained from Ohm 
and Lippold,D1 while the attributes for all other drugs were found in Baird et al.D2  
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Figure D.1. Comparison of octanol-water partition coefficient versus free energy of 
crystallization at 37 °C for various active pharmaceutical ingredients. Probucol (PRB) 
and phenytoin (PHY) are highlighted. 
 
 Aqueous solubility of glassy API may be estimated by: 
 𝐶@_`^^ = 𝐶K\]^𝛾 expΔ𝐺K\]^𝑅𝑇  (D.2) 
 𝛾 is the activity coefficient of glassy drug saturated with water (ranges from 0.5–1 for 
various drugs) and 𝐶K\]^ is the solubility of crystalline API.D3 Table D.1 lists the crystalline 
and expected glassy solubilities for phenytoin and probucol. 
 
Table D.1. Crystalline and expected glassy aqueous solubility at 37°C for phenytoin and 
probucol. 
  
𝐶@_`^^ 
[µg/mL] 
Drug 
𝐶K\]^ 
[µg/mL] 
𝛾 = 1 𝛾 = 0.5 
Phenytoin 30 960 480 
Probucol 4 × 10-8 4 × 10-7 2 × 10-7 
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D.2. Solid-state characterization of phenytoin and probucol solid dispersions 
 All SDs studied in this work had deflated sphere or sphere morphology, as 
determined by scanning electron microscopy (Figures D.2 and D.3A). No crystallinity was 
detected by wide-angle X-ray scattering for all SDs (Figure D.4), while the modulated 
differential scanning calorimetry reversing heat flow revealed all SDs had only 1 glass 
transition temperature, suggesting drug and HPMCAS were well-mixed (Figure D.5). 
Methods for wide-angle X-ray scattering and modulated differential scanning calorimetry 
are described in Ricarte et al.D4  
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Figure D.2. Scanning electron microscopy images of (A) 10 wt% PHY, (B) 25 wt% 
PHY, (C) 50 wt% PHY, (D) 10 wt% PRB, (E) 25 wt% PRB, and (F) 50 wt% PRB SDs. 
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Figure D.3. Scanning electron microscopy images of (A) 3.2 wt% PHY and (B) 
crystalline probucol. 
  
 
Figure D.4. Wide-angle X-ray scattering patterns of HPMCAS SDs featuring either (A) 
phenytoin or (B) probucol as the API. Patterns were shifted for clarity and normalized 
by the maximum intensity of the trace. Lack of Bragg peaks in SD patterns suggests API 
is amorphous. 
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Figure D.5. Modulated differential scanning calorimetry reversing heat flow curves of 
HPMCAS SDs containing either (A) phenytoin and (B) probucol as the API. Data were 
vertically shifted for clarity. Double-headed arrows represent an increment of 5 mW/g. 
The triangles indicate the glass transition temperatures, while the circles mark artifacts 
caused by melting of probucol crystals that formed during heating. 
 
D.3. PHY and PRB SDs dissolved in HPMCAS solutions 
 To achieve better understanding of nanoparticle formation, SDs featuring 25 wt% 
of either PHY or PRB were dissolved in PBS solutions containing 6 mg/mL of HPMCAS. 
Under these circumstances, PHY and PRB SDs exhibited very different behaviors. The 25 
wt% PHY SD dissolved in the HPMCAS solution achieved a plateau similar to 10 wt% 
PHY SD, albeit at a slightly lower concentration (Figure D.6A). However, cryo-TEM 
showed that the dissolution media at early times contained both ellipsoid nanoparticles and 
branched worm-like structures (Figure D.6B). The ellipsoids had a volumetric average 
radius of 25 ± 7 nm, larger than the nanoparticles in the pure PBS solvent, and the worms 
had an arithmetic average radius of 12 ± 3 nm and lengths that spanned from 100–5000 
nm. The appearance of the worms is possibly related to the semi-flexible nature of 
HPMCAS,5 but more experiments are needed to fully understand their origin. After 360 
min, both ellipsoids and worms disappear from solution (Figure D.6C). SAXS of the 
dissolution media also confirm the metastable nature of the structures, but the complexity 
of the solution prohibits quantitative analysis (Figure D.7A). Nevertheless, sensitivity of 
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shape to dissolution solvent reveals that the nanoparticle nucleation in PHY SD dissolution 
media may occur both during the release of drug from the SD particles and after the drug 
is already dissolved in solution. Conversely, the 25 wt% PRB SD dissolved in the 
HPMCAS solution achieves an almost identical dissolution profile and nanostructure 
evolution as the SD dissolved in pure PBS (Figures D.6E). The minimal influence of the 
dissolution solvent implies that nanoparticle nucleation in PRB SD dissolution media only 
occurs as drug is released from the SD particles. Conceivably, the extreme hydrophobicity 
of PRB induced nanoparticles to form once the glassy SD particles imbibed water. The 
contrasting behavior of PHY and PRB SDs shows that API physical properties dictate the 
nucleation and growth kinetics of the nanoparticles. 
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Figure D.6. (A) Dissolution profile 25 wt% phenytoin SD dissolved in HPMCAS 
solution compared with 10 and 25 wt% phenytoin SDs dissolved in PBS (same data as 
Figure 3A).(B) Cryo-TEM images of 25 wt% phenytoin SD dissolved in HPMCAS 
solution at 10 min and (C) 360 min. (D) Dissolution profile 25 wt% probucol SD 
dissolved in HPMCAS solution compared with 10 and 25 wt% probucol SDs dissolved 
in PBS (same data as Figure 6A). (B) Cryo-TEM images of 25 wt% probucol SD 
dissolved in HPMCAS solution at 4 min and (C) 360 min. 
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Figure D.7. SAXS patterns of (A) 25 wt% PHY SD and (B) 25 wt% PRB SD dissolved 
in 6 mg/mL HPMCAS solution. 
 
D.4. Dissolution of poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide) SDs 
 Poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide) (poly(NIPAm-co-
DMA)) is a polymer that was recently identified as an excellent excipient for stabilizing 
phenytoin in aqueous solution. Figure D.8A features the dissolution profile of a SD that is 
90 wt% poly(NIPAm-co-DMA) and 10 wt% phenytoin.D6 Figure D.8B features SAXS 
patterns of the 10 wt% SD dissolution media at each time point. The transformation of the 
SAXS patterns strongly suggests that the dissolution profile of the SD directly correlates 
with nanostructure evolution in solution. More experiments are needed to identify the 
structures that form in the dissolution media. 
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Figure D.8. (A) Dissolution profile of a 10 wt% PHY and 90 wt% poly(NIPAm-co-
DMA) SD.Molecular structure of poly(NIPAm-co-DMA) is displayed as the inset. (B) 
SAXS patterns of dissolution media at various time points. 
 
D.5. Small-angle neutron scattering of HPMCAS solutions 
 Small-angle neutron scattering (SANS) was used to probe the structure of 
HPMCAS in various solvents. SANS measurements were executed at the National Institute 
for Science and Technology on the NG7 30 m SANS instrument. The accessible q range 
was 0.009–3 nm-1. The contribution of incoherent scattering from solvent was removed 
from the patterns. Figure D.8 is a SANS pattern of a 9 mg/mL HPMCAS solution with 
deuterated phosphate buffered saline at 37 °C as the solvent. Similar to the SAXS patterns 
of HPMCAS solutions, the SANS pattern exhibits a power-law scaling of –1.2 and lacks 
obvious Rayleigh and Guinier regimes. SANS patterns for solutions featuring either 
phosphate buffered saline or tetrahydrofuran at 25 °C as solvent are identical to the 
aforementioned pattern, suggesting the solvent identity has minimal effect on the polymer 
structure in solution. More experiments are needed to fully understand the behavior of 
HPMCAS in solution. 
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Figure D.9. (A) Experimental SANS pattern and power law fit of 9 mg/mL HPMCAS 
in deuterated phosphate buffered saline (d-PBS).(B) Comparison of experimental SANS 
patterns of 9 mg/mL HPMCAS solutions featuring either deuterated phosphate buffer or 
tetrahydrofuran as the solvent. 
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